EP1237849A1 - Activators of soluble guanylate cyclase - Google Patents
Activators of soluble guanylate cyclaseInfo
- Publication number
- EP1237849A1 EP1237849A1 EP00973061A EP00973061A EP1237849A1 EP 1237849 A1 EP1237849 A1 EP 1237849A1 EP 00973061 A EP00973061 A EP 00973061A EP 00973061 A EP00973061 A EP 00973061A EP 1237849 A1 EP1237849 A1 EP 1237849A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- dimethylamino
- propyl
- phenyl
- chloro
- amide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 title claims abstract description 20
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 title claims abstract description 20
- 239000012190 activator Substances 0.000 title claims description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 151
- 125000003118 aryl group Chemical group 0.000 claims abstract description 104
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 94
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 77
- 125000004452 carbocyclyl group Chemical group 0.000 claims abstract description 51
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 41
- 239000001257 hydrogen Substances 0.000 claims abstract description 40
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 15
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract description 13
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims abstract description 12
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 7
- 230000004913 activation Effects 0.000 claims abstract description 4
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- -1 1 - [ 1 -(3 ,4-Dichloro-benzyl)-6-oxo- 1 , 6-dihydro-pyridin-3 -yl] -3 -(3 - dimethylamino-propyl)-urea 1 -(3-Dimethylamino-propyl)-3-(3-oxo- 1 ,2,3-triphenyl-propyl)-urea Chemical compound 0.000 claims description 108
- 125000000217 alkyl group Chemical group 0.000 claims description 91
- 239000004202 carbamide Substances 0.000 claims description 75
- IUNMPGNGSSIWFP-UHFFFAOYSA-N dimethylaminopropylamine Chemical compound CN(C)CCCN IUNMPGNGSSIWFP-UHFFFAOYSA-N 0.000 claims description 57
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 49
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 44
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 26
- 125000005518 carboxamido group Chemical group 0.000 claims description 22
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 21
- 239000011664 nicotinic acid Substances 0.000 claims description 16
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 16
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 13
- 125000001544 thienyl group Chemical group 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 6
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 5
- 208000002780 macular degeneration Diseases 0.000 claims description 5
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 5
- PKHAGSAEGXDDJI-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2,3-dimethyl-1h-indole-5-carboxylate Chemical compound CN(C)CCOC(=O)C1=CC=C2NC(C)=C(C)C2=C1 PKHAGSAEGXDDJI-UHFFFAOYSA-N 0.000 claims description 4
- DPQVMCUTEAOUBP-UHFFFAOYSA-N 2-(dimethylamino)ethyl n-cyclooctylcarbamodithioate Chemical compound CN(C)CCSC(=S)NC1CCCCCCC1 DPQVMCUTEAOUBP-UHFFFAOYSA-N 0.000 claims description 4
- NYBHOPDNYJSVCB-UHFFFAOYSA-N 2-acetamido-3-(4-chlorophenyl)-n-[3-(dimethylamino)propyl]prop-2-enamide;n-[1-[5-(4-bromophenyl)furan-2-yl]-3-[3-(dimethylamino)propylamino]-3-oxoprop-1-en-2-yl]-4-methylbenzamide Chemical compound CN(C)CCCNC(=O)C(NC(C)=O)=CC1=CC=C(Cl)C=C1.C=1C=C(C=2C=CC(Br)=CC=2)OC=1C=C(C(=O)NCCCN(C)C)NC(=O)C1=CC=C(C)C=C1 NYBHOPDNYJSVCB-UHFFFAOYSA-N 0.000 claims description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 4
- YIKSCQDJHCMVMK-UHFFFAOYSA-N Oxamide Chemical compound NC(=O)C(N)=O YIKSCQDJHCMVMK-UHFFFAOYSA-N 0.000 claims description 4
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims description 4
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims description 4
- FOALBVOKOPPUFL-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-3-phenylurea Chemical compound CN(C)CCCNC(=O)NC1=CC=CC=C1 FOALBVOKOPPUFL-UHFFFAOYSA-N 0.000 claims description 3
- HIVRPVGZEWAITM-UHFFFAOYSA-N 2-amino-n-[3-(dimethylamino)propyl]benzamide Chemical compound CN(C)CCCNC(=O)C1=CC=CC=C1N HIVRPVGZEWAITM-UHFFFAOYSA-N 0.000 claims description 3
- WKZBNKFBRFPHQP-UHFFFAOYSA-N 4-(4-chlorophenoxy)-n-[3-(dimethylamino)propyl]-3-nitrobenzamide Chemical compound [O-][N+](=O)C1=CC(C(=O)NCCCN(C)C)=CC=C1OC1=CC=C(Cl)C=C1 WKZBNKFBRFPHQP-UHFFFAOYSA-N 0.000 claims description 3
- VOYMKRQFRSPQIT-UHFFFAOYSA-N 5-chloro-n-[3-(dimethylamino)propyl]-3-phenyl-1h-indole-2-carboxamide Chemical compound CN(C)CCCNC(=O)C=1NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 VOYMKRQFRSPQIT-UHFFFAOYSA-N 0.000 claims description 3
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims description 3
- JOZVBLZUUUJSKC-UHFFFAOYSA-N CC(N(C)C)C(C)(C)OC(=O)c1oc2ccccc2c1C Chemical compound CC(N(C)C)C(C)(C)OC(=O)c1oc2ccccc2c1C JOZVBLZUUUJSKC-UHFFFAOYSA-N 0.000 claims description 3
- 125000004617 chromonyl group Chemical group O1C(=CC(C2=CC=CC=C12)=O)* 0.000 claims description 3
- 125000001041 indolyl group Chemical group 0.000 claims description 3
- CBASRSQMWYMBKZ-UHFFFAOYSA-N n,n-dimethyl-3-[5-(4-nitrophenyl)-2-phenylimino-1,3-thiazol-3-yl]propan-1-amine Chemical compound CN(C)CCCN1C=C(C=2C=CC(=CC=2)[N+]([O-])=O)SC1=NC1=CC=CC=C1 CBASRSQMWYMBKZ-UHFFFAOYSA-N 0.000 claims description 3
- IOOYNVHBFUZWPB-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-3-[2-[2-(phenylsulfamoyl)phenyl]sulfanylphenyl]urea Chemical compound CN(C)CCCNC(=O)NC1=CC=CC=C1SC1=CC=CC=C1S(=O)(=O)NC1=CC=CC=C1 IOOYNVHBFUZWPB-UHFFFAOYSA-N 0.000 claims description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 2
- JHBCXLUMFMJTBY-UHFFFAOYSA-N 8-[2-[3-(dimethylamino)propylcarbamoylamino]phenyl]sulfanyl-n-methylnaphthalene-1-carboxamide Chemical compound C=12C(C(=O)NC)=CC=CC2=CC=CC=1SC1=CC=CC=C1NC(=O)NCCCN(C)C JHBCXLUMFMJTBY-UHFFFAOYSA-N 0.000 claims description 2
- LPWPCRBCPQMCEW-UHFFFAOYSA-N CN(CCCNC(C1=C(C=CC=C1)C(=O)N1C(C=2NC3=CC=CC=C3C=2CC1)C(F)(F)F)=O)C Chemical compound CN(CCCNC(C1=C(C=CC=C1)C(=O)N1C(C=2NC3=CC=CC=C3C=2CC1)C(F)(F)F)=O)C LPWPCRBCPQMCEW-UHFFFAOYSA-N 0.000 claims description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 2
- 208000003782 Raynaud disease Diseases 0.000 claims description 2
- 208000012322 Raynaud phenomenon Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 239000004305 biphenyl Substances 0.000 claims description 2
- 201000001881 impotence Diseases 0.000 claims description 2
- KJFFDYAUUOEXTH-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]-2-[2-(phenylsulfamoyl)phenyl]sulfanylbenzamide Chemical compound CN(C)CCCNC(=O)C1=CC=CC=C1SC1=CC=CC=C1S(=O)(=O)NC1=CC=CC=C1 KJFFDYAUUOEXTH-UHFFFAOYSA-N 0.000 claims description 2
- HZXOVCBKJUESLO-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]-2-phenylquinoline-4-carboxamide Chemical compound N=1C2=CC=CC=C2C(C(=O)NCCCN(C)C)=CC=1C1=CC=CC=C1 HZXOVCBKJUESLO-UHFFFAOYSA-N 0.000 claims description 2
- PETVGFRMWDPCFD-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]-2-pyren-1-ylacetamide Chemical compound C1=C2C(CC(=O)NCCCN(C)C)=CC=C(C=C3)C2=C2C3=CC=CC2=C1 PETVGFRMWDPCFD-UHFFFAOYSA-N 0.000 claims description 2
- XGVDOHSEFDHZFJ-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]-4-oxo-2,3,4-triphenylbutanamide Chemical compound C=1C=CC=CC=1C(C(=O)NCCCN(C)C)C(C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 XGVDOHSEFDHZFJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000001968 nicotinic acid Nutrition 0.000 claims description 2
- 201000011461 pre-eclampsia Diseases 0.000 claims description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 2
- HJZYBDPHAHGHAZ-UHFFFAOYSA-N thiadiazole-4-carboxylic acid Chemical compound OC(=O)C1=CSN=N1 HJZYBDPHAHGHAZ-UHFFFAOYSA-N 0.000 claims description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 2
- 229940124549 vasodilator Drugs 0.000 claims description 2
- 239000003071 vasodilator agent Substances 0.000 claims description 2
- ONOAANKKJJMEJA-UHFFFAOYSA-N 2,6-bis[3-(dimethylamino)propylamino]-3-nitrobenzonitrile;n'-[2-(2,4-dichlorophenoxy)phenyl]-n-[3-(dimethylamino)propyl]oxamide Chemical compound CN(C)CCCNC1=CC=C([N+]([O-])=O)C(NCCCN(C)C)=C1C#N.CN(C)CCCNC(=O)C(=O)NC1=CC=CC=C1OC1=CC=C(Cl)C=C1Cl ONOAANKKJJMEJA-UHFFFAOYSA-N 0.000 claims 2
- NLCUDXZNBOAEFO-UHFFFAOYSA-N C(C)C1=NC(=CC=C1OCCCN(C)C)C.ClC=1C=C(C=C(C1)Cl)NC(CCNCCCN(C)C)=O Chemical compound C(C)C1=NC(=CC=C1OCCCN(C)C)C.ClC=1C=C(C=C(C1)Cl)NC(CCNCCCN(C)C)=O NLCUDXZNBOAEFO-UHFFFAOYSA-N 0.000 claims 2
- ZYXVNPBFYKGIGJ-UHFFFAOYSA-N CN(CCCNC(=O)C1=NC2=CC=CC=C2C(N1NC(=O)NC)=O)C.ClC1=C(C(=NO)NCCCN(C)C)C=CC(=C1)Cl Chemical compound CN(CCCNC(=O)C1=NC2=CC=CC=C2C(N1NC(=O)NC)=O)C.ClC1=C(C(=NO)NCCCN(C)C)C=CC(=C1)Cl ZYXVNPBFYKGIGJ-UHFFFAOYSA-N 0.000 claims 2
- FOLUGRWAVGQPLT-UHFFFAOYSA-N ClC1=CC=C(C=C1)NC(=O)NCCCN(C)C.ClC1=C(C(=CC=C1)Cl)C1=NOC(=C1C(=O)NC(=O)NCCCN(C)C)C Chemical compound ClC1=CC=C(C=C1)NC(=O)NCCCN(C)C.ClC1=C(C(=CC=C1)Cl)C1=NOC(=C1C(=O)NC(=O)NCCCN(C)C)C FOLUGRWAVGQPLT-UHFFFAOYSA-N 0.000 claims 2
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 claims 1
- WHXCJFLQBSHTHX-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-3-(2-phenoxyphenyl)urea Chemical compound CN(C)CCCNC(=O)NC1=CC=CC=C1OC1=CC=CC=C1 WHXCJFLQBSHTHX-UHFFFAOYSA-N 0.000 claims 1
- VAJAHOQNSSTFAS-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-3-(pyren-1-ylmethyl)urea Chemical compound C1=C2C(CNC(=O)NCCCN(C)C)=CC=C(C=C3)C2=C2C3=CC=CC2=C1 VAJAHOQNSSTFAS-UHFFFAOYSA-N 0.000 claims 1
- YEZUQADZJFUQSH-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-3-[4-(2-fluorophenyl)phenyl]urea Chemical compound C1=CC(NC(=O)NCCCN(C)C)=CC=C1C1=CC=CC=C1F YEZUQADZJFUQSH-UHFFFAOYSA-N 0.000 claims 1
- HRUBTGWRPWOMNK-UHFFFAOYSA-N 1-[3-[(3,4-dichlorophenyl)methylsulfanyl]thiophen-2-yl]-3-[3-(dimethylamino)propyl]urea Chemical compound S1C=CC(SCC=2C=C(Cl)C(Cl)=CC=2)=C1NC(=O)NCCCN(C)C HRUBTGWRPWOMNK-UHFFFAOYSA-N 0.000 claims 1
- UQXRJHGJPBYMKM-UHFFFAOYSA-N 1-[4-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]phenyl]-3-[3-(dimethylamino)propyl]urea Chemical compound C1=CC(NC(=O)NCCCN(C)C)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)=CS1 UQXRJHGJPBYMKM-UHFFFAOYSA-N 0.000 claims 1
- AJDJOLDGXURXQF-UHFFFAOYSA-N 2-(dimethylamino)-1-(3-methyl-1-benzothiophen-2-yl)propan-1-one 2-[3-(dimethylamino)propylamino]benzene-1,3-dicarbonitrile Chemical compound CN(C)C(C(=O)C1=C(C2=C(S1)C=CC=C2)C)C.CN(CCCNC2=C(C#N)C=CC=C2C#N)C AJDJOLDGXURXQF-UHFFFAOYSA-N 0.000 claims 1
- RBQJXOHBGQSSQB-UHFFFAOYSA-N 2-[2-[3-(dimethylamino)propylcarbamoylamino]phenyl]-n-(4-fluorophenyl)benzamide Chemical compound CN(C)CCCNC(=O)NC1=CC=CC=C1C1=CC=CC=C1C(=O)NC1=CC=C(F)C=C1 RBQJXOHBGQSSQB-UHFFFAOYSA-N 0.000 claims 1
- AXEZLZNVMNDJJJ-UHFFFAOYSA-N 8-[2-[3-(dimethylamino)propylcarbamoyl]phenyl]sulfanyl-n-methylnaphthalene-1-carboxamide Chemical compound C=12C(C(=O)NC)=CC=CC2=CC=CC=1SC1=CC=CC=C1C(=O)NCCCN(C)C AXEZLZNVMNDJJJ-UHFFFAOYSA-N 0.000 claims 1
- HQIYMNMULDWYBV-UHFFFAOYSA-N CN(C)CCCNC(=O)c1ccc2c(c1)nc(SCc1ccc(Cl)cc1)n(C)c2=O Chemical compound CN(C)CCCNC(=O)c1ccc2c(c1)nc(SCc1ccc(Cl)cc1)n(C)c2=O HQIYMNMULDWYBV-UHFFFAOYSA-N 0.000 claims 1
- DAQDANBZINBRIW-UHFFFAOYSA-N CN(CCCNC(=O)C=1NC2=CC=C(C=C2C1C1=CC=CC=C1)Cl)C.CN(CCCNC(=O)C1=NN(C(=C1)C1=CC=C(C=C1)Cl)C1=CC=CC=C1)C Chemical compound CN(CCCNC(=O)C=1NC2=CC=C(C=C2C1C1=CC=CC=C1)Cl)C.CN(CCCNC(=O)C1=NN(C(=C1)C1=CC=C(C=C1)Cl)C1=CC=CC=C1)C DAQDANBZINBRIW-UHFFFAOYSA-N 0.000 claims 1
- QFUJYNZQHQFLDI-UHFFFAOYSA-N CN(CCCNC(C1=CC(=CC=C1)OC1=CC=CC=C1)=O)C.C(C1=CC=CC=C1)SC1=C(C(=O)NCCCN(C)C)C=CC=C1 Chemical compound CN(CCCNC(C1=CC(=CC=C1)OC1=CC=CC=C1)=O)C.C(C1=CC=CC=C1)SC1=C(C(=O)NCCCN(C)C)C=CC=C1 QFUJYNZQHQFLDI-UHFFFAOYSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 description 68
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 51
- 239000000203 mixture Substances 0.000 description 48
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 46
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 36
- 229910052736 halogen Inorganic materials 0.000 description 35
- 150000002367 halogens Chemical class 0.000 description 35
- 229910052757 nitrogen Inorganic materials 0.000 description 33
- 238000006243 chemical reaction Methods 0.000 description 32
- 238000003756 stirring Methods 0.000 description 27
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
- 125000003545 alkoxy group Chemical group 0.000 description 24
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 24
- 125000001188 haloalkyl group Chemical group 0.000 description 23
- 238000010626 work up procedure Methods 0.000 description 23
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 21
- 239000000460 chlorine Substances 0.000 description 20
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 19
- 229910052801 chlorine Inorganic materials 0.000 description 19
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 18
- 125000004429 atom Chemical group 0.000 description 18
- 125000004438 haloalkoxy group Chemical group 0.000 description 18
- 125000005368 heteroarylthio group Chemical group 0.000 description 18
- 229920005989 resin Polymers 0.000 description 18
- 239000011347 resin Substances 0.000 description 18
- 239000002904 solvent Substances 0.000 description 17
- BJDDKZDZTHIIJB-UHFFFAOYSA-N 4,5,6,7-tetrafluoro-2-benzofuran-1,3-dione Chemical compound FC1=C(F)C(F)=C2C(=O)OC(=O)C2=C1F BJDDKZDZTHIIJB-UHFFFAOYSA-N 0.000 description 16
- 125000004414 alkyl thio group Chemical group 0.000 description 16
- 125000005110 aryl thio group Chemical group 0.000 description 16
- 125000004104 aryloxy group Chemical group 0.000 description 16
- 125000004093 cyano group Chemical group *C#N 0.000 description 16
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 16
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 13
- 125000005553 heteroaryloxy group Chemical group 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- 125000002837 carbocyclic group Chemical group 0.000 description 11
- 239000012043 crude product Substances 0.000 description 11
- 238000003818 flash chromatography Methods 0.000 description 11
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 11
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 10
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 10
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 9
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 9
- 239000011737 fluorine Substances 0.000 description 9
- 229910052731 fluorine Inorganic materials 0.000 description 9
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 239000007821 HATU Substances 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 125000005843 halogen group Chemical group 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 239000002585 base Substances 0.000 description 7
- 125000004076 pyridyl group Chemical group 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- SRTJVBPBQMMYDZ-UHFFFAOYSA-N CN(C)C(C(=O)C1=C(C2=C(S1)C=CC=C2)C)C Chemical compound CN(C)C(C(=O)C1=C(C2=C(S1)C=CC=C2)C)C SRTJVBPBQMMYDZ-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 150000002431 hydrogen Chemical group 0.000 description 6
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 6
- 125000000335 thiazolyl group Chemical group 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 5
- 210000004623 platelet-rich plasma Anatomy 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000011651 chromium Substances 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 description 4
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 4
- WDFQBORIUYODSI-UHFFFAOYSA-N 4-bromoaniline Chemical compound NC1=CC=C(Br)C=C1 WDFQBORIUYODSI-UHFFFAOYSA-N 0.000 description 3
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 229920002536 Scavenger resin Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 235000013681 dietary sucrose Nutrition 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 3
- XKMLYUALXHKNFT-UHFFFAOYSA-N rGTP Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O XKMLYUALXHKNFT-UHFFFAOYSA-N 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 230000009919 sequestration Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 2
- QEAFGQCAOGSQOC-UHFFFAOYSA-N 2,4-dichloro-n'-[3-(dimethylamino)propyl]-n-hydroxybenzenecarboximidamide Chemical compound CN(C)CCCN=C(NO)C1=CC=C(Cl)C=C1Cl QEAFGQCAOGSQOC-UHFFFAOYSA-N 0.000 description 2
- OMCOACHXKJOZMD-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1=CC=C2C(=O)C(CN(C)C)CCC2=C1 OMCOACHXKJOZMD-UHFFFAOYSA-N 0.000 description 2
- KFJQPSVAFIDGTN-UHFFFAOYSA-N 2-[3-(dimethylamino)propylamino]benzene-1,3-dicarbonitrile Chemical compound CN(C)CCCNc1c(cccc1C#N)C#N KFJQPSVAFIDGTN-UHFFFAOYSA-N 0.000 description 2
- IHPJAYWBFCHBRJ-UHFFFAOYSA-N 2-benzylsulfanyl-n-[3-(dimethylamino)propyl]benzamide Chemical compound CN(C)CCCNC(=O)C1=CC=CC=C1SCC1=CC=CC=C1 IHPJAYWBFCHBRJ-UHFFFAOYSA-N 0.000 description 2
- BJAGHCBHGOMAKS-UHFFFAOYSA-N 3-(4-chlorophenyl)-4-cyano-5-(2-methylpropylsulfanyl)thiophene-2-carboxylic acid Chemical compound N#CC1=C(SCC(C)C)SC(C(O)=O)=C1C1=CC=C(Cl)C=C1 BJAGHCBHGOMAKS-UHFFFAOYSA-N 0.000 description 2
- HFAJXVNSNRLMIS-UHFFFAOYSA-N 3-(4-chlorophenyl)-4-cyano-n-[3-(dimethylamino)propyl]-5-(2-methylpropylsulfanyl)thiophene-2-carboxamide Chemical compound N#CC1=C(SCC(C)C)SC(C(=O)NCCCN(C)C)=C1C1=CC=C(Cl)C=C1 HFAJXVNSNRLMIS-UHFFFAOYSA-N 0.000 description 2
- XYHMCPHXQJGLMU-UHFFFAOYSA-N 3-(methylcarbamoylamino)-4-oxoquinazoline-2-carboxylic acid Chemical compound C1=CC=C2C(=O)N(NC(=O)NC)C(C(O)=O)=NC2=C1 XYHMCPHXQJGLMU-UHFFFAOYSA-N 0.000 description 2
- NWUIDCVQFOXLQD-UHFFFAOYSA-N 3-amino-4-oxoquinazoline-2-carboxylic acid Chemical compound C1=CC=C2C(=O)N(N)C(C(O)=O)=NC2=C1 NWUIDCVQFOXLQD-UHFFFAOYSA-N 0.000 description 2
- KWJADNWWTWULOB-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-[3-(dimethylamino)propyl]-1-phenylpyrazole-3-carboxamide Chemical compound C=1C=CC=CC=1N1N=C(C(=O)NCCCN(C)C)C=C1C1=CC=C(Cl)C=C1 KWJADNWWTWULOB-UHFFFAOYSA-N 0.000 description 2
- SKKNGENANNQMRG-UHFFFAOYSA-N 5-bromo-n-[3-(dimethylamino)propyl]-2-hydroxybenzamide Chemical compound CN(C)CCCNC(=O)C1=CC(Br)=CC=C1O SKKNGENANNQMRG-UHFFFAOYSA-N 0.000 description 2
- SNDVFTHADGEFOS-UHFFFAOYSA-N BrC1=CC=C(C=C1)C=1N(C(SC1)=NC1=CC=CC=C1)CCCN(C)C.CN(CCOC(C1=CC(=CC(=C1)[N+](=O)[O-])[N+](=O)[O-])=O)C.CN(CCCOC(C=CC1=CC=CC=C1)=O)C Chemical compound BrC1=CC=C(C=C1)C=1N(C(SC1)=NC1=CC=CC=C1)CCCN(C)C.CN(CCOC(C1=CC(=CC(=C1)[N+](=O)[O-])[N+](=O)[O-])=O)C.CN(CCCOC(C=CC1=CC=CC=C1)=O)C SNDVFTHADGEFOS-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229960001123 epoprostenol Drugs 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 2
- XUZFUNXMTUFMNH-UHFFFAOYSA-N n-(2,4-dichlorophenyl)-6-[2-(dimethylamino)ethylsulfanyl]-4-(trifluoromethyl)pyridine-3-carboxamide Chemical compound C1=NC(SCCN(C)C)=CC(C(F)(F)F)=C1C(=O)NC1=CC=C(Cl)C=C1Cl XUZFUNXMTUFMNH-UHFFFAOYSA-N 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- 125000001725 pyrenyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 2
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 125000004933 β-carbolinyl group Chemical group C1(=NC=CC=2C3=CC=CC=C3NC12)* 0.000 description 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- 125000006736 (C6-C20) aryl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical group C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- HWKBYALMWFJWOM-UHFFFAOYSA-N 1-(6-bromo-2-thiophen-3-ylquinolin-4-yl)-3-[3-(dimethylamino)propyl]urea Chemical compound N=1C2=CC=C(Br)C=C2C(NC(=O)NCCCN(C)C)=CC=1C=1C=CSC=1 HWKBYALMWFJWOM-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical group O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 1
- 125000004825 2,2-dimethylpropylene group Chemical group [H]C([H])([H])C(C([H])([H])[H])(C([H])([H])[*:1])C([H])([H])[*:2] 0.000 description 1
- YOMZOJBFPXHVHU-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-6-methylquinoline-4-carboxylic acid Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(C(O)=O)=C(C=C(C)C=C2)C2=N1 YOMZOJBFPXHVHU-UHFFFAOYSA-N 0.000 description 1
- YWECCEXWKFHHQJ-UHFFFAOYSA-N 2-(4-chlorobenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(Cl)C=C1 YWECCEXWKFHHQJ-UHFFFAOYSA-N 0.000 description 1
- SLPIOULFKVECGU-UHFFFAOYSA-N 2-(4-chlorophenyl)-n-[3-(dimethylamino)propyl]-4-oxo-4-phenylbutanamide Chemical compound C=1C=C(Cl)C=CC=1C(C(=O)NCCCN(C)C)CC(=O)C1=CC=CC=C1 SLPIOULFKVECGU-UHFFFAOYSA-N 0.000 description 1
- FJAZVXUPZQSZKI-UHFFFAOYSA-N 2-(4-fluorobenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(F)C=C1 FJAZVXUPZQSZKI-UHFFFAOYSA-N 0.000 description 1
- GNLMDLMGBWBJPU-UHFFFAOYSA-N 2-[(3,4-dichlorophenyl)carbamoylamino]-n-[3-(dimethylamino)propyl]benzamide Chemical compound CN(C)CCCNC(=O)C1=CC=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 GNLMDLMGBWBJPU-UHFFFAOYSA-N 0.000 description 1
- AZIXTHVCNZTJSL-UHFFFAOYSA-N 2-[(5-chloro-1-methyl-3-phenylpyrazol-4-yl)methylsulfanyl]-n-[3-(dimethylamino)propyl]benzamide Chemical compound CN(C)CCCNC(=O)C1=CC=CC=C1SCC1=C(Cl)N(C)N=C1C1=CC=CC=C1 AZIXTHVCNZTJSL-UHFFFAOYSA-N 0.000 description 1
- NXRGWTAMRGUSDN-UHFFFAOYSA-N 2-[2-(phenylsulfamoyl)phenyl]sulfanylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1SC1=CC=CC=C1S(=O)(=O)NC1=CC=CC=C1 NXRGWTAMRGUSDN-UHFFFAOYSA-N 0.000 description 1
- LCWASYGSXBFYNN-UHFFFAOYSA-N 2-[2-[3-(dimethylamino)propylcarbamoylamino]phenyl]benzoic acid Chemical compound CN(C)CCCNC(=O)NC1=CC=CC=C1C1=CC=CC=C1C(O)=O LCWASYGSXBFYNN-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- IQMZULGMADGDLC-UHFFFAOYSA-N 2-benzylsulfanylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1SCC1=CC=CC=C1 IQMZULGMADGDLC-UHFFFAOYSA-N 0.000 description 1
- MBBUTABXEITVNY-UHFFFAOYSA-N 2-chloro-4-(trifluoromethyl)aniline Chemical compound NC1=CC=C(C(F)(F)F)C=C1Cl MBBUTABXEITVNY-UHFFFAOYSA-N 0.000 description 1
- PKRSYEPBQPFNRB-UHFFFAOYSA-N 2-phenoxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1OC1=CC=CC=C1 PKRSYEPBQPFNRB-UHFFFAOYSA-N 0.000 description 1
- PDMLUIXIWJEHOB-UHFFFAOYSA-N 3-(4-bromophenyl)-1-[3-(dimethylamino)propyl]-1-methylurea Chemical compound CN(C)CCCN(C)C(=O)NC1=CC=C(Br)C=C1 PDMLUIXIWJEHOB-UHFFFAOYSA-N 0.000 description 1
- UYCGTICAGNMSTM-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-[3-(dimethylamino)propyl]-1-methylurea Chemical compound CN(C)CCCN(C)C(=O)NC1=CC=C(Cl)C=C1 UYCGTICAGNMSTM-UHFFFAOYSA-N 0.000 description 1
- IIVBUJGYWCCLNG-UHFFFAOYSA-N 3-(dimethylamino)propylurea Chemical compound CN(C)CCCNC(N)=O IIVBUJGYWCCLNG-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- CVTTVZOGZBYZFH-UHFFFAOYSA-N 3-chloro-2-(1-methylimidazol-2-yl)sulfanyl-5-(trifluoromethyl)pyridine Chemical compound CN1C=CN=C1SC1=NC=C(C(F)(F)F)C=C1Cl CVTTVZOGZBYZFH-UHFFFAOYSA-N 0.000 description 1
- PFKITESTTSWHMP-UHFFFAOYSA-N 3-fluoro-4-phenylbenzoic acid Chemical compound FC1=CC(C(=O)O)=CC=C1C1=CC=CC=C1 PFKITESTTSWHMP-UHFFFAOYSA-N 0.000 description 1
- WQKQODZOQAFYPR-UHFFFAOYSA-N 3-fluoro-5-(trifluoromethyl)aniline Chemical compound NC1=CC(F)=CC(C(F)(F)F)=C1 WQKQODZOQAFYPR-UHFFFAOYSA-N 0.000 description 1
- UKDSGGJQRSNTHC-UHFFFAOYSA-N 4-(4-chlorophenyl)sulfanylthiophene-3-carboxylic acid Chemical compound OC(=O)C1=CSC=C1SC1=CC=C(Cl)C=C1 UKDSGGJQRSNTHC-UHFFFAOYSA-N 0.000 description 1
- WQTNWWULNLTMIX-UHFFFAOYSA-N 4-(4-phenyl-1,3-thiazol-2-yl)benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=NC(C=2C=CC=CC=2)=CS1 WQTNWWULNLTMIX-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- KKARGTVYYUVXPX-UHFFFAOYSA-N 4-chloro-n-[3-(dimethylamino)propyl]-2-phenoxybenzamide Chemical compound CN(C)CCCNC(=O)C1=CC=C(Cl)C=C1OC1=CC=CC=C1 KKARGTVYYUVXPX-UHFFFAOYSA-N 0.000 description 1
- QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 description 1
- MYDWMNUDBWOOMP-UHFFFAOYSA-N 5-(4-chlorophenyl)-1-phenylpyrazole-3-carboxylic acid Chemical compound C=1C=CC=CC=1N1N=C(C(=O)O)C=C1C1=CC=C(Cl)C=C1 MYDWMNUDBWOOMP-UHFFFAOYSA-N 0.000 description 1
- WQRNPWUZAVBEBC-UHFFFAOYSA-N 5-chloro-3-phenyl-1h-indole-2-carboxylic acid Chemical compound OC(=O)C=1NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 WQRNPWUZAVBEBC-UHFFFAOYSA-N 0.000 description 1
- CJTURQGHQPDNDA-UHFFFAOYSA-N 6,8-ditert-butyl-4-oxochromene-2-carboxylic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=CC(C(C)(C)C)=CC(C(C)(C)C)=C21 CJTURQGHQPDNDA-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- OMYXFRGZYJDEPI-UHFFFAOYSA-N C1=CC=[IH]=C1 Chemical group C1=CC=[IH]=C1 OMYXFRGZYJDEPI-UHFFFAOYSA-N 0.000 description 1
- VREUZOOOGIVUCU-UHFFFAOYSA-N CN(C)CCCNC(=O)C1CCCN1S(=O)(=O)c1cc(Cl)c(Cl)cc1Cl Chemical compound CN(C)CCCNC(=O)C1CCCN1S(=O)(=O)c1cc(Cl)c(Cl)cc1Cl VREUZOOOGIVUCU-UHFFFAOYSA-N 0.000 description 1
- HQDRHPVFKZLWMP-UHFFFAOYSA-N CN(C)CCCNC(=O)c1ccc(s1)-c1ccc(F)cc1 Chemical compound CN(C)CCCNC(=O)c1ccc(s1)-c1ccc(F)cc1 HQDRHPVFKZLWMP-UHFFFAOYSA-N 0.000 description 1
- WXDVOQJTSVXXRI-UHFFFAOYSA-N CN(C)CCCNC(=O)c1csc(n1)-c1ccc(Cl)cc1 Chemical compound CN(C)CCCNC(=O)c1csc(n1)-c1ccc(Cl)cc1 WXDVOQJTSVXXRI-UHFFFAOYSA-N 0.000 description 1
- LEYRRELMQBEIOB-UHFFFAOYSA-N CN(C)CCCNC(=O)c1csc(n1)-c1ccc2OCCc2c1 Chemical compound CN(C)CCCNC(=O)c1csc(n1)-c1ccc2OCCc2c1 LEYRRELMQBEIOB-UHFFFAOYSA-N 0.000 description 1
- OKCYIZJZXMHPSP-UHFFFAOYSA-N CN(C)CCCNC(=O)c1csc(n1)-c1cccc(c1)C(F)(F)F Chemical compound CN(C)CCCNC(=O)c1csc(n1)-c1cccc(c1)C(F)(F)F OKCYIZJZXMHPSP-UHFFFAOYSA-N 0.000 description 1
- ZWTJGKQLZGEOOR-UHFFFAOYSA-N CN(C)CCCNC(=O)c1sccc1Oc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O Chemical compound CN(C)CCCNC(=O)c1sccc1Oc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O ZWTJGKQLZGEOOR-UHFFFAOYSA-N 0.000 description 1
- UNLRXIQMXRORPO-UHFFFAOYSA-N CN(CCCNC(=O)C1=CC(=NC2=CC=C(C=C12)Br)C1=CSC=C1)C Chemical compound CN(CCCNC(=O)C1=CC(=NC2=CC=C(C=C12)Br)C1=CSC=C1)C UNLRXIQMXRORPO-UHFFFAOYSA-N 0.000 description 1
- JBTINSKYQFNPMA-UHFFFAOYSA-N CN(CCCNC(=O)C1=NN(C(C2=CC=CC=C12)=O)C1=CC(=CC=C1)C(F)(F)F)C Chemical compound CN(CCCNC(=O)C1=NN(C(C2=CC=CC=C12)=O)C1=CC(=CC=C1)C(F)(F)F)C JBTINSKYQFNPMA-UHFFFAOYSA-N 0.000 description 1
- WXJVVNXJBFRLII-UHFFFAOYSA-N CN(CCCNC(=O)C1CC=CCC1C1=C(C=C(C=C1)Cl)Cl)C Chemical compound CN(CCCNC(=O)C1CC=CCC1C1=C(C=C(C=C1)Cl)Cl)C WXJVVNXJBFRLII-UHFFFAOYSA-N 0.000 description 1
- TWPPXQOVBVVDKX-UHFFFAOYSA-N CN(CCCNC(=O)C=1OC2=C(C=C(C=C2C(C1)=O)C(C)(C)C)C(C)(C)C)C Chemical compound CN(CCCNC(=O)C=1OC2=C(C=C(C=C2C(C1)=O)C(C)(C)C)C(C)(C)C)C TWPPXQOVBVVDKX-UHFFFAOYSA-N 0.000 description 1
- IOJCLGZDYQYKNS-UHFFFAOYSA-N CN(CCCNC(=O)C=1SC=CC=1SCC1=CC(=C(C=C1)Cl)Cl)C Chemical compound CN(CCCNC(=O)C=1SC=CC=1SCC1=CC(=C(C=C1)Cl)Cl)C IOJCLGZDYQYKNS-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- PVDZFCKRKXKHOQ-UHFFFAOYSA-N N-(3-chloro-4-methylphenyl)-N'-[3-(dimethylamino)propyl]-3-phenylpentanediamide Chemical compound CN(CCCNC(CC(CC(=O)NC1=CC(=C(C=C1)C)Cl)C1=CC=CC=C1)=O)C PVDZFCKRKXKHOQ-UHFFFAOYSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- WPNMLCMTDCANOZ-UHFFFAOYSA-N [5-chloro-2-(methylamino)phenyl]-phenylmethanone Chemical compound CNC1=CC=C(Cl)C=C1C(=O)C1=CC=CC=C1 WPNMLCMTDCANOZ-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 150000003974 aralkylamines Chemical class 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000007163 central neurotransmission Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- GWZCCUDJHOGOSO-UHFFFAOYSA-N diphenic acid Chemical compound OC(=O)C1=CC=CC=C1C1=CC=CC=C1C(O)=O GWZCCUDJHOGOSO-UHFFFAOYSA-N 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000004468 heterocyclylthio group Chemical group 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- BYBHOBOZQWWMEF-UHFFFAOYSA-N n-(3-chloro-4-methylphenyl)-4-[3-(dimethylamino)propylcarbamoylamino]-3-phenylbutanamide Chemical compound C=1C=CC=CC=1C(CNC(=O)NCCCN(C)C)CC(=O)NC1=CC=C(C)C(Cl)=C1 BYBHOBOZQWWMEF-UHFFFAOYSA-N 0.000 description 1
- NIAHWJYCBNFDHF-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]-2-(furan-2-yl)quinoline-4-carboxamide Chemical compound N=1C2=CC=CC=C2C(C(=O)NCCCN(C)C)=CC=1C1=CC=CO1 NIAHWJYCBNFDHF-UHFFFAOYSA-N 0.000 description 1
- ISOONVOGJZMHMZ-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]-3-(2,4,5-trimethylphenyl)butanamide Chemical compound CN(C)CCCNC(=O)CC(C)C1=CC(C)=C(C)C=C1C ISOONVOGJZMHMZ-UHFFFAOYSA-N 0.000 description 1
- QCLJCUZAGVJCRH-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]-3-(4-phenoxyphenyl)propanamide Chemical compound C1=CC(CCC(=O)NCCCN(C)C)=CC=C1OC1=CC=CC=C1 QCLJCUZAGVJCRH-UHFFFAOYSA-N 0.000 description 1
- FRILSDDVRPNVEZ-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]-3-phenoxybenzamide Chemical compound CN(C)CCCNC(=O)C1=CC=CC(OC=2C=CC=CC=2)=C1 FRILSDDVRPNVEZ-UHFFFAOYSA-N 0.000 description 1
- HUUOKQLSKAZISK-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]-4-(4-phenyl-1,3-thiazol-2-yl)benzamide Chemical compound C1=CC(C(=O)NCCCN(C)C)=CC=C1C1=NC(C=2C=CC=CC=2)=CS1 HUUOKQLSKAZISK-UHFFFAOYSA-N 0.000 description 1
- LXJBLOVFGNKDCG-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]-5-[3-(trifluoromethyl)phenyl]furan-2-carboxamide Chemical compound O1C(C(=O)NCCCN(C)C)=CC=C1C1=CC=CC(C(F)(F)F)=C1 LXJBLOVFGNKDCG-UHFFFAOYSA-N 0.000 description 1
- OVZNWAWUJPSLHM-UHFFFAOYSA-N n-benzyl-3-nitroaniline Chemical compound [O-][N+](=O)C1=CC=CC(NCC=2C=CC=CC=2)=C1 OVZNWAWUJPSLHM-UHFFFAOYSA-N 0.000 description 1
- QHDJYTUZWBABGW-UHFFFAOYSA-N n-benzyl-4-methylpyridin-2-amine Chemical compound CC1=CC=NC(NCC=2C=CC=CC=2)=C1 QHDJYTUZWBABGW-UHFFFAOYSA-N 0.000 description 1
- LKNLVUCTBWTNPS-UHFFFAOYSA-N n-methyl-3,5-bis(trifluoromethyl)aniline Chemical compound CNC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 LKNLVUCTBWTNPS-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000004386 ocular blood flow Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 230000007161 peripheral neurotransmission Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000016732 phototransduction Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- ZUCRGHABDDWQPY-UHFFFAOYSA-N pyrazine-2,3-dicarboxylic acid Chemical compound OC(=O)C1=NC=CN=C1C(O)=O ZUCRGHABDDWQPY-UHFFFAOYSA-N 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical group OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 230000033904 relaxation of vascular smooth muscle Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000005156 substituted alkylene group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- MBYLVOKEDDQJDY-UHFFFAOYSA-N tris(2-aminoethyl)amine Chemical compound NCCN(CCN)CCN MBYLVOKEDDQJDY-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- C07D213/643—2-Phenoxypyridines; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/36—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/37—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a saturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/40—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/62—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/78—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/50—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
- C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/82—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
- C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/26—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
- C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C275/36—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with at least one of the oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. N-aryloxyphenylureas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/38—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by doubly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
- C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
- C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/16—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/38—One sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/24—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/56—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
- C07C2603/42—Ortho- or ortho- and peri-condensed systems containing four condensed rings containing only six-membered rings
- C07C2603/50—Pyrenes; Hydrogenated pyrenes
Definitions
- This invention relates to activators of soluble guanylate cyclase (sGC), to their preparation and to their use.
- sGC soluble guanylate cyclase
- Soluble guanylate cyclase is responsible for the enzymatic conversion of guanosine-5'-triphosphate (GTP) to cyclic guanosine-3',5'-monophosphate (cGMP).
- sGC is responsible for numerous physiological processes including vascular and non-vascular smooth muscle relaxation, peripheral and central neurotransmission, platelet reactivity and phototransduction (Hobbs A.J., TiPS, December 1997, Vol 18, p.484). Activators of sGC can therefore be expected to have valuable therapeutic properties.
- NO is known as an activator of sGC.
- this compound has a number of different physiological effects and its use in activating sGC therefore suffers from a myriad of side effects. There is therefore a need for selective activators of sGC.
- 3-(5'-hydroxymethyl-2'-furyl)-l-benzylindazole (YC-1) is a known NO independent activator of sGC (Hobbs, A.J., TiPS, December 1997, Vol 18, p.484). However, the activation achieved is not high.
- the present invention provides the use of a compound of the formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the activation of soluble guanylate cyclase
- R, and R 2 are the same or different and each represent a C,-C 6 alkyl group, or R, and R 2 together form a C 3 -C 6 alkylene group;
- Z is a C,-C 4 alkylene group
- P is a direct bond or a moiety -X-, -Y-, -W-, -XY-, -YW- or -XYW-, wherein:
- R 4 is C r C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, a group -R-A wherein R is -(C,-C 6 alkyl)-, -(C 2 -C alkenyl)- or -(C 2 -C 6 alkynyl)- and A is aryl, heteroaryl, carbocycyl or heterocyclyl, or R 4 is a group -COR' * ', -CO ⁇ , -S(O) 2 R or -CONR'R" wherein R' is hydrogen, C r C 6 alkyl, C 2 -C 6 alkenyl or
- C 2 -C 6 alkynyl and R" is is aryl, heteroaryl, carbocyclyl or heterocyclyl.
- the moiety -X- when present, is attached to R 4 and the moiety W, when present, is attached to Z.
- the moiety Y the moiety V is attached to W or, if W is not present, to Z, and the moiety U is attached to X or, if X is not present, to R 4 .
- a C,-C 6 alkyl group or moiety is a linear or branched alkyl group or moiety.
- Suitable alkyl groups and moieties include C r C 4 alkyl groups and moieties, for example, methyl, ethyl, n-propyl, i-propyl, n-butyl and t-butyl. Methyl, ethyl, n-propyl and t-butyl are preferred.
- a C r C 6 alkyl group or moiety can be substituted or unsubstituted at any position. Typically, it is unsubstituted or carries 1, 2 or 3 substituents. Suitable substituents include C r C 6 alkyl, C r C 6 alkylthio, C r C 6 alkoxy, C,-C 6 haloalkyl, for example -CF 3 and -CC1 3 , C r C 6 haloalkoxy, for example -OCF 3 and -OCCl 3 , halogen, hydroxy, cyano, nitro, aryl, aryloxy, arylthio, heteroaryl, heteroaryloxy, heteroarylthio, heterocyclyl, heterocyclyloxy, heterocyclythio, carbocyclyl, carbocyclyloxy, carbocyclylthio, oxo, -NR / R wherein R 7 and R" are the same or different and are hydrogen or C r C 6 al
- two substituents on the same atom can, together with the atom to which they are attached, form a carbocyclyl or heterocyclyl group.
- two preferred substituents on the same carbon atom may, together with the atom to which they are attached, form a carbocyclyl group, preferably a C 3 -C 6 cycloalkyl group.
- a C 2 -C 6 alkenyl group or moiety is a linear or branched alkenyl group or moiety.
- Suitable alkenyl groups and moieties include C 2 -C 4 alkenyl groups and moieties such as ethenyl, propenyl and butenyl groups and moieties. Ethenyl and propenyl are preferred.
- a C 2 -C 6 alkenyl group or moiety may be substituted or unsubstituted at any position.
- a C 2 -C 6 alkenyl group is typically unsubstituted or carries 1, 2, 3 or 4 substituents. Preferably, it carries at least two substituents. Suitable substituents include oxo, C r C 6 alkyl, C r C 6 alkylthio, C r C 6 alkoxy, C]-C 6 haloalkyl, for example -CF 3 and -CC1 3 , C r C 6 haloalkoxy, for example -OCF 3 and -OCCl 3 , halogen, hydroxy, cyano, nitro, aryl, aryloxy, arylthio, heteroaryl, heteroaryloxy, heteroarylthio, heterocyclyl, heterocyclyloxy, heterocyclythio, carbocyclyl, carbocyclyloxy, carbocyclylthio, -NR'R" wherein R' and R / are the same or different and are hydrogen or C r C 6 alkyl,
- two preferred substituents on the same carbon atom may, together with the atom to which they are attached, form a carbocyclyl group, preferably a C 3 -C 8 cycloalkyl group.
- substituents are halogen, for example chlorine and fluorine, C r C 4 alkyl, for example methyl, ethyl or t-butyl, aryl, for example phenyl, heteroaryl, for example furanyl, -CONH-aryl, for example -CONH-phenyl, -NH- CO 2 -(C,-C 4 alkyl), -NH-CO-(C,-C 4 alkyl), -NH-CO-aryl, for example -NH-CO- phenyl, heteroarylthio, for example pyrimidinethio and -CO-aryl, for example -CO- phenyl. It is also preferred that two substituents on the same carbon atom may, together with the atom to which they are attached, form a C 3 -C 8 cycloalkyl group.
- a C 2 -C 6 alkynyl group or moiety is typically an ethynyl, propynyl or butynyl group or moiety. It may be substituted or unsubstituted at any position. Typically, it is unsubstituted or carries 1 or 2 substituents.
- Suitable substituents include C r C 6 alkyl, C,-C 6 alkylthio, C r C 6 alkoxy, C r C 6 haloalkyl, for example -CF 3 and -CC1 3 , C r C 6 haloalkoxy, for example -OCF 3 and -OCCl 3 , halogen, hydroxy, cyano, nitro, aryl, aryloxy, arylthio, heteroaryl, heteroaryloxy, heteroarylthio, heterocyclyl, heterocyclyloxy, heterocyclythio, carbocyclyl, carbocyclyloxy, carbocyclylthio, -NR / R / wherein R' and R / are the same or different and are hydrogen or C r C 6 alkyl, -
- each R / can be the same or different and represents hydrogen or C r C 6 alkyl and each R can be the same or different and represents C r C 6 alkyl, aryl, heteroaryl, heterocyclyl or carbocyclyl, and -S-(C r C 6 alkyl)-R // and -O-(Cj-C 6 alkyl)-R wherein each R" 1 can be the same or different and represents aryl, heteroaryl, heterocyclyl or carbocyclyl.
- two substituents on the same atom can, together with the atom to which they are attached, form a carbocyclyl or heterocyclyl group.
- Preferred substituents include halogen, C r C 6 alkyl, aryl, arylthio, aryloxy, heteroaryl, heteroarylthio, heteroaryloxy and -CONHR and -NHCO 2 R wherein R is as defined above.
- two preferred substituents on the same carbon atom may, together with the atom to which they are attached, form a carbocyclyl group, preferably a C 3 -C 6 cycloalkyl group.
- substituents are halogen, for example chlorine and fluorine, C r C 4 alkyl, for example methyl, ethyl or t-butyl, aryl, for example phenyl, -CONH-aryl, for example -CONH-phenyl, -NH-CO 2 -(C ,-C 4 alkyl), heteroarylthio, for example pyrimidinethio and -CO-aryl, for example -CO-phenyl. It is also preferred that two substituents on the same carbon atom may, together with the atom to which they are attached, form a C 3 -C 6 cycloalkyl group.
- a C,-C 6 alkoxy group is typically a said C,-C 6 alkyl group attached to an oxygen atom.
- a C,-C 6 alkylthio group is typically a said C,-C 6 alkyl group attached to a sulphur atom.
- a said alkylene group is a divalent alkyl moiety. It may be unsubstituted or substituted at any position. Typically, it is unsubstituted or monosubstituted. Suitable substituents include halogen, for example chlorine and flourine, hydroxy, C C 4 alkyl such as methyl and ethyl, C C alkoxy, for example methoxy, C r C 4 haloalkyl, for example -CF 3 and -CC1 3 and C r C 4 haloalkoxy, for example -OCF 3 and -OCCl 3 . These substituents are typically themselves unsubstituted.
- a halogen is typically chlorine, fluorine, bromine or iodine. It is preferably chlorine.
- a haloalkyl or haloalkoxy group is typically a said alkyl or alkoxy group substituted by one or more said halogen atoms. Typically, it is substituted by 1, 2 or 3 said halogen atoms.
- Preferred haloalkyl and haloalkoxy groups include perhaloalkyl and perhaloalkoxy groups such as -CX 3 and -OCX 3 wherein X is a said halogen atom.
- Particularly preferred haloalkyl groups are CF 3 and CC1 3 .
- Particularly preferred haloalkoxy groups are -OCF 3 and -OCCl 3 .
- an aryl group or moiety is typically a C 6 -C 20 aryl group or moiety. Suitable such aryl groups and moieties include phenyl, naphthyl and pyrenyl. Phenyl and pyrenyl are preferred.
- An aryl group or moiety may be substituted or unsubstituted at any position. Typically, it is unsubstituted or carries 1, 2, 3 or 4 substituents. Suitable substituents include C,-C 6 alkyl, C r C 6 alkylthio, C r C 6 alkoxy, C r C 6 haloalkyl, for example -CF 3 and -CC1 3 , - haloalkoxy, for example -OCF 3 and -OCCl 3 , halogen, cyano, hydroxy, nitro, aryl, aryloxy, arylthio, heteroaryl, heteroaryloxy, heteroarylthio, heterocyclyl, heterocyclyloxy, heterocyclythio, carbocyclyl, carbocyclyloxy, carbocyclylthio, -NRR wherein R' and R" are the same or different and are hydrogen or C,-C 6 alkyl, -COR, -CONR /
- Preferred substituents include C C 6 alkyl, for example methyl and ethyl, C r C 6 alkoxy, for example methoxy, C r C 6 alkylthio, for example methylthio, C,-C 6 haloalkyl, for example -CF 3 and -CC1 3 , C r C 6 haloalkoxy, for example -OCF 3 and -OCCl 3 , halogen, for example chlorine and fluorine, nitro, cyano, aryl, for example phenyl, aryloxy, for example phenyloxy, arylthio, for example phenylthio, heteroaryl, heteroaryloxy, heteroarylthio, heterocyclyl, -NRR / wherein R f and R are the same or different and are hydrogen or C,-C 6 alkyl, -CONH-(C,-C 6 alkyl), -NHCONH-R wherein R is aryl, for example phen
- substituents are phenyl, in particular 4-phenyl, phenoxy, in particular 2-phenoxy, phenylthio, halogen, -CF 3 , -CC1 3 , nitro, cyano, -OCF 3 , -OCCl 3, C,-C 4 alkyl, C,-C 4 alkoxy, C,-C 4 alkylthio, -CONH-(C,-C 4 alkyl),
- An aryl group or moiety may be fused to a further said aryl group or to a carbocyclic, heterocyclic or heteroaryl group.
- an aryl group may be fused to a pyridine ring to form a quinoline or isoquinoline group, or to a furan ring. It may also, for example, be fused to a cyclopropyl or cyclohexyl group or to a tetrahydro furyl group, a 1,4-dioxolane group or a pyrimidone ring, for example a 4- pyrimidone ring.
- a carbocyclic group or moiety is a non-aromatic, saturated or unsaturated carbocyclic group or moiety. Typically, it has from 3 to 10, for example from 3 to 8, carbon atoms. Preferably, it has from 3 to 8, for example 3 to 6, carbon atoms.
- suitable carbocyclic groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclopetadienyl, cyclohexyl, cyclohexenyl and cyclooctanyl groups.
- Preferred carbocyclic groups include cyclohexyl, cyclooctanyl and cyclohexenyl groups.
- substituents on the same atom can, together with the atom to which they are attached, form a carbocyclyl or heterocyclyl group.
- Preferred substituents include oxo, C,-C 6 alkyl, for example methyl and ethyl, C r C 6 alkoxy, for example methoxy, C,-C 6 alkylthio, for example methylthio, C,-C 6 haloalkyl, for example -CF 3 and -CC1 3 , - haloalkoxy, for example -OCF 3 and -OCCl 3 , halogen, for example chlorine and fluorine, nitro, cyano, aryl, for example phenyl, aryloxy, for example phenyloxy, arylthio, for example phenythio, heteroaryl, heteroarylthio, heterocyclyl, -CONH-(C,-C 6 alkyl), -NHCONH-R wherein R is aryl
- a carbocyclic group or moiety may be fused to a further carbocyclic group or to an aryl, heteroaryl or heterocyclic group.
- a heteroaryl group or moiety is typically a 5- to 10- membered aryl ring containing at least one heteroatom, for example 1, 2 or 3 heteroatoms, selected from
- the heteroaryl group or moiety is a 5- or 6- membered ring.
- Suitable heteroaryl groups and moieties include pyridyl, pyranyl, furanyl, thienyl, pyrazolidinyl, pyrrolyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, imidazolyl, pyrazolyl, iso thiazolyl, isoxazolyl, furazanyl, triazolyl and thiadiazolyl groups.
- a heteroaryl group or moiety may be unsubstituted or substituted at any position. Typically, it is unsubstituted or carries up to three substituents. Suitable substituents include C r C 6 alkyl, C r C 6 alkylthio, C,-C 6 alkoxy, C,-C 6 haloalkyl, for example -CF 3 and -CC1 3 , C r C 6 haloalkoxy, for example -OCF 3 and -OCCl 3 , halogen, hydroxy, cyano, nitro, aryl, aryloxy, arylthio, heteroaryl, heteroaryloxy, heteroarylthio, heterocyclyl, heterocyclyloxy, heterocyclythio, carbocyclyl, carbocyclyloxy, carbocyclylthio, -NR / R / wherein R ; and R // are the same or different and are hydrogen or C r C 6 alkyl, -COR,
- each R can be the same or different and represents hydrogen or C r C 6 alkyl and each R can be the same or different and represents C r C 6 alkyl, aryl, heteroaryl, heterocyclyl or carbocyclyl, and -S-(C,-C 6 alkyl)-R and -O-(C 1 -C 6 alkyl)-R / wherein each R"' can be the same or different and represents aryl, heteroaryl, heterocyclyl or carbocyclyl.
- Preferred substituents include C r C 6 alkyl, for example methyl and ethyl,
- C r C 6 alkoxy for example methoxy, C r C 6 alkylthio, for example methylthio, C r C 6 haloalkyl, for example -CF 3 and -CC1 3 , C,-C 6 haloalkoxy, for example -OCF 3 and -OCCl 3 , halogen, for example chlorine, cyano, nitro, aryl, for example phenyl, aryloxy, for example phenoxy, arylthio, for example phenylthio and -O-(C,-C 6 alkyl)-R, -S-(C,-C 6 alkyl)-R, -S-(C,-C 6 alkyl)-CONH-R, -CO-R and
- R is an aryl group, for example a phenyl group.
- substituents include phenyl, halogen, for example chlorine, C r C 4 alkyl, for example methyl, -CF 3 , -CC1 3 , -OCF 3 , -OCCl 3 , phenylthio, phenoxy, -S-(C C 4 alkyl)-CONH-phenyl, -S-(C,-C 4 alkyl)-phenyl, -O-(C r C 4 alkyl)-phenyl, -CO-phenyl, cyano, C r C 4 alkylthio, nitro,
- a heteroaryl group may be fused to a said aryl or carbocyclic group or to a further heteroaryl group or to a heterocyclic group.
- fused heteroaryl groups include quinolyl, indolyl, isoindolyl, benzothiophenyl, imidazo[l,2- ]pyridyl and ⁇ -carbolinyl groups.
- a heterocyclic group or moiety is a non-aromatic, saturated or unsaturated cyclic group or moiety containing at least one, for example, one, two or three, heteroatoms selected from N, O and S. Typically, it is a 3- to 6- membered ring. Preferably, it is a 5- or 6- membered ring containing, as heteroatoms, one or two nitrogen atoms.
- Suitable heterocyclic groups and moieties include pyrazolidinyl, piperidyl, piperazinyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolinyl, 3,4-dihydro-2H-pyranyl, tetrahydropyrimidinyl (for example 1,2,3,4- or 1,4,5,6- tetrahydrapyrimidinyl), 2-hydropyridinyl, 2-hydrothiazolyl, tetrahydropyridinyl (for example 1,2,5,6- or 2,3,4,5-tetrahydropyridinyl) and tetrahydropyridazinyl, for example 3 ,4,5 ,6-tetrahydropyridazinyl.
- a heterocyclic group or moiety may be substituted or unsubstituted at any position. Typically, it is unsubstituted or carries 1, 2, 3, 4 or 5 substituents. Suitable substituents include oxo, C C 6 alkyl, C,-C 6 alkylthio, C r C 6 alkoxy, C r C 6 haloalkyl, for example -CF 3 and -CC1 3 , C r C 6 haloalkoxy, for example -OCF 3 and -OCCl 3 , halogen, hydroxy, cyano, nitro, aryl, aryloxy, arylthio, heteroaryl, heteroaryloxy, heteroarylthio, heterocyclyl, heterocyclyloxy, heterocyclythio, carbocyclyl, carbocyclyloxy, carbocyclylthio, -NRR / wherein R' and R /; are the same or different and are hydrogen or C,-C 6 alkyl,
- a heterocyclic group or moiety may be fused to a further said heterocyclic group or to a said carbocyclic, aryl or heteroaryl group. Typically, it is non- fused or is fused to a benzene ring or to an iodole group. Examples of such fused heterocyclic groups include chromanyl and chromonyl groups.
- An aryloxy, heteroaryloxy, heterocyclyloxy or carbocyclyloxy group is typically a said aryl, heteroaryl, heterocyclyl or carbocyclyl group attached to an oxygen atom.
- An arylthio, heteroarylthio, heterocyclylthio or carbocyclylthio group is typically a said aryl, heteroaryl, heterocyclyl or carbocyclyl group attached to a sulphur atom.
- R, and R 2 are the same or different and represent methyl, ethyl, propyl, n-butyl or t-butyl.
- the groups represented by R, and R 2 are unsubstituted or carry one or two substituents.
- substituents for R, and R 2 include C r C 4 alkyl, for example methyl and ethyl, C,-C alkoxy, for example methoxy and ethoxy, halogen, for example chlorine, Cj-C 4 haloalkyl, for example -CF 3 and -CC1 3 and C,-C 4 haloalkoxy, for example -OCF 3 and -OCCl 3 Typically, these substituents are themselves unsubstituted.
- R, and R 2 are methyl or Rj and R 2 together form a n-butylene group.
- Z is methylene, ethylene, propylene or butylene and is preferably propylene.
- Z is unsubstituted, monosubstituted or disubstituted.
- Preferred substituents for Z include C r C 4 alkyl, for example methyl and ethyl, C r C 4 alkoxy, for example methoxy and ethoxy, halogen, for example chlorine, C C 4 haloalkyl, for example -CF 3 and -CC1 3 and C,-C 4 haloalkoxy, for example -OCF 3 and -OCCl 3 .
- these substituents are themselves unsubstituted.
- Particularly preferred substituents for Z are C r C 4 alkyl groups, in particular methyl groups.
- a preferred substituted alkylene group is 2,2-dimethylpropylene.
- the moiety P is -Y-, -XY-, -YW- or -XY -.
- the moiety P is -XYW- or -YW-.
- P is typically an aryl, heteroaryl or heterocyclyl moiety and/or is typically substituted by an aryl, heteroaryl, heterocyclyl or carbocyclyl substituent.
- W is -O- or -NR 3 .
- R 3 is hydrogen or is methyl, ethyl, propyl, n-butyl or t-butyl.
- R 3 is unsubstituted or carries one or two substituents.
- Preferred substituents for R 3 include C,-C 4 alkyl, for example methyl and ethyl, Cj-C 4 alkoxy, for example methoxy and ethoxy, halogen, for example chlorine, C r C 4 haloalkyl, for example -CF 3 and -CC1 3 and C C 4 haloalkoxy, for example -OCF 3 and -OCCl 3 .
- these substituents are themselves unsubstituted.
- R 3 is hydrogen or methyl, most preferably hydrogen.
- V is preferably a direct bond.
- X is typically -NRg-.
- R 6 is typically C r C 4 alkyl, for example methyl, ethyl, propyl, n-butyl and t-butyl, aryl, for example phenyl, or heteroaryl, for example pyridyl.
- R ⁇ is unsubstituted or carries 1, 2 or 3 substituents.
- substituents for R 6 include C r C 4 alkyl, for example methyl and ethyl, C r C 4 alkoxy such as methoxy or ethoxy, halogen, for example fluorine or chlorine, C,-C 4 haloalkyl, for example -CF 3 and -CC1 3 , C,-C 4 haloalkoxy, for example -OCF 3 and -OCCl 3 , cyano, nitro and -NRR / wherein R' and R" are the same or different and are hydrogen or C r C alkyl. Typically, these substituents are themselves unsubstituted.
- X is -NH-.
- the group R 4 has up to 30 carbon atoms and up to 10 heteroatoms selected from N, O and S. Preferably, it has up to 25 carbon atoms and up to 7 heteroatoms.
- the group R 4 contains at least one, preferably at least two, aryl or heteroaryl rings.
- R 4 is C r C 6 alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, -(C,-C 6 alkyl)-aryl, -(C,-C 6 alkyl)-heteroaryl or -COR", -CO 2 R" or -CONR'R" wherein R' is hydrogen or C r C 6 alkyl and R" is an aryl, heteroaryl, carbocyclyl or heteroaryl group.
- R 4 is not a moiety (A) or (B).
- R is: hydrogen, aryl, heteroaryl, 3- to 6- membered heterocyclyl, -(C r C 4 alkyl)-R wherein R is aryl, heteroaryl or 3- to 6- membered heterocyclyl, C r C 4 alkyl, -CONA' 2 , -COA" or -SO 2 A" wherein each A' is the same or different and is selected from H, C,-C 4 alkyl and aryl and each A" is the same or different and is selected from C C 4 alkyl and aryl; and R' 3 and R' 4 are either:
- R 4 is not a 3- or 5- pyrazole or a 3- indazole group when P is a direct bond, -O- or -NH-. More preferably R 4 is not a pyrazole or indazole group when P is a direct bond, -O- or -NH-. More typically, R 4 is not a 3- or 5- pyrazole or a 3- indazole group or, more preferably, a pyrazole or indazole group when P does not contain the moiety U.
- R 4 is a pyridyl, pyrimidyl, thiazolyl or thienyl group.
- R 4 is typically also a pyridyl, pyrimidyl, thiazolyl or thienyl group when P does not contain the moiety U and R 4 is a heteroaryl group.
- Suitable pyridyl, pyrimidyl, thiazolyl and thienyl groups include groups fused to a said aryl or said carbocyclic group or to a said heteroaryl or said heterocyclic group.
- R may be substituted by one or more of the groups mentioned above as appropriate substituents for R 4 .
- Preferred compounds of the invention are those in which X is -NRg- wherein R is as defined above, and R 4 is aryl or heteroaryl.
- P is typically -XYW-.
- Y is typically -CO-.
- W is typically -NR 3 - wherein R 3 is as defined above.
- X is preferably -NH- and/or R 4 is preferably phenyl, thienyl or pyrazolyl.
- R 4 when R 4 is phenyl it is typically substituted by a phenoxy group or by a phenylthio group, in particular a 2-phenoxy or 2-phenylthio group, or by a further phenyl group, in particular a 4-phenyl group.
- R 4 when R 4 is thienyl or pyrazolyl, it is typically substituted by a phenyl or phenylthio group.
- substituents may be unsubstituted or may be further substituted at any position. Typically, they are unsubstituted or carry one, two or three further substituents.
- Preferred further substituents include halogen, for example chlorine and fluorine, C r C alkyl, for example methyl and ethyl, C r C 4 alkoxy, for example methoxy and ethoxy, C,-C 4 haloalkyl, for example -CF 3 and -CC1 3 , and -S(O) 2 NH-phenyl.
- R 4 is preferably
- P is -YW- and R 4 is an aryl, heterocyclyl or heteroaryl group.
- Y is typically -CO-.
- W is typically -NR 3 - wherein R 3 is as defined above.
- R 4 is preferably an oxo-substituted heterocyclic group such as a chromonyl group or is a pyrazolyl, thienyl, phenyl or indolyl group.
- R 4 is typically unsubstituted or substituted by one or more, for example, one, two or three substituents selected from
- C,-C 6 alkyl for example t-butyl, phenyl, thiazolyl, phenylthio, cyano, nitro, C r C 6 alkylthio, for example i-propylthio, C r C 6 alkoxy, halogen such as chlorine and -S-(C C 4 alkyl)-phenyl.
- substituents may be unsubstituted or may be substituted at any position. Typically, they are unsubstituted or carry one, two or three further substituents.
- Preferred further substituents include halogen, for example chlorine, C r C 4 haloalkyl, for example -CF 3 , phenyl and -S(O) 2 -NH-phenyl. These further substituents are typically themselves unsubstituted.
- Additional preferred compounds of the invention are those in which P is -W- or -YW- wherein Y is -CO- and W is -O-.
- Particularly preferred compounds of the invention are compounds of formula
- R ! and R 2 are the same or different and each represent a C r C 6 alkyl group, or Rj and R 2 together form an alkylene group having from 3 to . 6 carbon atoms;
- Z is an alkylene group having from 2 to 4 carbon atoms;
- R 3 is hydrogen or C r C 6 alkyl;
- Y is -CO- or -S(O) 2 -;
- X is a direct bond or -NR ⁇ - wherein R 6 is hydrogen, C r C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl or heteroaryl; and
- R 4 is C,-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, a group -R-A wherein R is -(C,-C 6 alkyl)-, -(C 2 -C 6 alkenyl)- or -(C 2 -C 6 alkynyl)- and A is aryl, heteroaryl, carbocycyl or heterocyclyl, or R 4 is a group -COR' or -CO 2 R' wherein R' is aryl, heteroaryl, carbocyclyl or heterocyclyl.
- Rj and R are methyl or together form a n-butylene group
- R 3 is hydrogen or methyl
- R 4 is as defined in the formula (I) or in the formula (I 7 ) and X is a direct bond or is -NRg- wherein R 6 is as defined above.
- R 4 is as defined as in the above preferred compounds of the invention.
- R 4 is as defined in the above further preferred compounds of the invention.
- the present invention includes pharmaceutically acceptable salts of the compounds of the invention.
- Suitable salts include salts with pharmaceutically acceptable acids, both inorganic acids such as hydrochloric, sulphuric, phosphoric, diphosphoric, hydrobromic or nitric acid and organic acids such as citric, fumaric, maleic, malic, ascorbic, succininc, tartaric, benzoic, acetic, methanesulphonic, ethanesulphonic, benzenesulphonic or p-toluenesulphonic acid. Salts may also be formed with pharmaceutically acceptable bases such as alkali metal (eg sodium or potassium) and alkali earth metal (eg calcium or magnesium) hydroxides and organic bases such as alkyl amines, aralkyl amines or heterocyclic amines.
- inorganic acids such as hydrochloric, sulphuric, phosphoric, diphosphoric, hydrobromic or nitric acid
- organic acids such as citric, fumaric, maleic, malic, ascorbic, succininc
- Particularly preferred compounds of the invention are: l-(3-Dimethylamino-propyl)-3-(2-phenoxy-phenyl)-urea l-[2-(4-Chloro-phenoxy)-pyridin-3-yl]-3-(3-dimethylaminopropyl)-urea l-(3-Dimethylamino-propyl)-3-pyren-l-ylmethyl-urea l-(3-Dimethylamino-propyl)-3-[(lR,2R)-5-phenyl-2-(l-phenyl-methanoyl)- cyclohexyl]-urea l-(3-Dimethylamino-propyl)-3-[2-(4-phenoxy-phenyl)-ethyl]-urea l-(3-Dimethylamino-propyl)-3-[3-methyl-5-(4-methyl-[l,2,3]thiadiazol-5- y
- R 4 is as defined above and U' is a group -UL wherein U is as defined above and L is a hydroxy group or a leaving group such as a halogen atom.
- Compounds of formulae (II) and (III) are known compounds, or may be prepared by analogy with known methods.
- the reaction takes place in the presence of a base such as diisopropylethylamine or the equivalent polymer bound resin N,N- (diisopropyl)amino-methylpolystyrene resin (PS-DIEA), and a coupling agent such as O-(7-azabenzotriazol- 1 -yl)-N,N, N, N-tetramethyluronium hexafluorophosphate (HATU).
- a base such as diisopropylethylamine or the equivalent polymer bound resin N,N- (diisopropyl)amino-methylpolystyrene resin (PS-DIEA)
- PS-DIEA polymer bound resin N,N- (diisopropyl)amino-methylpolystyrene resin
- HATU O-(7-azabenzotriazol- 1 -yl)-N,N, N, N-tetramethyluronium hex
- the work-up typically involves the use of a sequestration enabling reagent such as tetrafluorophthalic anhydride and polymer bound scavenger resins to remove unwanted starting materials.
- a sequestration enabling reagent such as tetrafluorophthalic anhydride and polymer bound scavenger resins.
- R 4 is as defined above.
- the reaction takes place in a hydrocarbon solvent such as toluene at a temperature of from 0 to 100 °C.
- a hydrocarbon solvent such as toluene
- the work-up typically involves the use of a sequestration enabling reagent such as tetrafluorophthalic anhydride and polymer bound scavenger resins to remove unwanted starting materials.
- the amides thereby prepared may be converted to the corresponding amidines by standard methods.
- the compounds of formula (IV) may be prepared by techniques known in the art. For example, they may be prepared by reacting a compound of formula (V)
- R 4 , X and U are as defined above and L is a hydroxy group or leaving group such as a 4-nitro-phenoxy group.
- the reaction takes place in a hydrocarbon solvent such as tetrahydrofuran at a temperature of from 60 to 70 °C.
- the work-up typically involves the use of a sequestration enabling reagent such as tetrafluorophthalic anhydride and polymer bound scavenger resins to remove unwanted starting material.
- the compounds of formula (NI) are known compounds or may be prepared by analogy with known methods.
- compounds of formula (VI) in which U is -CO- can be prepared by reacting a compound of formula (VII)
- a chloroformate for example an aromatic chloroformate such as 4-nitrophenyl chloroformate.
- the reaction takes place under reflux, in a solvent such as anhydrous THF.
- R 4 is other than -COR", -CO 2 R", S(O) 2 R" and -CONR'R" and X is as defined above, with a compound of formula (IX)
- Y, Z, Rj and R 2 are as defined above and L represents a hydroxy group or a leaving group such as a halogen.
- the reaction is typically conducted in the presence of a base at from -78°C to the reflux temperature of the solvent.
- R , X and U are as defined above and L represents a hydroxy group or a leaving group such as a halogen, with a compound of formula (XI) HWZNR,R 2 (XI)
- A is -X- or -W-, wherein X and W are as defined above and R 4 is other than -COR", -CO 2 R", -S(O) 2 R" and -CONR'R", with a compound of formula (XIII)
- reaction can be conducted under standard conditions. Typically, it takes place in the presence of a base in a solvent such as
- the compounds of formula (XII) are known compounds or may be prepared by analogy with known methods.
- the compounds of formula (XIII) are also known compounds or may be prepared by analogy with known methods. For example, they can be prepared from a corresponding compound of formula HO-Z-NR ⁇ by reaction with triflic anhydride or with PC1 5 .
- HA-Z-NR,R 2 (IXV) wherein A, Z, R, and R 2 are as defined above, with R 4 -L, wherein R ⁇ is as defined above and L is a hydroxy group or a leaving group, for example a halogen.
- the reaction can be conducted under standard conditions, such as those given above for the reaction of compounds of formulae (Vffl) and (IX).
- R 4 is aryl or heteroaryl, and a compound of formula (XVI)
- L is a hydroxy group, a group OR wherein R is alkyl, or a halogen, for example chlorine, and Z, V, R ⁇ and R 2 are as defined above.
- the reaction can be performed under conventional conditions, in the presence of a catalyst such as A1C1 3 .
- R 4 is as defined above, Y' is -U- or -X-U-, and L is a hydroxy group or a leaving group, for example a halogen atom, with an organometallic compound of formula (XVIII)
- B is -V-Z- wherein V and Z are as defined above, Rj and R 2 are as defined above and M is a metal-containing moiety such as Li or -MgX wherein X is a halogen atom such as bromine.
- M in the formula (XVIII) is Li.
- M in the formula (XVIII) is -MgX, it may be necessary to conduct the reaction at around -78 °C and to use a large excess of the compound of formula (XVII).
- the compounds of formula (XVII) are known compounds or may be prepared by analogy with known methods.
- the compounds of formula (XVIII) are also known compounds or may be prepared by analogy with known methods.
- compounds of formula (XVIII) in which M is Li can be prepared by reacting a corresponding compound of formula Br-B-N ⁇ with lithium or with magnesium.
- R 4 -P-L (IXX) wherein R 4 and P are as defined above and L is a leaving group such as a halogen atom or a triflate group, with a compound of formula (XX)
- the reaction can be conducted under conventional conditions. Typically, it is conducted in the presence of a base. If necessary, the NR]R 2 group can be protected during the reaction by conventional means.
- the compounds of formulae (IXX) and (XX) are knowN compounds, or may be prepared by analogy with known methods.
- the compounds of formula (IXX) can be prepared by reacting a corresponding compound of formula R 4 -P-OH with triflic anhydride or PC1 5 .
- Compounds in which P is a direct bond can be prepared by conventional synthetic techniques.
- a compound of the invention can, of course, be converted to a different compound of the invention by standard functional group intercon versions known to those of skill in the art.
- compositions of formula (I) may be prepared by salifying a compound of formula (I) with an appropriate acid or base.
- the compounds of the invention are activators of sGC. They can be used as selective sGC activators.
- a compound of the invention can therefore be used as a vasodilator or to inhibit platelet aggregation. It can be used for the treatment or prevention of peripheral vascular diseases such as hypertension, angina pectoris, arteriosclerosis, or for the treatment or prevention of glaucoma, preeclampsia, Raynaud's Syndrome, stroke or erectile dysfunction. Further, the compounds of the invention are effective in improving ocular blood flow.
- ASD age-related macular degeneration
- AMD age-related macular degeneration
- sGC vascular endothelial growth factor
- the present invention also provides a compound of formula (I), as defined above, or a pharmaceutically acceptable salt thereof, for use in the treatment of the human or animal body, wherein R,, R 2 , Z, R 3 , Y, X and R 4 are as defined above.
- the compounds of the invention may be administered in a variety of dosage forms. Thus, they can be administered orally, for example as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules.
- the compounds of the invention may also be administered parenterally, either subcutaneously, intravenously, intramuscularly, intrasternally, transdermally or by infusion techniques.
- the compounds may also be administered as suppositories.
- a compound of the invention is typically formulated for administration with a pharmaceutically acceptable carrier or diluent.
- solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents; e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g.
- Such pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tabletting, sugar-coating, or film coating processes.
- Liquid dispersions for oral administration may be syrups, emulsions and suspensions.
- the syrups may contain as carriers, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.
- Suspensions and emulsions may contain as carrier, for example a natural gum, agar, sodium alginte, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.
- the suspensions or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and if desired, a suitable amount of lidocaine hydrochloride.
- Solutions for intravenous or infusions may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions.
- a therapeutically effective amount of a compound of the invention is administered to a patient.
- a typical daily dose is from about 0.1 to 50 mg per kg of body weight, according to the activity of the specific compound, the age, weight and conditions of the subject to be treated , the type and severity of the disease and the frequency and route of administration.
- daily dosage levels are from 5 mg to 2 g. The Examples which follow illustrate the invention.
- Tetrafluorophthalic anhydride (65 mg, 0.3 mmol) was then added and the reaction mixture was shaken under nitrogen for 18 hours.
- Macroporous triethylammonium methylpolystyrene carbonate resin (MP-carbonate), (610 mg, 1.96 mmol, loading 3.18 mmol/g) was then added and the reaction mixture was shaken under nitrogen for a further 48 hours.
- the reactions were then filtered through filter syringes into vials and washed with methanol. The solvent was removed on a vacuum concentrator and each product was weighed and analysed by LC-MS.
- Examples 70 to 99 The aryl acid (different for each reaction) (0.1 mmol) was stirred under nitrogen in anhydrous toluene (2 mL) and heated to 50 °C. Triethylamine (10 mg, 0.1 mmol) dissolved in 1 L of anhydrous toluene was then added. The temperature was raised to 80 °C and diphenylphosphorylazide (DPP A), (27.0 mg, 0.1 mmol) was added. The reaction was kept at this temperature for 1 hour then cooled to room temperature while still stirring under nitrogen.
- DPP A diphenylphosphorylazide
- the reaction mixture was cooled to room temperature and tetrafluorophthalic anhydride (191.0 mg, 0.87 mmol) was added.
- the reaction was stirred at room temperature under nitrogen for 1 hour, then 6 equivalents of tris-(2-aminoethyl)amine polystyrene resin (PS-trisamine), (500 mg, 1.74 mmol, loading 3.5 mmol/g) was added and the reaction stirred for 2 hours.
- PS-trisamine tris-(2-aminoethyl)amine polystyrene resin
- Example 100 Prepared as in Example 100 using 4-nitrophenyl chloroformate (77.2 mg, 0.38 mmol), 4-bromoaniline (30.0 mg, 0.174 mmol) and triethylamine (38.8 mg, 0.38 mmol) to form the intermediate followed by 3-(dimethylamino)propylamine (26.6 mg, 0.26 mmol) to form the desired product. Work-up as in Example 100. The crude product was purified by flash chromatography using MeOH/CHCl 3 (40:60).
- Example 100 Prepared as in Example 100 using 4-nitrophenyl chloroformate (87.0 mg, 0.436 mmol), 4-bromoaniline (50.0 mg, 0.29 mmol) and triethylamine (44.0 mg, 0.436 mmol) refluxed for 5 hours in anhydrous THF (20mL) to form the intermediate. Then N,N,N-trimethyl-l,3-propanediamine (50.5 mg, 0.436 mmol) was added and the reaction mixture refluxed for 18 hours to form the title compound. Work-up as in Example 100.
- Example 100 Prepared as in Example 100 using 4-nitrophenyl chloroformate (45.5 mg, 0.226 mmol), 5-phenyl- ⁇ -anisidine (30.0 mg, 0.151 mmol) and triethylamine (22.8 mg, 0.226 mmol) refluxed in anhydrous THF (20 mL) for 18 hours to form the intermediate followed by 3-(dimethylamino)-propylamine (23.1 mg, 0.226 mmol) and refluxed for a further 5 hours to form the title compound. Work-up as in
- Example 105 l-(3- ⁇ itrophenyl)-l-benzyl-3-(3-dimethylamino propyl) urea (CFM2270) Prepared as in Example 100 using 4-nitrophenyl chloroformate (66.0 mg, 0.328 mmol), N-benzyl-3-nitroaniline (50.0 mg, 0.219 mmol) and triethylamine (33.0 mg,
- Example 106 l-Benzyl-l-(4-methyI-3-pyridinyl)-3-(3-dimethylamino propyl) urea (CFM2271) Prepared as in Example 100 using 4-nitrophenyl chloroformate (76.0 mg, 0.378 mmol), 2-benzylamino-4-methyl-pyridine (50.0 mg, 0.25 mmol) and triethylamine (38.0 mg, 0.378 mmol) refluxed in anhydrous THF (20 mL) for 5 hours to form the intermediate followed by 3-(dimethylamino)propylamine (38.0 mg, 0.378 mmol) and refluxed for a further 18 hours to form the desired product. Work-up as in Example 100. The crude product was purified by flash chromatography using a gradient from 10 to 50 % MeOH (in CHC1 3 ) to give the title compound.
- Example 100 Prepared as in Example 100 using 4-nitrophenyl chloroformate (62.0 mg, 0.308 mmol), N-methyl-3,5-bis(trifluoromethyl)aniline (50.0 mg, 0.206 mmol) and triethylamine (31.0 mg, 0.308 mmol) refluxed in anhydrous THF (20 mL) for 5 hours to form the intermediate followed by 3-(dimethylamino)propylamine (31.5 mg, 0.308 mmol) and refluxed for a further 18 hours to form the desired product. Work-up as in Example 100. The crude product was purified by flash chromatography using a gradient from 10 to 40 % MeOH (in CHC1 3 ) to give the title compound.
- Example 109 4-Nitrophenyl chloroformate (61.5 mg, 0.31 mmol), 5-chloro-2-(methylamino)- benzophenone (50.0 mg, 0.20 mmol) and triethylamine (30.80 mg, 0.31 mmol) were refluxed for 5 hours in anhydrous THF (20 mL) as in Example 100 to form the intermediate. Then 3-(dimethylamino)-propylamine (32.0 mg, 0.31 mmol) was added and the mixture was refluxed for a further 5 hours to form the desired product. Work-up as in Example 100. The crude product was purified by flash chromatography using a gradient from 10 - 40% MeOH (in CHC1 3 ) to give the title compound.
- Example 109 l-(2-Chloro-4-trifluoromethylphenyl)-3-(3-dimethylaminopropyl) urea
- Example 100 4-Nitrophenyl chloroformate (77.0 mg, 0.39 mmol), 4-amino-3-chloro- benzotrifluoride (50.0 mg, 0.26 mmol) and triethylamine (38.0 mg, 0.39 mmol) were refluxed for 18 hours in anhydrous THF (20 mL) as in Example 100 to form the intermediate. Then 3-(dimethylamino)-propylamine (38.0 mg, 0.39 mmol) was added and the mixture was refluxed for a further 5 hours to form the desired product. Work-up as in Example 100. The crude product was purified by flash chromatography using a gradient from 10 - 40% MeOH (in CHC1 3 ) to give the title compound.
- Example 100 4-Nitrophenyl chloroformate (84.0 mg, 4.19 mmol), 3-amino-5- fluorobenzotrifluoride (50.0 mg, 0.28 mmol) and triethylamine (42.0 mg, 4.19 mmol) were refluxed for 18 hours in anhydrous THF (20 mL) as in Example 100 to form the intermediate. Then 3-(dimethylamino)-propylamine (42.0 mg, 4.19 mmol) was added and the mixture was refluxed for a further 5 hours to form the desired product. Work-up as in Example 100. The crude product was purified by flash chromatography using a gradient from 10 - 40% MeOH (in CHC1 3 ) to give the title compound.
- Example 112 4-Nitrophenyl chloroformate (3.13 g, 15.54 mmol), 3-amino-l-(N-tert-butoxy- carbonyl)benzylamine (2.30 g, 10.36 mmol) and triethylamine (1.56 g, 15.54 mmol) was refluxed for 18 hours in anhydrous THF (100 mL) as in Example 100 to form the intermediate. Then 3-(dimethylamino)propylamine (1.58 g, 15.54 mmol) was added and the mixture was refluxed for a further 5 hours to form the desired product. Work-up same as in Example 100. The crude product was purified by flash chromatography using a gradient from 10 - 40% MeOH (in CHC1 3 ) to give the title compound.
- Example 112 4-Nitrophenyl chloroformate (3.13 g, 15.54 mmol), 3-amino-l-(N-tert-butoxy- carbonyl)benzylamine
- N-(3-Dimethylamino-propyl)-2-[l-(4-fluorobenzoyl]-benzamide (CFM2262) 2-(4-Fluorobenzoyl)benzoic acid (1.25 g, 5.12 mmol), N,N-(diisopropyl)amino- methylpolystyrene resin (PS-DIEA), (4.30 g, 15.36 mmol), and O-(7-azabenzotriazol-l- yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (HATU) (1.95 g, 5.12 mmol) was stirred in anhydrous acetonitrile (50 mL) at room temperature under nitrogen for 5 minutes.
- PS-DIEA N,N-(diisopropyl)amino- methylpolystyrene resin
- HATU O-(7-azabenzotriazol-
- 2-(4-Chlorobenzoyl)-benzoic acid (1.25 g, 4.80 mmol), N,N-(diisopropyl)amino- methylpolystyrene resin (PS-DIEA), (4.00 g, 14.38 mmol), and O-(7- azabenzotriazol- 1 -yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (HATU) (1.82 g, 4.80 mmol) was stirred in anhydrous acetonitrile (50 mL) at room temperature under nitrogen for 5 minutes.
- PS-DIEA N,N-(diisopropyl)amino- methylpolystyrene resin
- HATU O-(7- azabenzotriazol- 1 -yl)-N,N,N,N-tetramethyluronium hexafluorophosphate
- 2-(2-Phenylsulfamoyl-phenylsulfanyl)-benzoic acid (1.10 g, 2.60 mmol), NN- (diisopropyl)amino-methylpolystyrene resin (PS-DIEA), (2.18g, 7.78 mmol), and O- (7-azabenzotriazol-l -yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (HATU) (0.98 g, 2.6 mmol) was stirred in anhydrous acetonitrile (50 mL) at room temperature under nitrogen for 5 minutes.
- PS-DIEA diisopropyl)amino-methylpolystyrene resin
- HATU O- (7-azabenzotriazol-l -yl)-N,N,N,N-tetramethyluronium hexafluorophosphate
- 2-Phenoxybenzoic acid (1.50 g, 7.00 mmol) was stirred in anhydrous toluene (50 mL) at 50 °C under nitrogen.
- triethylamine (0.71 g, 7.00 mmol) and the temperature was increased to 80 °C at which stage diphenylphosphorylazide (DPP A) (1.92 g, 7.00 mmol) was added and the mixture was left to stir at this temperature for 5 hours.
- DPP A diphenylphosphorylazide
- 3- (dimethylamino)propylamine (0.71 g, 7.00 mmol) was added and the mixture was left to stir at 80 °C overnight under nitrogen.
- Activity Example 1 Compounds of the invention were assayed to determine their ability to activate sGC.
- the assay employed was an enzyme immunoassay to measure changes in cGMP.
- IBMX enzyme immunoassay to measure changes in cGMP.
- To perform the assay recombinant soluble Guanylate cyclase was added to 1.1 mg/ml IBMX, 2.6 mg/ml GTP, 667 nM DeaNO and the test compound (lO ⁇ M). The mixture was then incubated at room temperature for 10 minutes.
- Compounds were formulated in DMSO diluted in Tris HCI (pH 7.4) buffer and with a final DMSO concentration of ⁇ 0.5%.
- BiotrakTM cGMP enzyme immunoassay system commercially available from AmershamTM was used.
- the assay is based on the competition between unlabelled cGMP and a fixed quantity of peroxidase labelled cGMP for a limited amount of cGMP specific antibody.
- the peroxidase ligand that is bound to the antibody is immobilised on precoated microtitre wells.
- the amount of labelled cGMP is determind using a one pot stabilised substrate.
- the concentration of unlabelled cGMP in a sample is determined by interpolation from a standard curve.
- Tables 4 to 7 The results are shown in Tables 4 to 7.
- Tables 6 and 7 relate to commercially available compounds.
- IC 50 values were measured as set out below.
- PGI 2 (0.15 ⁇ g/ml) added and centrifuged at 950 g for 10 mins to sediment the platelets.
- the resultant platelet poor plasma (PPP) was discarded and the platelet pellet was resuspended in an equal volume of Tyrodes buffer by gently pipetting up and down.
- the suspension was centrifuged at 870 g for lOmins at 4 °C.
- the supernatant was discarded and the platelet pellet was resuspended in an equal volume of Tyrodes buffer as before.
- the platelets were counted (using a Coulter Counter model T540 (address)) and normalised to 250,000cells/ ⁇ l using Tyrodes.
- the resultant suspension was placed on ice for approximately 1 hour until use.
- Platelet A says Platelet aggregation was monitored using either a Chrono-Log model 560-CA dual channel ormodel 570-4S four channel aggregometer (Chrono-Log Co ., Havertown, PA). Aggregation was analysed by using 0.5 mL aliquots of the platelet suspension at 37 °C using % light transmittance.
- the amplitude of each aggregatory response was used to plot dose-response curves.
- the concentration of drug that inhibited collagen-induced platelet aggregation by 50% (IC 50 ) was calculated from the dose-response curves.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Vascular Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pyridine Compounds (AREA)
- Furan Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Indole Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the activation of soluble guanylate cyclase, wherein: R1 and R2 are the same or different and each represent a C1-C6 alkyl group, or R1 and R2 together form a C3-C6 alkylene group; Z is a C1-C4 alkylene group; P is a direct bond or a moiety -X-, -Y-, -W-, -XY-, -YW- or -XYW-, wherein; W is -O-, -S-, or -NR3, wherein R3 is hydrogen or C1-C6 alkyl; Y is a moiety -U-V- wherein V is a direct bond or a C1-C6 alkylene group and U is -CS-, -CO-, -S(O)2- or -C(=NR)- wherein R is hydrogen, hydroxy or C1-C6 alkyl; X is -O- or -NR6- wherein R6 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl or heteroaryl; and R4 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, a group -R-A wherein R is -(C1-C6 alkyl)-, -(C2-C6 alkenyl)- or -(C2-C6 alkynyl)- and A is aryl, heteroaryl, carbocyclyl or heterocyclyl, or R4 is a group -COR', -CO2R', -S(O)2R' or -CONR'R' wherein R' is hydrogen, C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl and R' is aryl, heteroaryl, carbocyclyl or heterocyclyl.
Description
ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE
This invention relates to activators of soluble guanylate cyclase (sGC), to their preparation and to their use.
Soluble guanylate cyclase is responsible for the enzymatic conversion of guanosine-5'-triphosphate (GTP) to cyclic guanosine-3',5'-monophosphate (cGMP).
The enzyme is stimulated by NO binding to the enzyme. sGC is responsible for numerous physiological processes including vascular and non-vascular smooth muscle relaxation, peripheral and central neurotransmission, platelet reactivity and phototransduction (Hobbs A.J., TiPS, December 1997, Vol 18, p.484). Activators of sGC can therefore be expected to have valuable therapeutic properties.
As explained above, NO is known as an activator of sGC. However, this compound has a number of different physiological effects and its use in activating sGC therefore suffers from a myriad of side effects. There is therefore a need for selective activators of sGC.
3-(5'-hydroxymethyl-2'-furyl)-l-benzylindazole (YC-1) is a known NO independent activator of sGC (Hobbs, A.J., TiPS, December 1997, Vol 18, p.484). However, the activation achieved is not high.
Accordingly, the present invention provides the use of a compound of the formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the activation of soluble guanylate cyclase
** \ P κz\ NRιR2 a)
wherein:
R, and R2 are the same or different and each represent a C,-C6 alkyl group, or R, and R2 together form a C3-C6 alkylene group;
Z is a C,-C4 alkylene group;
P is a direct bond or a moiety -X-, -Y-, -W-, -XY-, -YW- or -XYW-, wherein:
W is -O-, -S-, or -NR3, wherein R3 is hydrogen or CrC6 alkyl;
Y is a moiety -U-V- wherein V is a direct bond or a C,-C6 alkylene group and U is -CS-, -CO-, -S(O)2- or -C(=NR)- wherein R is hydrogen, hydroxy or C,-C6 alkyl; X is -O- or -N g- wherein Rg is hydrogen, CrC6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl or heteroaryl; and
R4is CrC6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, a group -R-A wherein R is -(C,-C6 alkyl)-, -(C2-C alkenyl)- or -(C2-C6 alkynyl)- and A is aryl, heteroaryl, carbocycyl or heterocyclyl, or R4 is a group -COR'*', -CO^, -S(O)2R or -CONR'R" wherein R' is hydrogen, CrC6 alkyl, C2-C6 alkenyl or
C2-C6 alkynyl and R" is is aryl, heteroaryl, carbocyclyl or heterocyclyl. In the moiety P, the moiety -X-, when present, is attached to R4 and the moiety W, when present, is attached to Z. In the moiety Y, the moiety V is attached to W or, if W is not present, to Z, and the moiety U is attached to X or, if X is not present, to R4.
As used herein, a C,-C6 alkyl group or moiety is a linear or branched alkyl group or moiety. Suitable alkyl groups and moieties include CrC4 alkyl groups and moieties, for example, methyl, ethyl, n-propyl, i-propyl, n-butyl and t-butyl. Methyl, ethyl, n-propyl and t-butyl are preferred.
A CrC6 alkyl group or moiety can be substituted or unsubstituted at any position. Typically, it is unsubstituted or carries 1, 2 or 3 substituents. Suitable substituents include CrC6 alkyl, CrC6 alkylthio, CrC6 alkoxy, C,-C6 haloalkyl, for example -CF3 and -CC13, CrC6 haloalkoxy, for example -OCF3 and -OCCl3, halogen, hydroxy, cyano, nitro, aryl, aryloxy, arylthio, heteroaryl, heteroaryloxy, heteroarylthio, heterocyclyl, heterocyclyloxy, heterocyclythio, carbocyclyl, carbocyclyloxy, carbocyclylthio, oxo, -NR/R wherein R7 and R" are the same or different and are hydrogen or CrC6 alkyl, =NR, -COR, -CONR/R, -CO2R, -NR/COR, -NR/CO2R, -NR/CONR/R, -S(O)2R and -S(O)2NR/R wherein each R, can be the same or different and represents hydrogen or CrC6 alkyl and each R can be the same or different and represents CrC6 alkyl, aryl, heteroaryl, heterocyclyl or carbocyclyl, and
-S-(CrC6 alkyl)-Rwand -O-(C,-C6 alkyl)-Rw wherein each R"' can be the same or different and represents aryl, heteroaryl, heterocyclyl or carbocyclyl. Further, two substituents on the same atom can, together with the atom to which they are attached, form a carbocyclyl or heterocyclyl group. Preferred substituents include oxo, halogen, C,-C6 alkyl, aryl, arylthio, aryloxy, heteroaryl, heteroarylthio, heteroaryloxy and -NRR/, =N-R, -CONHR and -NHCO2R wherein R, R7 and R are as defined above. Further, two preferred substituents on the same carbon atom may, together with the atom to which they are attached, form a carbocyclyl group, preferably a C3-C6 cycloalkyl group. More preferred substituents are oxo, halogen, for example chlorine and fluorine, CrC4 alkyl, for example methyl, ethyl or t-butyl, aryl, for example phenyl, -CONH-aryl, for example -CONH-phenyl, =N-aryl, for example =N-phenyl, -NH- CO2-(CrC4 alkyl), heteroarylthio, for example pyrimidinethio and -CO-aryl, for example -CO-phenyl. It is also preferred that two substituents on the same carbon atom may, together with the atom to which they are attached, form a C3-C6 cycloalkyl group.
As used herein, a C2-C6 alkenyl group or moiety is a linear or branched alkenyl group or moiety. Suitable alkenyl groups and moieties include C2-C4 alkenyl groups and moieties such as ethenyl, propenyl and butenyl groups and moieties. Ethenyl and propenyl are preferred. A C2-C6 alkenyl group or moiety may be substituted or unsubstituted at any position.
A C2-C6 alkenyl group is typically unsubstituted or carries 1, 2, 3 or 4 substituents. Preferably, it carries at least two substituents. Suitable substituents include oxo, CrC6 alkyl, CrC6 alkylthio, CrC6 alkoxy, C]-C6 haloalkyl, for example -CF3 and -CC13, CrC6 haloalkoxy, for example -OCF3 and -OCCl3, halogen, hydroxy, cyano, nitro, aryl, aryloxy, arylthio, heteroaryl, heteroaryloxy, heteroarylthio, heterocyclyl, heterocyclyloxy, heterocyclythio, carbocyclyl, carbocyclyloxy, carbocyclylthio, -NR'R" wherein R' and R/ are the same or different and are hydrogen or CrC6 alkyl, =N-R, -COR, -CONR/R, -CO2R, -NR/COR, -NR/CO2R, -NR/CONR/R, -S(O)2R and -S(O)2NR/R wherein each R, can be the same or different and represents hydrogen or CrC6 alkyl and each R can be the same or
different and represents CrC6 alkyl, aryl, heteroaryl, heterocyclyl or carbocyclyl, and -S-(C,-C6 alky -R^ and -O-(C,-C6 alkylJ-R'" wherein each R"' can be the same or different and represents aryl, heteroaryl, heterocyclyl or carbocyclyl. Further, two substituents on the same atom can, together with the atom to which they are attached, form a carbocyclyl or heterocyclyl group.
Preferred substituents include oxo, halogen, C,-C6 alkyl, aryl, arylthio, aryloxy, heteroaryl, heteroarylthio, heteroaryloxy and -NRR , =N-R, -CONHR and -NHCO2R wherein R, R; and R/ are as defined above. Further, two preferred substituents on the same carbon atom may, together with the atom to which they are attached, form a carbocyclyl group, preferably a C3-C8 cycloalkyl group.
More preferred substituents are halogen, for example chlorine and fluorine, CrC4 alkyl, for example methyl, ethyl or t-butyl, aryl, for example phenyl, heteroaryl, for example furanyl, -CONH-aryl, for example -CONH-phenyl, -NH- CO2-(C,-C4 alkyl), -NH-CO-(C,-C4 alkyl), -NH-CO-aryl, for example -NH-CO- phenyl, heteroarylthio, for example pyrimidinethio and -CO-aryl, for example -CO- phenyl. It is also preferred that two substituents on the same carbon atom may, together with the atom to which they are attached, form a C3-C8 cycloalkyl group.
A C2-C6 alkynyl group or moiety is typically an ethynyl, propynyl or butynyl group or moiety. It may be substituted or unsubstituted at any position. Typically, it is unsubstituted or carries 1 or 2 substituents. Suitable substituents include CrC6 alkyl, C,-C6 alkylthio, CrC6 alkoxy, CrC6 haloalkyl, for example -CF3 and -CC13, CrC6 haloalkoxy, for example -OCF3 and -OCCl3, halogen, hydroxy, cyano, nitro, aryl, aryloxy, arylthio, heteroaryl, heteroaryloxy, heteroarylthio, heterocyclyl, heterocyclyloxy, heterocyclythio, carbocyclyl, carbocyclyloxy, carbocyclylthio, -NR/R/ wherein R' and R/ are the same or different and are hydrogen or CrC6 alkyl, -
COR, -CONR/R, -CO2R, -NR/COR, -NR/CO2R, -NR/CONR/R, -S(O)2R and -S(O)2NR/R wherein each R/ can be the same or different and represents hydrogen or CrC6 alkyl and each R can be the same or different and represents CrC6 alkyl, aryl, heteroaryl, heterocyclyl or carbocyclyl, and -S-(CrC6 alkyl)-R// and -O-(Cj-C6 alkyl)-R wherein each R"1 can be the same or different and represents aryl, heteroaryl, heterocyclyl or carbocyclyl. Further, two substituents on the same
atom can, together with the atom to which they are attached, form a carbocyclyl or heterocyclyl group.
Preferred substituents include halogen, CrC6 alkyl, aryl, arylthio, aryloxy, heteroaryl, heteroarylthio, heteroaryloxy and -CONHR and -NHCO2R wherein R is as defined above. Further, two preferred substituents on the same carbon atom may, together with the atom to which they are attached, form a carbocyclyl group, preferably a C3-C6 cycloalkyl group.
More preferred substituents are halogen, for example chlorine and fluorine, CrC4 alkyl, for example methyl, ethyl or t-butyl, aryl, for example phenyl, -CONH-aryl, for example -CONH-phenyl, -NH-CO2-(C ,-C4 alkyl), heteroarylthio, for example pyrimidinethio and -CO-aryl, for example -CO-phenyl. It is also preferred that two substituents on the same carbon atom may, together with the atom to which they are attached, form a C3-C6 cycloalkyl group.
A C,-C6 alkoxy group is typically a said C,-C6 alkyl group attached to an oxygen atom. A C,-C6 alkylthio group is typically a said C,-C6 alkyl group attached to a sulphur atom.
As used herein, a said alkylene group is a divalent alkyl moiety. It may be unsubstituted or substituted at any position. Typically, it is unsubstituted or monosubstituted. Suitable substituents include halogen, for example chlorine and flourine, hydroxy, C C4 alkyl such as methyl and ethyl, C C alkoxy, for example methoxy, CrC4 haloalkyl, for example -CF3 and -CC13 and CrC4 haloalkoxy, for example -OCF3 and -OCCl3. These substituents are typically themselves unsubstituted.
A halogen is typically chlorine, fluorine, bromine or iodine. It is preferably chlorine.
A haloalkyl or haloalkoxy group is typically a said alkyl or alkoxy group substituted by one or more said halogen atoms. Typically, it is substituted by 1, 2 or 3 said halogen atoms. Preferred haloalkyl and haloalkoxy groups include perhaloalkyl and perhaloalkoxy groups such as -CX3 and -OCX3 wherein X is a said halogen atom. Particularly preferred haloalkyl groups are CF3 and CC13. Particularly preferred haloalkoxy groups are -OCF3 and -OCCl3.
As used herein, an aryl group or moiety is typically a C6-C20 aryl group or moiety. Suitable such aryl groups and moieties include phenyl, naphthyl and pyrenyl. Phenyl and pyrenyl are preferred.
An aryl group or moiety may be substituted or unsubstituted at any position. Typically, it is unsubstituted or carries 1, 2, 3 or 4 substituents. Suitable substituents include C,-C6 alkyl, CrC6 alkylthio, CrC6 alkoxy, CrC6 haloalkyl, for example -CF3 and -CC13, - haloalkoxy, for example -OCF3 and -OCCl3, halogen, cyano, hydroxy, nitro, aryl, aryloxy, arylthio, heteroaryl, heteroaryloxy, heteroarylthio, heterocyclyl, heterocyclyloxy, heterocyclythio, carbocyclyl, carbocyclyloxy, carbocyclylthio, -NRR wherein R' and R" are the same or different and are hydrogen or C,-C6 alkyl, -COR, -CONR/R, -CO2R, -NR/COR, -NR/CO2R, -NR/CONR/ R, -S(O)2R and -S(O)2NR/R wherein each R7 can be the same or different and represents hydrogen or C C6 alkyl and each R can be the same or different and represents C,-C6 alkyl, aryl, heteroaryl, heterocyclyl or carbocyclyl, and -S-(C,-C6 alkyl)-R and -O-(C,-C6 alkyl)-R wherein each R/ can be the same or different and represents aryl, heteroaryl, heterocyclyl or carbocyclyl.
Preferred substituents include C C6 alkyl, for example methyl and ethyl, CrC6 alkoxy, for example methoxy, CrC6 alkylthio, for example methylthio, C,-C6 haloalkyl, for example -CF3 and -CC13, CrC6 haloalkoxy, for example -OCF3 and -OCCl3, halogen, for example chlorine and fluorine, nitro, cyano, aryl, for example phenyl, aryloxy, for example phenyloxy, arylthio, for example phenylthio, heteroaryl, heteroaryloxy, heteroarylthio, heterocyclyl, -NRR/ wherein Rf and R are the same or different and are hydrogen or C,-C6 alkyl, -CONH-(C,-C6 alkyl), -NHCONH-R wherein R is aryl, for example phenyl, or heteroaryl, -S(O)2NHR wherein R' is aryl, for example phenyl, or heteroaryl, -S-(CrC6 alkyl)-R/ wherein R// is aryl, for example phenyl, or heteroaryl and -COR// wherein R is heterocycyl, heteroaryl or aryl.
Particularly preferred substituents are phenyl, in particular 4-phenyl, phenoxy, in particular 2-phenoxy, phenylthio, halogen, -CF3, -CC13, nitro, cyano, -OCF3, -OCCl3, C,-C4 alkyl, C,-C4 alkoxy, C,-C4 alkylthio, -CONH-(C,-C4 alkyl),
-CO-phenyl, -S(O)2NH-phenyl, -S-(C,-C4 alkyl)-phenyl, -S-(CrC4 alkyl)-pyrazole,
-S-(C,-C4 alkyl)-pyrimidine, -(CrC4 alkyl)-NH-CO2-(C,-C4 alkyl), thiazole, -COR wherein R is be zothiophenyl or β-carbolinyl and -NH-(CH2)nNRR/ wherein n is from 2 to 4 and R' and R// are the same or different and are CrC4 alkyl.
An aryl group or moiety may be fused to a further said aryl group or to a carbocyclic, heterocyclic or heteroaryl group. For example, an aryl group may be fused to a pyridine ring to form a quinoline or isoquinoline group, or to a furan ring. It may also, for example, be fused to a cyclopropyl or cyclohexyl group or to a tetrahydro furyl group, a 1,4-dioxolane group or a pyrimidone ring, for example a 4- pyrimidone ring. As used herein, a carbocyclic group or moiety is a non-aromatic, saturated or unsaturated carbocyclic group or moiety. Typically, it has from 3 to 10, for example from 3 to 8, carbon atoms. Preferably, it has from 3 to 8, for example 3 to 6, carbon atoms. Examples of suitable carbocyclic groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclopetadienyl, cyclohexyl, cyclohexenyl and cyclooctanyl groups. Preferred carbocyclic groups include cyclohexyl, cyclooctanyl and cyclohexenyl groups.
A carbocyclic group or moiety may be unsubstituted or substituted at any position. Typically, it carries up to 3 substituents. Suitable substituents include oxo, C,- alkyl, C,-C6 alkylthio, CrC6 alkoxy, C C6 haloalkyl, for example -CF3 and - CC13, C,-C6 haloalkoxy, for example -OCF3 and -OCCl3, halogen, hydroxy, cyano, nitro, aryl, aryloxy, arylthio, heteroaryl, heteroaryloxy, heteroarylthio, heterocyclyl, heterocyclyloxy, heterocyclythio, carbocyclyl, carbocyclyloxy, carbocyclylthio, - NRR wherein R' and R" are the same or different and are hydrogen or CrC6 alkyl, =NR, -COR, -CONR/R, -CO2R, -NR/COR, -NR/CO2R, -NR/CONR/R, -S(O)2R and -S(O)2NR/R wherein each R, can be the same or different and represents hydrogen or CrC6 alkyl and each R can be the same or different and represents CrC6 alkyl, aryl, heteroaryl, heterocyclyl or carbocyclyl, and -S-(C,-C6 alkyl)-R/;and -O-(CrC6 alkyl)-^ wherein each R"' can be the same or different and represents aryl, heteroaryl, heterocyclyl or carbocyclyl. Further, two substituents on the same atom can, together with the atom to which they are attached, form a carbocyclyl or heterocyclyl group.
Preferred substituents include oxo, C,-C6 alkyl, for example methyl and ethyl, CrC6 alkoxy, for example methoxy, C,-C6 alkylthio, for example methylthio, C,-C6 haloalkyl, for example -CF3 and -CC13, - haloalkoxy, for example -OCF3 and -OCCl3, halogen, for example chlorine and fluorine, nitro, cyano, aryl, for example phenyl, aryloxy, for example phenyloxy, arylthio, for example phenythio, heteroaryl, heteroarylthio, heterocyclyl, -CONH-(C,-C6 alkyl), -NHCONH-R wherein R is aryl, for example phenyl, or heteroaryl, =NR wherein R' is aryl, for example phenyl, or heteroaryl, -S(O)2NHR wherein R" is aryl, for example phenyl, or heteroaryl, -S-(C,-C6 alkyl)-R/ wherein R / is aryl, for example phenyl, or heteroaryl, and -COR wherein R/ is heterocyclyl, heteroaryl or aryl.
Particularly preferred substituents are oxo, =N-aryl, for example ^N-phenyl, aryl, for example phenyl, and -CO-aryl, for example -CO-phenyl.
A carbocyclic group or moiety may be fused to a further carbocyclic group or to an aryl, heteroaryl or heterocyclic group. A heteroaryl group or moiety is typically a 5- to 10- membered aryl ring containing at least one heteroatom, for example 1, 2 or 3 heteroatoms, selected from
0, S and N. Preferably, the heteroaryl group or moiety is a 5- or 6- membered ring.
Suitable heteroaryl groups and moieties include pyridyl, pyranyl, furanyl, thienyl, pyrazolidinyl, pyrrolyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, imidazolyl, pyrazolyl, iso thiazolyl, isoxazolyl, furazanyl, triazolyl and thiadiazolyl groups. Pyridyl, pyrrolyl, thienyl, thiazolyl, furanyl, pyrazinyl and
1, 2, 3-thiadiazolyl groups are preferred.
A heteroaryl group or moiety may be unsubstituted or substituted at any position. Typically, it is unsubstituted or carries up to three substituents. Suitable substituents include CrC6 alkyl, CrC6 alkylthio, C,-C6 alkoxy, C,-C6 haloalkyl, for example -CF3 and -CC13, CrC6 haloalkoxy, for example -OCF3 and -OCCl3, halogen, hydroxy, cyano, nitro, aryl, aryloxy, arylthio, heteroaryl, heteroaryloxy, heteroarylthio, heterocyclyl, heterocyclyloxy, heterocyclythio, carbocyclyl, carbocyclyloxy, carbocyclylthio, -NR/R/ wherein R; and R// are the same or different and are hydrogen or CrC6 alkyl, -COR, -CONR/R, -CO2R, -NR/COR, -NR/CO2R,
-NR/CONR/R, -S(O)2R and -S(O)2NR/R wherein each R, can be the same or different
and represents hydrogen or CrC6 alkyl and each R can be the same or different and represents CrC6 alkyl, aryl, heteroaryl, heterocyclyl or carbocyclyl, and -S-(C,-C6 alkyl)-R and -O-(C1-C6alkyl)-R/ wherein each R"' can be the same or different and represents aryl, heteroaryl, heterocyclyl or carbocyclyl. Preferred substituents include CrC6 alkyl, for example methyl and ethyl,
CrC6 alkoxy, for example methoxy, CrC6 alkylthio, for example methylthio, CrC6 haloalkyl, for example -CF3 and -CC13, C,-C6 haloalkoxy, for example -OCF3 and -OCCl3, halogen, for example chlorine, cyano, nitro, aryl, for example phenyl, aryloxy, for example phenoxy, arylthio, for example phenylthio and -O-(C,-C6 alkyl)-R, -S-(C,-C6 alkyl)-R, -S-(C,-C6 alkyl)-CONH-R, -CO-R and
-CO-NH-R, wherein R is an aryl group, for example a phenyl group.
Particularly preferred substituents include phenyl, halogen, for example chlorine, CrC4 alkyl, for example methyl, -CF3, -CC13, -OCF3, -OCCl3, phenylthio, phenoxy, -S-(C C4 alkyl)-CONH-phenyl, -S-(C,-C4alkyl)-phenyl, -O-(CrC4 alkyl)-phenyl, -CO-phenyl, cyano, CrC4 alkylthio, nitro,
2,3-dihydrobenzafuranyl and -CO-NH-(l, 2, 3, 4-tetrahydranaphthalen-8-yl).
A heteroaryl group may be fused to a said aryl or carbocyclic group or to a further heteroaryl group or to a heterocyclic group. Examples of such fused heteroaryl groups include quinolyl, indolyl, isoindolyl, benzothiophenyl, imidazo[l,2- ]pyridyl and β-carbolinyl groups.
As used herein, a heterocyclic group or moiety is a non-aromatic, saturated or unsaturated cyclic group or moiety containing at least one, for example, one, two or three, heteroatoms selected from N, O and S. Typically, it is a 3- to 6- membered ring. Preferably, it is a 5- or 6- membered ring containing, as heteroatoms, one or two nitrogen atoms.
Suitable heterocyclic groups and moieties include pyrazolidinyl, piperidyl, piperazinyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolinyl, 3,4-dihydro-2H-pyranyl, tetrahydropyrimidinyl (for example 1,2,3,4- or 1,4,5,6- tetrahydrapyrimidinyl), 2-hydropyridinyl, 2-hydrothiazolyl, tetrahydropyridinyl (for example 1,2,5,6- or 2,3,4,5-tetrahydropyridinyl) and tetrahydropyridazinyl, for example 3 ,4,5 ,6-tetrahydropyridazinyl.
A heterocyclic group or moiety may be substituted or unsubstituted at any position. Typically, it is unsubstituted or carries 1, 2, 3, 4 or 5 substituents. Suitable substituents include oxo, C C6 alkyl, C,-C6 alkylthio, CrC6 alkoxy, CrC6 haloalkyl, for example -CF3 and -CC13, CrC6 haloalkoxy, for example -OCF3 and -OCCl3, halogen, hydroxy, cyano, nitro, aryl, aryloxy, arylthio, heteroaryl, heteroaryloxy, heteroarylthio, heterocyclyl, heterocyclyloxy, heterocyclythio, carbocyclyl, carbocyclyloxy, carbocyclylthio, -NRR/ wherein R' and R/; are the same or different and are hydrogen or C,-C6 alkyl, -NR, -COR, -CONR/R, -CO2R, -NR/COR, -NR/CO2R, -NR/CONR/R, -S(O)2R and -S(O)2NR/R wherein each R, can be the same or different and represents hydrogen or Cj-C6 alkyl and each R can be the same or different and represents CrC6 alkyl, aryl, heteroaryl, heterocyclyl or carbocyclyl, and -S-(C,-C6
-O-(CrC6 alkyl)-R / wherein each R'" can be the same or different and represents aryl, heteroaryl, heterocyclyl or carbocyclyl. Further, two substituents on the same atom can, together with the atom to which they are attached, form a carbocyclyl or heterocyclyl group.
Preferred substituents include oxo, CrC6 alkyl, for example methyl and ethyl, Cj-C6 alkoxy, for example methoxy, CrC6 alkylthio, for example methylthio, CrC6 haloalkyl, for example -CF3 and
for example -OCF3 and -OCCl3, halogen, for example chlorine and fluorine, nitro, cyano, aryl, for example phenyl, aryloxy, for example phenyloxy, arylthio, for example phenythio, heteroaryl, heteroarylthio, heterocyclyl, -CONH-(CrC6 alkyl), -NHCONH-R wherein R is aryl, for example phenyl, or heteroaryl, =NR wherein R' is aryl, for example phenyl, or heteroaryl, -S(O)2NHR wherein R" is aryl, for example phenyl, or heteroaryl, -S-(C,-C6 alkyl)-R/ wherein R"1 is aryl, for example phenyl, or heteroaryl, and -COR//// wherein R/ is heterocyclyl, heteroaryl or aryl.
Particularly preferred substituents are oxo, =N-aryl, for example =N-Ph, aryl, for example phenyl, halogen, CrC4 alkyl, for example methyl and ethyl, CrC4 alkoxy, for example methoxy and ethoxy, Cj-C4 haloalkyl, for example -CF3 and -CC13 and C,-C4 haloalkoxy, for example -OCF3 and -OCCl3. Heterocyclic groups carrying one oxo substituent and up to 2, for example 0,
1 or 2, further substituents are particularly prefered.
A heterocyclic group or moiety may be fused to a further said heterocyclic group or to a said carbocyclic, aryl or heteroaryl group. Typically, it is non- fused or is fused to a benzene ring or to an iodole group. Examples of such fused heterocyclic groups include chromanyl and chromonyl groups. An aryloxy, heteroaryloxy, heterocyclyloxy or carbocyclyloxy group is typically a said aryl, heteroaryl, heterocyclyl or carbocyclyl group attached to an oxygen atom. An arylthio, heteroarylthio, heterocyclylthio or carbocyclylthio group is typically a said aryl, heteroaryl, heterocyclyl or carbocyclyl group attached to a sulphur atom. Typically, R, and R2 are the same or different and represent methyl, ethyl, propyl, n-butyl or t-butyl. Preferably the groups represented by R, and R2 are unsubstituted or carry one or two substituents. Preferred substituents for R, and R2 include CrC4 alkyl, for example methyl and ethyl, C,-C alkoxy, for example methoxy and ethoxy, halogen, for example chlorine, Cj-C4 haloalkyl, for example -CF3 and -CC13 and C,-C4 haloalkoxy, for example -OCF3 and -OCCl3 Typically, these substituents are themselves unsubstituted.
More preferably, R, and R2 are methyl or Rj and R2 together form a n-butylene group.
Z is methylene, ethylene, propylene or butylene and is preferably propylene. Preferably Z is unsubstituted, monosubstituted or disubstituted. Preferred substituents for Z include CrC4 alkyl, for example methyl and ethyl, CrC4 alkoxy, for example methoxy and ethoxy, halogen, for example chlorine, C C4 haloalkyl, for example -CF3 and -CC13 and C,-C4 haloalkoxy, for example -OCF3 and -OCCl3. Typically, these substituents are themselves unsubstituted. Particularly preferred substituents for Z are CrC4 alkyl groups, in particular methyl groups. A preferred substituted alkylene group is 2,2-dimethylpropylene.
Typically, the moiety P is -Y-, -XY-, -YW- or -XY -. Preferably, the moiety P is -XYW- or -YW-. When P is -W- or is a direct bond, P , is typically an aryl, heteroaryl or heterocyclyl moiety and/or is typically substituted by an aryl, heteroaryl, heterocyclyl or carbocyclyl substituent.
Typically, W is -O- or -NR3. Typically, R3 is hydrogen or is methyl, ethyl,
propyl, n-butyl or t-butyl. Preferably, R3 is unsubstituted or carries one or two substituents. Preferred substituents for R3 include C,-C4 alkyl, for example methyl and ethyl, Cj-C4 alkoxy, for example methoxy and ethoxy, halogen, for example chlorine, CrC4 haloalkyl, for example -CF3 and -CC13 and C C4 haloalkoxy, for example -OCF3 and -OCCl3. Typically, these substituents are themselves unsubstituted.
More preferably, R3 is hydrogen or methyl, most preferably hydrogen. V is preferably a direct bond. U is preferably -CO-, -S(O)2-, -C(=NH)- or -C(=NOH)-, more preferably -CO-. X is typically -NRg-. When X is a group -NR6-, R6 is typically CrC4 alkyl, for example methyl, ethyl, propyl, n-butyl and t-butyl, aryl, for example phenyl, or heteroaryl, for example pyridyl. Preferably, R^ is unsubstituted or carries 1, 2 or 3 substituents. Preferred substituents for R6 include CrC4 alkyl, for example methyl and ethyl, CrC4 alkoxy such as methoxy or ethoxy, halogen, for example fluorine or chlorine, C,-C4 haloalkyl, for example -CF3 and -CC13, C,-C4 haloalkoxy, for example -OCF3 and -OCCl3, cyano, nitro and -NRR/ wherein R' and R" are the same or different and are hydrogen or CrC alkyl. Typically, these substituents are themselves unsubstituted.
Preferably, X is -NH-. Typically, the group R4 has up to 30 carbon atoms and up to 10 heteroatoms selected from N, O and S. Preferably, it has up to 25 carbon atoms and up to 7 heteroatoms. Typically, the group R4 contains at least one, preferably at least two, aryl or heteroaryl rings.
Preferably, R4 is CrC6 alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, -(C,-C6 alkyl)-aryl, -(C,-C6 alkyl)-heteroaryl or -COR", -CO2R" or -CONR'R" wherein R' is hydrogen or CrC6 alkyl and R" is an aryl, heteroaryl, carbocyclyl or heteroaryl group.
Suitable substituents for the group R4 are oxo, CrC6 alkyl, C,-C6 alkylthio, CrC6 alkoxy, CrC6 haloalkyl, for example -CF3 and -CC13, CrC6 haloalkoxy, for example -OCF3 and -OCCl3, halogen, hydroxy, cyano, nitro, aryl, aryloxy, arylthio, heteroaryl, heteroaryloxy, heteroarylthio, heterocyclyl, heterocyclyloxy,
heterocyclythio, carbocyclyl, carbocyclyloxy, carbocyclylthio, -NR/R/ wherein R7 and R/ are the same or different and are hydrogen or CrC6 alkyl, =NR, -COR, -CONR/R, -CO2R, -NR/COR, -NR/CO2R, -NR/CONR/R, -S(O)2R and -S(O)2NR,R wherein each R/ can be the same or different and represents hydrogen or CrC6 alkyl and each R can be the same or different and represents CrC6 alkyl, aryl, heteroaryl, heterocyclyl or carbocyclyl, and -S-(C,-C6 alkyl)-R; and -O-(C,-C6 alkyty-R"' wherein each R// can be the same or different and represents aryl, heteroaryl, heterocyclyl or carbocyclyl. Further, two substituents on the same atom can, together with the atom to which they are attached, form a carbocyclyl or heterocyclyl group. Substituents on the group R4 may be further substituted.
Typically, when P is a direct bond, -O- or -NH-, R4 is not a moiety (A) or (B).
wherein:
R is: hydrogen, aryl, heteroaryl, 3- to 6- membered heterocyclyl, -(CrC4 alkyl)-R wherein R is aryl, heteroaryl or 3- to 6- membered heterocyclyl, CrC4 alkyl, -CONA'2, -COA" or -SO2A" wherein each A' is the same or different and is selected from H, C,-C4 alkyl and aryl and each A" is the same or different and is selected from C C4 alkyl and aryl; and R'3 and R'4 are either:
(a) the same or different and selected from -CO2 A' wherein A' is as defined above, -CF3, -CC13, halogen, CrC4 alkoxy, -(Cj-C4 alkyl)- aryl, -(C,-C4 alkyl)-heteroaryl, hydrogen, CrC4 alkyl, C3-C6 carbocyclyl, 3- to 6- membered heterocyclyl, -SO2NA'2 wherein A' is
as defined above, and -CONZjZ2 wherein Z, and Z2, which are the same or different, represent H, CrC4 alkyl, aryl, heteroaryl, C3-C6 carbocyclyl, 3- to 6- membered heterocyclyl or -( - alkyl)-R wherein R is aryl, heteroaryl, 3- to 6- membered heterocyclyl or C3-C6 carbocyclyl, or Z, and Z2, together with the nitrogen atom to which they are attached, denote a 5- or 6- membered N-containing heterocyclic group; or (b) different, one of R'3 and R'4 being aryl or heteroaryl and the other being as defined above or R', is as defined above and R'3 and R'4 together form the divalent group,
-(CH)4-, which group is optionally substituted.
Preferably, R4 is not a 3- or 5- pyrazole or a 3- indazole group when P is a direct bond, -O- or -NH-. More preferably R4 is not a pyrazole or indazole group when P is a direct bond, -O- or -NH-. More typically, R4 is not a 3- or 5- pyrazole or a 3- indazole group or, more preferably, a pyrazole or indazole group when P does not contain the moiety U.
More preferably, when P is a direct bond, -O- or -NH- and R4 is a heteroaryl group, R4 is a pyridyl, pyrimidyl, thiazolyl or thienyl group. R4 is typically also a pyridyl, pyrimidyl, thiazolyl or thienyl group when P does not contain the moiety U and R4 is a heteroaryl group. Suitable pyridyl, pyrimidyl, thiazolyl and thienyl groups include groups fused to a said aryl or said carbocyclic group or to a said heteroaryl or said heterocyclic group. In such compounds, R,, may be substituted by one or more of the groups mentioned above as appropriate substituents for R4.
Preferred compounds of the invention are those in which X is -NRg- wherein R is as defined above, and R4 is aryl or heteroaryl. In these preferred compounds, P is typically -XYW-. Y is typically -CO-. W is typically -NR3- wherein R3 is as defined above. X is preferably -NH- and/or R4 is preferably phenyl, thienyl or pyrazolyl.
In the above preferred compounds, when R4 is phenyl it is typically substituted by a phenoxy group or by a phenylthio group, in particular a 2-phenoxy or 2-phenylthio group, or by a further phenyl group, in particular a 4-phenyl group. When R4 is thienyl or pyrazolyl, it is typically substituted by a phenyl or phenylthio group. These substituents may be unsubstituted or may be further substituted at any position. Typically, they are unsubstituted or carry one, two or three further
substituents. Preferred further substituents include halogen, for example chlorine and fluorine, CrC alkyl, for example methyl and ethyl, CrC4 alkoxy, for example methoxy and ethoxy, C,-C4 haloalkyl, for example -CF3 and -CC13, and -S(O)2NH-phenyl. These further substituents are typically themselves unsubstituted. In the above preferred compounds of the invention, R4 is preferably
2-phenoxyphenyl, 2-fluoro-diphen-4-yl, 5-(4-chlorophenylthio)rthien-3-yl, 4-(4-fluorophenyl)-thien-2-yl, 5-(4-chlorophenyl)- 1 -(3,4-dichlorophenyl)-pyrazol-3- yl or -(C6H4)-S-( H4)-S(O)2-NH-(C6H4).
Further preferred compounds of the invention are those in which P is -YW- and R4 is an aryl, heterocyclyl or heteroaryl group. In these further preferred compounds, Y is typically -CO-. W is typically -NR3- wherein R3 is as defined above. Further, R4 is preferably an oxo-substituted heterocyclic group such as a chromonyl group or is a pyrazolyl, thienyl, phenyl or indolyl group.
In the above further preferred compounds, R4 is typically unsubstituted or substituted by one or more, for example, one, two or three substituents selected from
C,-C6 alkyl, for example t-butyl, phenyl, thiazolyl, phenylthio, cyano, nitro, CrC6 alkylthio, for example i-propylthio, CrC6 alkoxy, halogen such as chlorine and -S-(C C4 alkyl)-phenyl. These substituents may be unsubstituted or may be substituted at any position. Typically, they are unsubstituted or carry one, two or three further substituents. Preferred further substituents include halogen, for example chlorine, CrC4 haloalkyl, for example -CF3, phenyl and -S(O)2-NH-phenyl. These further substituents are typically themselves unsubstituted.
Additional preferred compounds of the invention are those in which P is -W- or -YW- wherein Y is -CO- and W is -O-. Particularly preferred compounds of the invention are compounds of formula
(V) and pharmaceutically acceptable salts thereof,
R4 Y z
\ / \ / \
X N NR.!R2 W
R3
wherein:
R! and R2 are the same or different and each represent a CrC6 alkyl group, or Rj and R2 together form an alkylene group having from 3 to . 6 carbon atoms;
Z is an alkylene group having from 2 to 4 carbon atoms; R3 is hydrogen or CrC6 alkyl; Y is -CO- or -S(O)2-;
X is a direct bond or -NR^- wherein R6 is hydrogen, CrC6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl or heteroaryl; and
R4is C,-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, a group -R-A wherein R is -(C,-C6 alkyl)-, -(C2-C6 alkenyl)- or -(C2-C6 alkynyl)- and A is aryl, heteroaryl, carbocycyl or heterocyclyl, or R4 is a group -COR' or -CO2R' wherein R' is aryl, heteroaryl, carbocyclyl or heterocyclyl.
Further particularly preferred compounds of the invention are compounds of formula (I"), and pharmaceutically acceptable salts thereof
wherein Rj and R are methyl or together form a n-butylene group, R3 is hydrogen or methyl, R4 is as defined in the formula (I) or in the formula (I7) and X is a direct bond or is -NRg- wherein R6 is as defined above. Preferably, when X in the formula (I") is -NRg-, R4 is as defined as in the above preferred compounds of the invention. Preferably, when X in the formula (I") is a direct bond, R4 is as defined in the above further preferred compounds of the invention. The present invention includes pharmaceutically acceptable salts of the compounds of the invention. Suitable salts include salts with pharmaceutically
acceptable acids, both inorganic acids such as hydrochloric, sulphuric, phosphoric, diphosphoric, hydrobromic or nitric acid and organic acids such as citric, fumaric, maleic, malic, ascorbic, succininc, tartaric, benzoic, acetic, methanesulphonic, ethanesulphonic, benzenesulphonic or p-toluenesulphonic acid. Salts may also be formed with pharmaceutically acceptable bases such as alkali metal (eg sodium or potassium) and alkali earth metal (eg calcium or magnesium) hydroxides and organic bases such as alkyl amines, aralkyl amines or heterocyclic amines.
Particularly preferred compounds of the invention are: l-(3-Dimethylamino-propyl)-3-(2-phenoxy-phenyl)-urea l-[2-(4-Chloro-phenoxy)-pyridin-3-yl]-3-(3-dimethylaminopropyl)-urea l-(3-Dimethylamino-propyl)-3-pyren-l-ylmethyl-urea l-(3-Dimethylamino-propyl)-3-[(lR,2R)-5-phenyl-2-(l-phenyl-methanoyl)- cyclohexyl]-urea l-(3-Dimethylamino-propyl)-3-[2-(4-phenoxy-phenyl)-ethyl]-urea l-(3-Dimethylamino-propyl)-3-[3-methyl-5-(4-methyl-[l,2,3]thiadiazol-5- yl)- 1 -(4-trifluoromethoxy-phenyl)- 1 H-pyrazol-4-yl]-urea
2'-[3-(3-Dimethylamino-propyl)-ureido]-biphenyl-2-carboxylic acid (4- fluoro-phenyι)-amide
N-(3-Chloro-4-methyl-phenyl)-4-[3-(3-dimethylamino-propyl)-ureido]-3- phenyl-butyramide l-[4-(4-Chloro-phenylsulfanyl)-thiophen-3-yl]-3-(3-dimethylamino-propyl)- urea l-[2-(3,4-Dimethoxy-phenyl)-6-methyl-quinolin-4-yl]-3-(4-dimethylamino- propyl)-urea 1 -(6-Bromo-2-thiophen-3-yl-quinolin-4-yl)-3 -(3-dimethylamino-propyl)-urea l-[3-(4-Chloro-phenyl)-4-cyano-5-isobutylsulfanyl-thiophen-2-yl]-3-(3- dimethylamino-propyl)-urea l-[6-(2,4-Dichloro-phenyl)-cyclohex-3-enyl]-3-(3-dimethylamino-propyl)- urea l-(2-Benzylsulfanyl-phenyl)-3-(3-dimethylamino-propyl)-urea
2-{2-[3-(3-Dimethylamino-propyl)-ureido]-phenylsulfanyl}-N-phenyl-
benzenesulfonamide l-(3-Dimethylamino-propyl)-3-(2'-fluoro-biphenyl-4-yl)-urea
N-(3,5-Dichloro-phenyl)-2-{3-[3-(3-dimethylamino-propyl)-ureido]-pyridin-
2-ylsulfanyl} -acetamide l-(3-Dimethylamino-propyl)-3-{2-[l-(l-trifluoromethyl-l,3,4,9-tetrahydro-b- carbolin-2-yl)-methanoyl]-phenyl}-urea
8-{2-[3-(3-Dimethylamino-propyl)-ureido]-phenylsulfanyl}-naphthalene-l- carboxylic acid methylamide l-[l-(3,4-Dichloro-benzyl)-6-oxo-l,6-dihydro-pyridin-3-yl]-3-(3- dimethylamino-propyl)-urea l-(3-Dimethylamino-propyl)-3-(3-oxo-l ,2,3-triphenyl-propyl)-urea l-[5-(4-Chloro-phenyl)-l-(3,4-dichloro-phenyl)-lH-pyrazol-3-yl]-3-(3- dimethylamino-propyl)-urea l-{4-[4-(4-Chloro-phenyl)-thiazol-2-yl]-phenyl}-3-(3-dimethylamino- propyl)-urea l-(3-Dimethylamino-propyl)-3-[5-(4-fluoro-phenyl)-thiophen-2-yl]-urea l-[3-(4-tert-Butyl-benzyloxy)-thiophen-2-yl]-3-(3-dimethylamino-propyl)- urea l-(3-Dimethylamino-propyl)-3-[4-(4-phenyl-thiazol-2-yl)-phenyl]-urea l-[3-(3,4-Dichloro-benzylsulfanyl)-thiophen-2-yl]-3-(3-dimethylamino- propyl)-urea l-[2-(5-Chloro-l-methyl-3-phenyl-lH-pyrazol-4-ylmethylsulfanyl)-phenyl]-
3 -(3 -dimethylamino-propyl)-urea l-[2-(4-Chloro-benzylsulfanyl)-3-methyl-4-oxo-3,4-dihydro-quinazolin-7-yl]- 3-(3-dimethylamino-propyl)-urea l-(3-Dimethylamino-propyl)-3-{4-[4-(4-methoxy-phenyl)-pyrimidin-2- ylsulfanylmethyl]-phenyl} -urea l-(4-Bromophenyl)-3-(3-(l-pyrrolidinyl) propyl) urea l-(4-Bromophenyl)-3-(3-dimethylamino propyl) urea 3-(4-Bromophenyl)- 1 -methyl- 1 -(3-dimethylamino propyl) urea l-(3-Phenyl-5-methoxy phenyl)-3-(3-dimethylamino propyl) urea
3-(4-Chlorophenyl)-l-methyl-l-(3-dimethylamino propyl) urea l-(3-Nitrophenyl)-l-benzyl-3-(3-dimethylamino propyl) urea l-Benzyl-l-(4-methyl-3-pyridinyl)-3-(3-dimethylamino propyl) urea l-Methyl-l-(3,5-bistrifluoromethylphenyl)-3-(3-dimethylaminopropyl)urea l-(2-Phenacyl-4-chorophenyl)-l-methyl-3-(3-dimethylamino propyl) urea l-(2-Chloro-4-trifluoromethylphenyl)-3-(3-dimethylaminopropyl) urea 1 -(3-Fluoro-5 -tri fluoromethylphenyl)-3 -(3 -dimethylaminopropyl) urea l-(3-N-tert-butoxycarbonyl-benzylamino)-3-(3-dimethylaminopropyl) urea N-(3-Dimethylamino-propyl)-2-[l-(4-fluorobenzoyl]-benzamide 2-[l-(4-Chlorobenzoyl]-N-(3-dimethylamino-propyl)-benzamide
5-(4-Chloro-ρhenyl)-l-phenyl-lH-pyrazole-3-carboxylic acid (3- dimethylamino-propyl)-amide
5 -Chloro-3 -phenyl- lH-indole-2-carboxylic acid (3-dimethylamino-propyl)- amide N-(3-Dimethylamino-propyl)-2-(2-phenylsulfamoyl-phenylsulfanyl)- benzamide
2-Benzylsulfanyl-N-(3-dimethylamino-propyl)-benzamide 6,8-Di-tert-butyl-4-oxo-4H-chromene-2-carboxylic acid (3-dimethylamino -propyl)-amide 3-(4-Chloro-phenyl)-4-cyano-5-isobutylsulfanyl-thiophene-2-carboxylic acid
(3 -dimethylamino-propyl)-amide
4-(4-Chloro-phenoxy)-N-(3-dimethylamino-propyl)-3-nitro-benzamide N-(3-Dimethylamino-propyl)-4-(4-phenyl-thiazol-2-yl)-benzamide 1 -(3 -Dimethylamino-propyl)-3 -(2-phenoxyphenyl)-urea l-[4-(4-Chloro-phenylsulfanyl)-thiophen-3-yl]-3-(3-dimethylamino-propyl)
-urea l-(3-Dimethylamino-propyl)-3-(2'-fluoro-biphenyl-4-yl)-urea N-(3-Dimethylamino-propyl)-2-[l-(4-fluorobenzoyl]-benzamide N-(3-Dimethylamino-propyl)-3-phenoxy-benzamide N-(3 -Dimethylamino-propyl)-2-phenoxy-benzamide
2-(4-Chloro-phenoxy)-N-(3-dimethylamino-propyl)-nicotinamide
4 '-n-Propyl-biphenyl-4-carboxylic acid (3-dimethylamino-propyl)-arnide
2-[l-(4-Bromo-phenyl)-methanoyl]-cyclohexanecarboxylic acid (3- dimethylamino-propyl)-amide
5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid (3-dimethylamino- propyl)-amide
2-[l-(4-Chlorobenzoyl]-N-(3-dimethylamino-propyl)-benzamide
2-Phenyl-quinoline-4-carboxylic acid (3-dimethylamino-propyl)-amide
2-[l-(4-Chloro-3-nitrobenzoyl)]-N-(3-dimethylamino-propyl)-benzamide
N-(3-Dimethylamino-propyl)-2-pyren- 1 -yl-acetamide N-(3-Dimethylamino-propyl)-2-[l-(3-methyl-benzo[b]thiophen-2-yl)- methanoylj-benzamide
4-Chloro-N-(3-dimethylamino-propyl)-2-phenoxy-benzamide
N-(3-Dimethylamino-propyl)-3-(4-phenoxy-phenyl)-propionamide
N-(3 -Dimethylamino-propyl)-2-[ 1 -( 1 -trifluoromethyl- 1 ,3 ,4,9-tetrahydro-b- carbolin-2-yl)-methanoyl] -benzamide l-(4-Chloro-phenyl)-2,5-dimethyl-l-pyrrole-3-carboxylic acid (3- dimethylamino-propyl)-amide
2- { 1 -[(3-Dimethylamino-propylcarbamoyl)-methyl]-cyclopentyl} -N-(4- trifluoromethoxy-phenyl)-acetamide 8-[2-(3-Dimethylamino-propylcarbamoyl)-phenylsulfanyl]-naphthalene-l- carboxylic acid methylamide
3-Methyl-5-(4-methyl-[l,2,3]thiadiazol-5-yl)-l-(4-trifluoromethoxy-phenyl)- lH-pyrazole-4-carboxylic acid (3-dimethylamino-propyl)-amide
6,8-Di-tert-butyl-4-oxo-4H-chromene-2-carboxylic acid (3-dimethylamino- propyl)-amide
2-(Furan-2-yl)-quinoline-4-carboxylic acid (3-dimethylamino-propyl)-amide
Biphenyl-2,2 '-dicarboxylic acid 2 '-[(3-dimethylamino-propyl)-amide]-2-[(4- fluoro-phenyl)-amide]
3-Phenyl-pentanedioic acid (3-chloro-4-methyl-phenyl)-amide (3- dimethylamino-propyl)-amide
2-(3,4-Dimethoxy-phenyl)-6-methyl-quinoline-4-carboxylic acid (3-
dimethylamino-propy l)-ami de
6-Bromo-(2-thiophen-3-yl)-quinoline-4-carboxylic acid (3-dimethylamino- propyl)-amide
3-(4-Chloro-phenyl)-4-cyano-5-isobutylsulfanyl-thiophene-2-carboxylic acid (3-dimethylamino-propyl)-amide
4-(4-Chloro-phenoxy)-N-(3-dimethylamino-propyl)-3-nitro-benzamide
6-(2,4-Dichloro-phenyl)-cyclohex-3-ene carboxylic acid (3-dimethylamino- propyl)-amide
N-(3-Dimethylamino-propyl)-2-(2-phenylsulfamoyl-phenylsulfanyl)- benzamide
2'-Fluoro-[l,r-biphenyl]-4-carboxylic acid (3-dimethylamino-propyl)-amide
2-Benzylsulfanyl-N-(3-dimethylamino-propyl)-benzamide
Pyrazine-2,3-dicarboxylic acid 2-[(3-dimethylamino-propyl)-amide] 3-
[(5 ,6,7,8-tetrahydro-naphthalen- 1 -yl)-amide] 2-[(3,5-Dichloro-phenylcarbamoyl)-methylsulfanyl]-N-(3-dimethylamino- propyl)-nicotinamide
2-(3-Trifluoromethyl-phenyl)-thiazole-4-carboxylic acid (3-dimethylamino- propyl)-amide
2-(4-Chloro-phenyl)-thiazole-4-carboxylic acid (3-dimethylamino-propyl)- amide
5-Chloro-l-(2,4-dichloro-benzyl)-6-oxo-l,6-dihydro-pyridine-3-carboxylic acid (3 -dimethylamino-propyl)-amide l-(2,4-Dichloro-benzyl)-6-oxo-l,6-dihydro-pyridine-3-carboxylic acid (3- dimethylamino-propyl)-amide 5-Chloro-l -(3 ,4-dichloro-benzyl)-6-oxo-l,6-dihydro-pyridine-3 -carboxylic acid (3 -dimethylamino-propyl)-amide l-(3,4-Dichloro-benzyl)-6-oxo-l,6-dihydro-pyridine-3-carboxylic acid (3- dimethylamino-propyl)-amide
5-Chloro-l-(2,6-dichloro-benzyl)-6-oxo-l,6-dihydro-pyridine-3-carboxylic acid (3-dimethylamino-propyl)-amide l,l-Dimethyl-indan-4-carboxylic acid (3-dimethylamino-propyl)-amide
N-(3-Dimethylamino-propyl)-2-[l-(4-ethyl-phenyl)-methanoyl]-benzamide
N-(3-Dimethylamino-propyl)-3-(2,4,5-trimethyl-phenyl)-butyr amide
2-[3-(3,4-Dichloro-phenyl)-ureido]-N-(3-dimethylamino-propyl)-benzamide
N-(3-Dimethylamino-propyl)-4-oxo-2,3,4-triphenyl-butyramide 5-(4-Chloro-phenylsulfanyl)-[l,2,3]thiadiazole-4-carboxylic acid (3- dimethylamino-propyl)-amide
2-(3-Chloro-5-trifluoromethyl-pyridin-2-ylsulfanyl)-3-methyl-3H-imidazole-
4-carboxylic acid (3-dimethylamino-propyl)-amide
2-(2-Chloro-4-trifluoromethyl-phenyl)-[l,3]-thiazole-4-carboxylic acid (3- dimethylamino-propyl)-amide
2-(2,3-Dihydro- 1 -benzofuran-5-yl)- 1 ,3-thiazole-4-carboxylic acid (3- dimethylamino-propyl)-amide
2-(2,3-Dichloro-phenyl)- 1 ,3-thiazole-4-carboxylic acid (3-dimethylamino- propyl)-amide 4-[4-(4-Chloro-phenyl)-thiazol-2-yl]-N-(3-dimethylamino-propyl)-benzamide
5-(4-Fluoro-phenyl)-thiophene-2-carboxylic acid (3-dimethylamino-propyl)- amide
4-Methyl-2-(3-trifluoromethyl-phenyl)-thiazole-5-carboxylic acid (3- dimethylamino-propyl)-amide 3-(4-tert-Butyl-benzyloxy)-thiophene-2-carboxylic acid (3-dimethylamino- propyl)-amide
4-Oxo-3-(3-trifluoromethyl-phenyl)-3,4-dihydro-phthalazine-l-carboxylic acid (3-dimethylamino-propyl)-amide
2-(4-Chloro-phenyl)-N-(3-dimethylamino-propyl)-4-oxo-4-phenyl- butyramide
5-(4-Chloro-phenyl)-l-phenyl-lH-pyrazole-3-carboxylic acid (3- dimethylamino-propyl)-amide
N-(3-Dimethylamino-propyl)-4-(4-phenyl-thiazol-2-yl)-benzamide
1 -(2,4,5-Trichloro-phenylsulfonyl)-pyrrolidine-2-carboxylic acid (3- dimethylamino-propyl)-amide
3-(3,4-Dichloro-benzylsulfanyl)-thiophene-2-carboxylic acid (3-
dimethylamino-propyl)-amide
5-Chloro-3-phenyl-lH-indole-2-carboxylic acid (3-dimethylamino-propyl)- amide
N-(3-Dimethylamino-propyl)-2-[l-(4-fluoro-benzyl)-lH-indol-3-yl]- acetamide
2-Phenyl-imidazo[l,2-a]pyridine-3-carboxylic acid (3-dimethylamino- propyl)-amide
N-(3-Dimethylamino-propyl)-2-(7-ethyl-lH-indol-3-yl)-4-oxo-4-phenyl- butyr amide Phenyl-trifluoromethyl-thieno[3,2-b]pyridine-2-carboxylic acid (3- dimethylamino-propyl)-amide
3-(4-Nitro-3-trifluoromethyl-phenoxy)-thiophene-2-carboxylic acid (3- dimethylamino-propyl)-amide
2-(5-Chloro-l-methyl-3-phenyl-lH-pyrazol-4-ylmethylsulfanyl)-N-(3- dimethylamino-propyl)-benzamide
2-(4-Chloro-benzylsulfanyl)-3-methyl-4-oxo-3,4-dihydro-quinazoline-7
-carboxylic acid (3-dimethylamino-propyl)-amide
N-(3 -Dimethylamino-propyl)-4- [4-(4-methoxy-phenyl)-pyrimidin-2
-ylsulfanylmethyl]-benzamide 1 -(4-chlorobenzyl)-3-(2-N,N-dimethylethylamido)-6-pyridone l-(2,6-dichlorobenzyl)-3-(3-N,N-dimethylpropylamido)-6-pyridone
1 -(3 -trifluoromethylbenzyl)-3 -(2-N,N-dimethylethylamido)-2-pyridone l-(2,6-dichlorobenzyl)-3-(2-N,N-dimethylethylamido)-2-pyridone l-(3,4-dichlorobenzyl)-3-(N-[2,N,N-dimethylaminoethylamido])-2-pyridone l-(2,6-dichlorobenzyl)-3-(N-[2-N,N-dimethylaminoethylamido])-6-pyridone
5-chloro-l-(3,4-dichlorobenzyl)-3-(2-N,N-dimethylaminoethylamido)-6
-pyridone
5-chloro-3-(2-N,N-dimethylaminoethylamido)-l-(3-trifluoromethylbenzyl)-6- pyridone 5-chloro-l-(3,4-dichlorobenzyl)-3-N-(2-[N',N'-dimethylaminoethylamido])-2- pyridone
5-chloro-l-(4-chlorobenzyl)-3-N-(2-(N',N'-dimethylamino)ethyl)amido-2- pyridone
5-chloro-l-(3-trifluoromethylbenzyl)-3-N-(2-(N',N'-dimethylamino)ethyl) amido-2-pyridone 5 l-benzyl-5-chloro-3-N-(2-[N',N'-dimethylamino]ethyl)carboxamido-6- pyridone
5-chloro-l-(4-chlorobenzyl)-3-N-(2-[N',N,-dimethylamino]ethyl)carboxamido
-6-pyridone
4-(2,4-dichlorobenzoyl)pyrrole-2-N-dimethylaminopropylcarboxamide 10 4-[(N-[3-(N',N'-dimethylaminopropyl)]carboxamido]-2-phenylthiazole
4-(N-(3-N,,N'-dimethylaminopropyl)carboxamido)-2-(4-pyridinyl)thiazole
2-[4-(N-[3-N',N'-dimethylaminopropyl]carboxamido)phenyl-4-
(3-trifluoromethylphenyl)]thiazole
4-(4-chlorophenyl)-2-(4-[3-N',N'-dimethylaminopropyl]carboxamido)phenyl) 15. thiazole l-(3,5-bis(trifluoromethyl)benzyl)-3-[N-(2-dimethylaminoethyl) carboxamido]-2[lH]-pyridone
N-(3-dimethylaminopropyl)-4-(3-chloro-5-trifluoromethyl-2-pyridyloxy) phenyl sulfonami de 20 Nl-[3-(dimethylamino)propyl]-3-[3-chloro-5-(trifluoromethyl)-2-pyridyl] propanamide
3-(N-(2-dimethylaminoethyl)carboxamido]-l-(4-trifluoromethylbenzyl))-2
[lH]-pyridone l-ethyl-3-(3-dimethylaminopropyl)urea 25 1 -(3-(dimethylamino)-propyl)-3-phenylurea
Nl-[2-(2,4-dichlorophenoxy)phenyl]-N2-[3-(dimethylamino)propyl] ethanediamide
N4-[3-(dimethylamino)propyl]-3-(2,6-dichlorophenyl)-5-methylisoxazole-4-c arboxamide 30 N-[[3-(2,6-dichlorophenyl)-5-methylisoxazol-4-yl]carbonyl]-N'-[3-(dimethyla mino)propy 1] urea
N-(4-chlorophenyl)-N'-[3-dimethylaminopropyl]urea N-(3,5-Dichloro-phenyl)-3-(3-dimethylamino-propylamino)-propionamide [3-(2-Ethyl-6-methyl-pyridin-3-yloxy)-propyl]-dimethyl-amine 8-(3-Dimethylamino-propoxy)-l,3,7-trimethyl-3,7-dihydro-purine-2,6-dione 2-(3 -Dimethylamino-propylamino)-isophthalonitrile
Dimethylamino-(3-methyl-benzo[b]thiophen-2-yl)-propan-l-one (HCl) N-Benzo[l,3]dioxol-5-ylmethyl-N,N-dimethyl-propane-l,3-diamine N,N-Dimethyl-N-(5-nitro-quinolin-8-yl)-propane-l,3-diamine l-(4-Chloro-phenyl)-3-(3-dimethylamino-propyl)-urea 2- Amino-N-(3-dimethylamino-propyl)-benzamide
3-Phenyl-acrylic acid 3-dimethylamino-propyl ester 3,5-Dinitro-benzoic acid 2-dimethylamino-ethyl ester [4-(4-Bromo-phenyl)-3-(3-dimethylamino-propyl)-3H-thiazol-2-ylidene]- phenyl-amine 3-Methyl-benzofuran-2-carboxylic acid dimethylamino-dimethyl-propyl ester
N'-(2-Chloro-4-nitro-phenyl)-N,N-dimethyl-propane-l,3-diamine [3-(3-Dimethylamino-propyl)-5-(4-nitro-phenyl)-3H-thiazol-2-ylidene]- phenyl-amine [3-(10,l l-Dihydro-dibenzo[a,d]cyclohepten-5-ylidene)-propyl]-dimethyl- amine
2,3-Dimethyl-lH-indole-5-carboxylic acid 2-dimethylamino-ethyl ester
N'-(3,4-Dinitro-5-pyridin-2-yl-thiophen-2-yl)-N,N-dimethyl-propane-l,3- diamine
Cyclooctyl-dithiocarbamic acid 2-dimethylamino-ethyl ester (HCI) N-(2,6-Difluoro-phenyl)-C-dimethylamino-acetamide
2-Acetylamino-3-(4-chloro-phenyl)-N-(3-dimethylamino-propyl)-acrylamide N-[2-[5-(4-Bromo-phenyl)-furan-2-yl]-l-(3-dimethylamino-propyl carbamoyl)-vinyl]-4-methyl-benzamide 2,6-Bis-(3-dimethylamino-propylamino)-3-nitro-benzonitrile N-[2-(2,4-Dichloro-phenoxy)-phenyl]-N'-(3-dimethylamino-propyl)- oxalamide
3,5-Dichloro-N-(3-dimethylamino-propyl)-2,6-dimethoxy-benzamide
2-Dimethylaminomethyl-3 ,4-dihydro-2H-naphthalen- 1 -one (HCI)
2-( { 1 - [N-(3 -Dimethylamino-propyl)-3 -trifluoromethyl-phenyl]- methanimidoyl} -amino)-6-fluoro-benzoic acid 2,4-Dichloro-N-(3-dimethylamino-propyl)-N'-hydroxy-benzamidine
3-(3-Methyl-ureido)-4-oxo-3,4-dihydro-quinazoline-2-carboxylic acid
(3 -dimethylamino-propyl)-amide
5-Bromo-N-(3-dimethylamino-propyl)-2-hydroxy-benzamide
N-(2,4-Dichloro-phenyl)-6-(2-dimethylamino-ethylsulfanyl)-4- trifluoromethyl-nicotinamide
1 -(2,6-Dichloro-benzyl)-2-oxo-l ,2-dihydro-pyridine-3-carboxylic acid
(2-dimethylamino-ethyl)-amide
3-Amino-4-oxo-3,4-dihydro-quinazoline-2-carboxylic acid
(3-dimethylamino-propyl)-amide Certain compounds of the invention are novel. Thus, the present invention also provides a compound of the formula (I), or a pharmaceutically acceptable salt thereof, in which R R2, Z, R3, Y, X and R^ are as defined above except for:
2-Benzylsulfanyl-N-(3-dimethylamino-propyl)-benzamide
N-(3-Dimethylamino-propyl)-3-phenoxy-benzamide 1 -(4-chlorobenzyl)-3-(2-N,N-dimethylethylamido)-6-pyridone l-(2,6-dichlorobenzyl)-3-(3-N,N-dimethylpropylamido)-6-pyridone l-(3-trifluoromethylbenzyl)-3-(2-N,N-dimethylethylamido)-2-pyridone l-(2,6-dichlorobenzyl)-3-(2-N,N-dimethylethylamido)-2-pyridone l-(3,4-dichlorobenzyl)-3-(N-[2,N,N-dimethylaminoethylamido])-2-pyridone l-(2,6-dicUorobeιιzyl)-3-(^-[2-N,N-dimethylaminoethylamido])-6-pyridone
5-chloro-l-(3,4-dichlorobenzyl)-3-(2-N,N-dimethylaminoethylamido)-6- pyridone
5-chloro-3-(2-N,N-dimethylaminoethylamido)-l-(3-trifluoromethylbenzyl)-6- pyridone 5-chloro-l-(3,4-dichlorobenzyl)-3-N-(2-[N',N'-dimethylaminoethylamido])-2- pyridone
5-chloro-l-(4-chlorobenzyl)-3-N-(2-(N',N'-dimethylamino)ethyl)amido-2- pyridone
5-chloro-l-(3-trifluoromethylbenzyl)-3-N-(2-(N',N'-dimethylamino)ethyl) amido-2-pyridone l-benzyl-5-chloro-3-N-(2-[N',N'-dimethylamino]ethyl)carboxamido-6- pyridone
5 -chloro- 1 -(4-chlorobenzyl)-3 -N-(2- [N',N'-dimethylamino] ethyl) carboxamido-6-pyridone
4-(2,4-dichlorobenzoyl)pyrrole-2-N-dimethylaminopropylcarboxamide 4-[(N-[3-(N',N'-dimethylaminopropyl)]carboxamido]-2-phenylthiazole
4-(N-(3-N',N'-dimethylaminopropyl)carboxamido)-2-(4-pyridinyl)thiazole
2-[4-(N-[3-N',N'-dimethylaminopropyl]carboxamido)phenyl-4-
(3-trifluoromethylphenyl]thiazole
4-(4-chlorophenyl)-2-(4-[3-N',N'-dimethylaminopropyl]carboxamido)phenyl) thiazole l-(3,5-bis(trofluoromethyl)benzyl)-3-[N-(2-dimethylaminoethyl) carboxamido]-2[lH]-pyridone
N-(3-dimethylaminopropyl)-4-(3-chloro-5-trifluoromethyl-2-pyridyloxy) phenylsulfonamide Nl-[3-(dimethylamino)propyl]-3-[3-chloro-5-(trifluoromethyl)-2-pyridyl] propanamide
3-(N-(2-dimethylaminoethyl)carboxamido]-l-(4-trifluoromethylbenzyl))-2
[lH]-pyridone l-ethyl-3-(3-dimethylaminopropyl)urea 1 -(3 -(dimethylamino)-propyl)-3-phenylurea
Nl-[2-(2,4-dichlorophenoxy)phenyl]-N2-[3-(dimethylamino)propyl] ethanediamide
N4-[3-(dimethylamino)propyl]-3-(2,6-dichlorophenyl)-5-methylisoxazole-4-c arboxamide N-[[3-(2,6-dichlorophenyl)-5-methylisoxazol-4-yl]carbonyl]-N'-[3-
(dimethy lamino)propyl] urea
N-(4-chlorophenyl)-N'-[3-dimethylaminopropyl]urea N-(3,5-Dichloro-phenyl)-3-(3-dimethylamino-propylamino)-propionamide [3-(2-Ethyl-6-methyl-pyridin-3-yloxy)-propyl]-dimethyl-amine 8-(3-Dimethylamino-propoxy)-l,3,7-trimethyl-3,7-dihydro-purine-2,6-dione 2-(3-Dimethylamino-propylamino)-isophthalonitrile
Dimethylamino-(3-methyl-benzo[b]thiophen-2-yl)-propan-l-one (HCI) N-Benzo[l,3]dioxol-5-ylmethyl-N,N-dimethyl-propane-l,3-diamine N,N-Dimethyl-N-(5-nitro-quinolin-8-yl)-propane-l,3-diamine l-(4-Chloro-phenyl)-3-(3-dimethylamino-propyl)-urea 2-Amino-N-(3-dimethylamino-propyl)-benzamide
3 -Phenyl -acrylic acid 3-dimethylamino-propyl ester 3,5-Dinitro-benzoic acid 2-dimethylamino-ethyl ester [4-(4-Bromo-phenyl)-3-(3-dimethylamino-propyl)-3H-thiazol-2-ylidene]- phenyl-amine 3-Methyl-benzofuran-2-carboxylic acid dimethylamino-dimethyl-propyl ester
N'-(2-Chloro-4-nitro-phenyl)-N,N-dimethyl-propane-l,3-diamine [3-(3-Dimethylamino-propyl)-5-(4-nitro-phenyl)-3H-thiazol-2-ylidene]- phenyl-amine [3-(10,l l-Dihydro-dibenzo[a,d]cyclohepten-5-ylidene)-propyl]-dimethyl- amine
2,3-Dimethyl-lH-indole-5-carboxylic acid 2-dimethylamino-ethyl ester
N'-(3,4-Dinitro-5-pyridin-2-yl-thiophen-2-yl)-N,N-dimethyl-propane-l,3- diamine
Cyclooctyl-dithiocarbamic acid 2-dimethylamino-ethyl ester (HCI) N-(2,6-Difluoro-phenyl)-C-dimethylamino-acetamide
2-Acetylamino-3-(4-chloro-phenyl)-N-(3-dimethylamino-propyl)-acrylamide N-[2-[5-(4-Bromo-phenyl)-furan-2-yl]-l-(3-dimethylamino- propylcarbamoyl)-vinyl]-4-methyl-benzamide 2,6-Bis-(3-dimethylamino-propylamino)-3-nitro-benzonitrile N-[2-(2,4-Dichloro-phenoxy)-phenyl]-N'-(3-dimethylamino-propyl)- oxalamide
3,5-Dichloro-N-(3-dimethylamino-propyl)-2,6-dimethoxy-benzamide
2-Dimethylaminomethyl-3,4-dihydro-2H-naphthalen-l -one (HCI)
2-( { 1 -[N-(3-Dimethylamino-propyl)-3-trifluoromethyl-phenyl]- methanimidoyl} -amino)-6-fluoro-benzoic acid 2,4-Dichloro-N-(3-dimethylamino-propyl)-N'-hydroxy-benzamidine
3-(3-Methyl-ureido)-4-oxo-3,4-dihydro-quinazoline-2-carboxylic acid
(3 -dimethylamino-propyl)-amide
5-Bromo-N-(3-dimethylamino-propyl)-2-hydroxy-benzamide
N-(2,4-Dichloro-phenyl)-6-(2-dimethylamino-ethylsulfanyl)-4- trifluoromethyl-nicotinamide l-(2,6-Dichloro-benzyl)-2-oxo-l,2-dihydro-pyridine-3 -carboxylic acid
(2-dimethylamino-ethyl)-amide
3-Amino-4-oxo-3,4-dihydro-quinazoline-2-carboxylic acid
(3-dimethylamino-propyl)-amide Compounds of the invention in which P is -U-W- may be prepared by reacting a compound of formula (II)
Z
W7 NR5R2 W
wherein Z, R} and R2 are as defined above and W is a group WH wherein W is as defined above, with a compound of formula (III)
R4— i (m)
wherein R4 is as defined above and U' is a group -UL wherein U is as defined above and L is a hydroxy group or a leaving group such as a halogen atom.
Compounds of formulae (II) and (III) are known compounds, or may be prepared by analogy with known methods.
Typically, the reaction takes place in the presence of a base such as diisopropylethylamine or the equivalent polymer bound resin N,N- (diisopropyl)amino-methylpolystyrene resin (PS-DIEA), and a coupling agent such as O-(7-azabenzotriazol- 1 -yl)-N,N, N, N-tetramethyluronium hexafluorophosphate (HATU). The reaction typically takes place in a solvent such as acetonitrile at a temperature of from 0 to 100 °C, preferably from 20 to 80 °C. The work-up typically involves the use of a sequestration enabling reagent such as tetrafluorophthalic anhydride and polymer bound scavenger resins to remove unwanted starting materials. Such techniques are described in Parlow et al Tetrahedron Lett., 1997, 38, 7959.
Compounds of the invention wherein P is -ΝH-CO-W- can be prepared by reacting a compound of formula (II) above with a compound of formula (IV)
R4 — ΝOO (IV)
wherein R4 is as defined above.
Typically, the reaction takes place in a hydrocarbon solvent such as toluene at a temperature of from 0 to 100 °C. The work-up typically involves the use of a sequestration enabling reagent such as tetrafluorophthalic anhydride and polymer bound scavenger resins to remove unwanted starting materials. The amides thereby prepared may be converted to the corresponding amidines by standard methods.
The compounds of formula (IV) may be prepared by techniques known in the art. For example, they may be prepared by reacting a compound of formula (V)
wherein R4 is as defined above, with diphenylphosphoryl azide (DPP A), in the presence of a base such as triethylamine. Typically, the reaction takes place under reflux, in a solvent such as toluene. Compounds of formula (N) are known compounds or may be prepared by analogy with known methods.
Compounds of the invention wherein P is -X-U-W- wherein X, U and W are as defined above can be prepared by reacting a compound of formula (II) above with a compound of formula (VI)
wherein R4, X and U are as defined above and L is a hydroxy group or leaving group such as a 4-nitro-phenoxy group. Typically, the reaction takes place in a hydrocarbon solvent such as tetrahydrofuran at a temperature of from 60 to 70 °C. The work-up typically involves the use of a sequestration enabling reagent such as tetrafluorophthalic anhydride and polymer bound scavenger resins to remove unwanted starting material.
The compounds of formula (NI) are known compounds or may be prepared by analogy with known methods. For example, compounds of formula (VI) in which U is -CO- can be prepared by reacting a compound of formula (VII)
R4XH (YD)
wherein R4 and X are as defined above, with a chloroformate, for example an aromatic chloroformate such as 4-nitrophenyl chloroformate. Typically, the reaction takes place under reflux, in a solvent such as anhydrous THF. Further, compounds of formula (NI) in which U is -C-(=ΝH)- can, for example, be prepared from the corresponding nitrile of formula R^-X-C≡N, for example by reaction with hydrochloric acid.
Compounds of the invention in which P is -X-Y- or -X-Y-W- and R4 is other than -COR", -CO2R", -S(O)2R" and -CONR'R" can be made by standard techniques, for example by reacting a compound of formula (NIII)
R4-X-H (vπi)
wherein R4 is other than -COR", -CO2R", S(O)2R" and -CONR'R" and X is as defined above, with a compound of formula (IX)
L-Y-ZNR,R2 (IX)
wherein Y, Z, Rj and R2 are as defined above and L represents a hydroxy group or a leaving group such as a halogen. The reaction is typically conducted in the presence of a base at from -78°C to the reflux temperature of the solvent.
The compounds of formulae (VIII) and (IX) are known compounds or may be prepared by analogy with known methods.
Compounds of the invention in which P is -X-U-W- and R4 is -COR", -CO2R", -S(O)2R" or -CONR'R" can be made in an analogous fashion by reacting a compound of formula (X)
R4X-U-L (X)
wherein R , X and U are as defined above and L represents a hydroxy group or a leaving group such as a halogen, with a compound of formula (XI)
HWZNR,R2 (XI)
wherein W, Z, R, and R2 are as defined above.
The compounds of formula (X) and (XI) are known compounds or may be prepared by analogy with known methods.
Compounds in which P is X or W and R4 is other than -COR", -CO2R", -S(O)2R" and -CONR'R" can be prepared, for example, by reacting a compound of formula (XII)
R4-AH (XII)
wherein A is -X- or -W-, wherein X and W are as defined above and R4 is other than -COR", -CO2R", -S(O)2R" and -CONR'R", with a compound of formula (XIII)
L-Z-NR, μR2. (XIII)
wherein Z, R, and R2 are as defined above and L is a leaving group such as a triflate group or a halogen atom. The reaction can be conducted under standard conditions. Typically, it takes place in the presence of a base in a solvent such as
DMF.
The compounds of formula (XII) are known compounds or may be prepared by analogy with known methods. The compounds of formula (XIII) are also known compounds or may be prepared by analogy with known methods. For example, they can be prepared from a corresponding compound of formula HO-Z-NR^ by reaction with triflic anhydride or with PC15.
Compounds of the invention in which P is X or W and R4 is -COR", -CO2R", -S(O)2R" or CONR'R" can be prepared by reacting a compound of formula (IXV)
HA-Z-NR,R2 (IXV)
wherein A, Z, R, and R2 are as defined above, with R4-L, wherein R^ is as defined above and L is a hydroxy group or a leaving group, for example a halogen. The reaction can be conducted under standard conditions, such as those given above for the reaction of compounds of formulae (Vffl) and (IX).
Compounds of formula (IXV) and compounds of formula ^-L are known compounds or may be prepared by analogy with known methods.
Compounds of the invention in which P is Y, Y is -CO- and R,, is aryl or heteroaryl may be prepared, for example, by a Friedel-Crafts reaction between a compound of formula (XV)
R4-H (XV)
wherein R4 is aryl or heteroaryl, and a compound of formula (XVI)
wherein L is a hydroxy group, a group OR wherein R is alkyl, or a halogen, for example chlorine, and Z, V, Rλ and R2 are as defined above. The reaction can be performed under conventional conditions, in the presence of a catalyst such as A1C13.
Examples of such reactions are described in section 1-15 of "Advanced Organic
Chemistry", 3rd Edition, by Jerry March. The compounds of formulae (XV) and (XVI) are known compounds or may be prepared by analogy with known methods.
Compounds in which P is -Y- or -XY- and in which X, Y and ^ are as defined above may be prepared, for example, by reacting a compound of formula
(XVII)
, .
R4' L (xvn)
wherein R4 is as defined above, Y' is -U- or -X-U-, and L is a hydroxy group or a leaving group, for example a halogen atom, with an organometallic compound of formula (XVIII)
M-B-NR,R2 (XVIII)
wherein B is -V-Z- wherein V and Z are as defined above, Rj and R2 are as defined above and M is a metal-containing moiety such as Li or -MgX wherein X is a halogen atom such as bromine.
The reaction can be carried out under conventional conditions. Preferably, M in the formula (XVIII) is Li. When M in the formula (XVIII) is -MgX, it may be necessary to conduct the reaction at around -78 °C and to use a large excess of the compound of formula (XVII).
The compounds of formula (XVII) are known compounds or may be prepared by analogy with known methods. The compounds of formula (XVIII) are also known compounds or may be prepared by analogy with known methods. For example, compounds of formula (XVIII) in which M is Li can be prepared by reacting a corresponding compound of formula Br-B-N ^ with lithium or with magnesium.
In some cases, it may be necessary to protect the -NR^ group during the synthesis of the compounds of formula (XVIII) or during the reaction between the compounds of formulae (XVIII) and (XVII). This can be done by standard techniques.
Compounds of the invention in which P is -Y-W- or -XYW-, wherein Y is - UV- and -V- is -(C,-C6 alkyl)-, can be made, for example, by reacting a compound of formula (IXX)
R4-P-L (IXX)
wherein R4 and P are as defined above and L is a leaving group such as a halogen atom or a triflate group, with a compound of formula (XX)
HW-ZNR,R2 (XX)
wherein W, Z, R^ and R2 are as defined above. The reaction can be conducted under conventional conditions. Typically, it is conducted in the presence of a base. If necessary, the NR]R2 group can be protected during the reaction by conventional means.
The compounds of formulae (IXX) and (XX) are knowN compounds, or may be prepared by analogy with known methods. For example, the compounds of formula (IXX) can be prepared by reacting a corresponding compound of formula R4-P-OH with triflic anhydride or PC15. Compounds in which P is a direct bond can be prepared by conventional synthetic techniques.
A compound of the invention can, of course, be converted to a different compound of the invention by standard functional group intercon versions known to those of skill in the art. For example, a compound of the invention in which U is -CO- can be converted to a compound of the invention in which U is -C(=NR)- by reaction with a compound of formula RNH2. Suitable such reactions are described in section 6-14 of "Advanced Organic Chemistry" 3rd Edition, by Jerry March.
Pharmaceutically acceptable salts of the compounds of formula (I) may be prepared by salifying a compound of formula (I) with an appropriate acid or base. The compounds of the invention are activators of sGC. They can be used as selective sGC activators. A compound of the invention can therefore be used as a vasodilator or to inhibit platelet aggregation. It can be used for the treatment or prevention of peripheral vascular diseases such as hypertension, angina pectoris, arteriosclerosis, or for the treatment or prevention of glaucoma, preeclampsia, Raynaud's Syndrome, stroke or erectile dysfunction. Further, the compounds of the invention are effective in improving ocular blood flow. They can therefore be used
in the treatment and prevention of age-related macular degeneration (AMD). For example, they can be used in the treatment and prevention of non-exudative or exudative AMD. They can also be used in the treatment and prevention of neo vascular or non-neovascular AMD. Conditions attributable to down regulation of sGC can thus be alleviated.
Accordingly, the present invention also provides a compound of formula (I), as defined above, or a pharmaceutically acceptable salt thereof, for use in the treatment of the human or animal body, wherein R,, R2, Z, R3, Y, X and R4 are as defined above. The compounds of the invention may be administered in a variety of dosage forms. Thus, they can be administered orally, for example as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules. The compounds of the invention may also be administered parenterally, either subcutaneously, intravenously, intramuscularly, intrasternally, transdermally or by infusion techniques. The compounds may also be administered as suppositories.
A compound of the invention is typically formulated for administration with a pharmaceutically acceptable carrier or diluent. For example, solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents; e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g. starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents, such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations. Such pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tabletting, sugar-coating, or film coating processes.
Liquid dispersions for oral administration may be syrups, emulsions and suspensions. The syrups may contain as carriers, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.
Suspensions and emulsions may contain as carrier, for example a natural
gum, agar, sodium alginte, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol. The suspensions or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and if desired, a suitable amount of lidocaine hydrochloride.
Solutions for intravenous or infusions may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions.
A therapeutically effective amount of a compound of the invention is administered to a patient. A typical daily dose is from about 0.1 to 50 mg per kg of body weight, according to the activity of the specific compound, the age, weight and conditions of the subject to be treated , the type and severity of the disease and the frequency and route of administration. Preferably, daily dosage levels are from 5 mg to 2 g. The Examples which follow illustrate the invention.
EXAMP ES
The synthesis of some of the compounds of the invention is detailed below.
Examples 1 to 69 The aryl acid (different for each reaction) (0.1 mmol), 3-(dimethylamino)- propylamine (10 mg, 0.1 mmol), N, N-(diisopropyl)amino-methylpolystyrene resin (PS-DIEA), (86.0 mg, 0.3 mmol, loading 3.5 mmol/g) and O-(7-azabenzotriazol-l- yI)-N, N, N, N-tetramethyluronium hexafluorophosphate (HATU) (38 mg, 0.1 mmol) were shaken under nitrogen in anhydrous acetonitrile (4 mL) and heated to 50 °C for 5 hours. After this time the reaction mixture was cooled to room temperature.
Tetrafluorophthalic anhydride (65 mg, 0.3 mmol) was then added and the reaction mixture was shaken under nitrogen for 18 hours. Macroporous triethylammonium methylpolystyrene carbonate resin (MP-carbonate), (610 mg, 1.96 mmol, loading 3.18 mmol/g) was then added and the reaction mixture was shaken under nitrogen for a further 48 hours. The reactions were then filtered through filter syringes into vials and washed with methanol. The solvent was removed on a vacuum concentrator and each product was weighed and analysed by LC-MS.
This method was used to synthesise the following compounds. The molecular weight, purity and yield of the compounds synthesised is shown in Table 1.
10
10
10
10
Table 1
Examples 70 to 99 The aryl acid (different for each reaction) (0.1 mmol) was stirred under nitrogen in anhydrous toluene (2 mL) and heated to 50 °C. Triethylamine (10 mg, 0.1 mmol) dissolved in 1 L of anhydrous toluene was then added. The temperature was raised to 80 °C and diphenylphosphorylazide (DPP A), (27.0 mg, 0.1 mmol) was added.
The reaction was kept at this temperature for 1 hour then cooled to room temperature while still stirring under nitrogen.
3-(Dimethylamino)-propylamine (10 mg, 0.1 mmol) was added and the whole mixture was stirred at room temperature overnight. Tetrafluorophthalic anhydride (64.7 mg, 0.3 mmol) was added and the reaction stirred for a further 18 hours. Following this 20 equivalents of macroporous triethylammonium methylpolystyrene carbonate resin (MP-carbonate), (610 mg, 1.96 mmol) was added and the reactions were stirred for another 24 hours. Each reaction was then filtered through filter syringes into vials and washed with methanol. The solvent was removed using a vacuum concentrator and each product was weighed and analysed by LC-MS.
This method was used to synthesise the following compounds. The molecular weight, purity and yield of the compounds synthesised is shown in Table 2.
Table 2
Example 100 l-(4-Bromophenyl)-3-(3-(l-pyrrolidinyl) propyl) urea (CFM2138)
4-Nitrophenyl chloroformate (87.0 mg, 0.436 mmol), 4-bromoaniline (50.0 mg, 0.29 mmol) and triethylamine (44.0 mg, 0.436 mmol) were refluxed under nitrogen in
anhydrous THF (20 mL) for 18 hours. After this time l-(3-aminopropyl) pyrrolidine (55.0 mg, 0.436 mmol) was added and the whole reaction mixture was refluxed for a further 2 hours.
The reaction mixture was cooled to room temperature and tetrafluorophthalic anhydride (191.0 mg, 0.87 mmol) was added. The reaction was stirred at room temperature under nitrogen for 1 hour, then 6 equivalents of tris-(2-aminoethyl)amine polystyrene resin (PS-trisamine), (500 mg, 1.74 mmol, loading 3.5 mmol/g) was added and the reaction stirred for 2 hours. Following this 20 equivalents of Dowex AG1 resin (OH' form) (1.68 g, 5.8 mmol, loading 3.45 mmol/g) was added and the mixture was stirred for 18 hours at room temperature.
It should be noted that the Cl" form of the resin was converted to the OH" form by washing with 20 volumes of IM NaOH solution, followed by distilled water until the washings are neutral. Another 20 equivalents of the resin was added after this time and the reaction was stirred for a further 2 hours. The reaction mixture was then filtered and the solvent removed using a vacuum concentrator.
Example 101 l-(4-Bromophenyl)-3-(3-dimethylamino propyl) urea (CFM2134)
Prepared as in Example 100 using 4-nitrophenyl chloroformate (77.2 mg, 0.38 mmol), 4-bromoaniline (30.0 mg, 0.174 mmol) and triethylamine (38.8 mg, 0.38 mmol) to form the intermediate followed by 3-(dimethylamino)propylamine (26.6 mg, 0.26 mmol) to form the desired product. Work-up as in Example 100. The crude product was purified by flash chromatography using MeOH/CHCl3 (40:60).
Example 102
3-(4-Bromophenyl)-l-methyl-l-(3-dimethylamino propyl) urea (CFM2139)
Prepared as in Example 100 using 4-nitrophenyl chloroformate (87.0 mg, 0.436 mmol), 4-bromoaniline (50.0 mg, 0.29 mmol) and triethylamine (44.0 mg, 0.436 mmol) refluxed for 5 hours in anhydrous THF (20mL) to form the intermediate. Then N,N,N-trimethyl-l,3-propanediamine (50.5 mg, 0.436 mmol) was added and
the reaction mixture refluxed for 18 hours to form the title compound. Work-up as in Example 100.
Example 103 l-(3-Phenyl-5-methoxy phenyl)-3-(3-dimethylamino propyl) urea (CFM2148)
Prepared as in Example 100 using 4-nitrophenyl chloroformate (45.5 mg, 0.226 mmol), 5-phenyl-ø-anisidine (30.0 mg, 0.151 mmol) and triethylamine (22.8 mg, 0.226 mmol) refluxed in anhydrous THF (20 mL) for 18 hours to form the intermediate followed by 3-(dimethylamino)-propylamine (23.1 mg, 0.226 mmol) and refluxed for a further 5 hours to form the title compound. Work-up as in
Example 100.
Example 104
3-(4-Chlorophenyl)-l-methyl-l-(3-dimethylamino propyl) urea (CFM2200) Prepared as in Example 100 using 4-nitrophenyl chloroformate (830 mg, 4.12 mmol),
4-chloroaniline (350 mg, 2.75 mmol) and triethylamine (416 mg, 4.12 mmol) refluxed for 7 hours in anhydrous THF (30mL) to form the intermediate. Then NNN'-trimethyl-l,3-propanediamine (478 mg, 4.12 mmol) was added and the reaction mixture refluxed for 18 hours to form the title compound. Work-up as in Example 100.
Example 105 l-(3-Νitrophenyl)-l-benzyl-3-(3-dimethylamino propyl) urea (CFM2270) Prepared as in Example 100 using 4-nitrophenyl chloroformate (66.0 mg, 0.328 mmol), N-benzyl-3-nitroaniline (50.0 mg, 0.219 mmol) and triethylamine (33.0 mg,
0.328 mmol) refluxed in anhydrous THF (20 mL) for 6 hours to form the intermediate followed by 3-(dimethylamino)propylamine (44.6 mg, 0.438 mmol) and refluxed for a further 36 hours to form the title compound. Work-up as in Example 100.
Example 106
l-Benzyl-l-(4-methyI-3-pyridinyl)-3-(3-dimethylamino propyl) urea (CFM2271) Prepared as in Example 100 using 4-nitrophenyl chloroformate (76.0 mg, 0.378 mmol), 2-benzylamino-4-methyl-pyridine (50.0 mg, 0.25 mmol) and triethylamine (38.0 mg, 0.378 mmol) refluxed in anhydrous THF (20 mL) for 5 hours to form the intermediate followed by 3-(dimethylamino)propylamine (38.0 mg, 0.378 mmol) and refluxed for a further 18 hours to form the desired product. Work-up as in Example 100. The crude product was purified by flash chromatography using a gradient from 10 to 50 % MeOH (in CHC13) to give the title compound.
Example 107 l-Methyl-l-(3,5-bistrifluoromethylphenyl)-3-(3-dimethylaminopropyl)urea (CFM2311)
Prepared as in Example 100 using 4-nitrophenyl chloroformate (62.0 mg, 0.308 mmol), N-methyl-3,5-bis(trifluoromethyl)aniline (50.0 mg, 0.206 mmol) and triethylamine (31.0 mg, 0.308 mmol) refluxed in anhydrous THF (20 mL) for 5 hours to form the intermediate followed by 3-(dimethylamino)propylamine (31.5 mg, 0.308 mmol) and refluxed for a further 18 hours to form the desired product. Work-up as in Example 100. The crude product was purified by flash chromatography using a gradient from 10 to 40 % MeOH (in CHC13) to give the title compound.
Example 108 l-(2-Phenacyl-4-chorophenyl)-l-methyl-3-(3-dimethylamino propyl) urea
(CFM2310)
4-Nitrophenyl chloroformate (61.5 mg, 0.31 mmol), 5-chloro-2-(methylamino)- benzophenone (50.0 mg, 0.20 mmol) and triethylamine (30.80 mg, 0.31 mmol) were refluxed for 5 hours in anhydrous THF (20 mL) as in Example 100 to form the intermediate. Then 3-(dimethylamino)-propylamine (32.0 mg, 0.31 mmol) was added and the mixture was refluxed for a further 5 hours to form the desired product. Work-up as in Example 100. The crude product was purified by flash chromatography using a gradient from 10 - 40% MeOH (in CHC13) to give the title compound.
Example 109 l-(2-Chloro-4-trifluoromethylphenyl)-3-(3-dimethylaminopropyl) urea
(CFM2421)
4-Nitrophenyl chloroformate (77.0 mg, 0.39 mmol), 4-amino-3-chloro- benzotrifluoride (50.0 mg, 0.26 mmol) and triethylamine (38.0 mg, 0.39 mmol) were refluxed for 18 hours in anhydrous THF (20 mL) as in Example 100 to form the intermediate. Then 3-(dimethylamino)-propylamine (38.0 mg, 0.39 mmol) was added and the mixture was refluxed for a further 5 hours to form the desired product. Work-up as in Example 100. The crude product was purified by flash chromatography using a gradient from 10 - 40% MeOH (in CHC13) to give the title compound.
Example 110 l-(3-Fluoro-5-trifluoromethylphenyl)-3-(3-dimethylarainopropyl) urea (CFM2422)
4-Nitrophenyl chloroformate (84.0 mg, 4.19 mmol), 3-amino-5- fluorobenzotrifluoride (50.0 mg, 0.28 mmol) and triethylamine (42.0 mg, 4.19 mmol) were refluxed for 18 hours in anhydrous THF (20 mL) as in Example 100 to form the intermediate. Then 3-(dimethylamino)-propylamine (42.0 mg, 4.19 mmol) was added and the mixture was refluxed for a further 5 hours to form the desired product. Work-up as in Example 100. The crude product was purified by flash chromatography using a gradient from 10 - 40% MeOH (in CHC13) to give the title compound.
Example 111 l-(3-N-tørt-butoxycarbonyl-benzylamino)-3-(3-dimethylaminopropyl) urea CFM2374
4-Nitrophenyl chloroformate (3.13 g, 15.54 mmol), 3-amino-l-(N-tert-butoxy- carbonyl)benzylamine (2.30 g, 10.36 mmol) and triethylamine (1.56 g, 15.54 mmol) was refluxed for 18 hours in anhydrous THF (100 mL) as in Example 100 to form the intermediate. Then 3-(dimethylamino)propylamine (1.58 g, 15.54 mmol) was
added and the mixture was refluxed for a further 5 hours to form the desired product. Work-up same as in Example 100. The crude product was purified by flash chromatography using a gradient from 10 - 40% MeOH (in CHC13) to give the title compound. Example 112
N-(3-Dimethylamino-propyl)-2-[l-(4-fluorobenzoyl]-benzamide (CFM2262) 2-(4-Fluorobenzoyl)benzoic acid (1.25 g, 5.12 mmol), N,N-(diisopropyl)amino- methylpolystyrene resin (PS-DIEA), (4.30 g, 15.36 mmol), and O-(7-azabenzotriazol-l- yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (HATU) (1.95 g, 5.12 mmol) was stirred in anhydrous acetonitrile (50 mL) at room temperature under nitrogen for 5 minutes. Then 3-(dimethylamino)propylamine (0.52 g, 5.12 mmol) was added and the temperature was taken up to 50 °C and the mixture was left to stir at this temperature for 18 hours. The mixture was allowed to cool and tetrafluorophthalic anhydride (3.40 g, 15.36 mmol) was added and the mixture was allowed to stir for 5 hours. To the mixture was added water (5 mL) and the solvent was removed on a vacuum concentrator. The crude product was purified by flash chromatography using a gradient from 5 to 10% MeOH (in CHC13) and the title compound was isolated as a white solid 0.36 g, 22 % yield (mp 84 - 85 °C).
Example 113
2-[l-(4-Chlorobenzoyl]-Ν-(3-dimethylamino-propyl)-benzamide (CFM 2269)
2-(4-Chlorobenzoyl)-benzoic acid (1.25 g, 4.80 mmol), N,N-(diisopropyl)amino- methylpolystyrene resin (PS-DIEA), (4.00 g, 14.38 mmol), and O-(7- azabenzotriazol- 1 -yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (HATU) (1.82 g, 4.80 mmol) was stirred in anhydrous acetonitrile (50 mL) at room temperature under nitrogen for 5 minutes. Then 3-(dimethylamino)propylamine (0.50 g, 4.80 mmol) was added and the temperature was taken up to 50 °C and the mixture was left to stir at this temperature for 18 hours. The mixture was allowed to cool and tetrafluorophthalic anhydride (3.20 g, 14.40 mmol) was added and the mixture was left to stir for 5 hours. The workup and purification was the same as
described in Example 112. The title compound was isolated as a white solid 0.68g, 41 % yield (mp 108-110 °C).
Example 114 5-(4-Chloro-phenyl)-l-phenyl-lH-pyrazole-3-carboxylic acid (3-dimethylamino- propyl)-amide (CFM2404)
5-(4-Chlorophenyl)-l-phenyl-lH-pyrazole-3-carboxylic acid (1.10 g, 4.09 mmol), N,N-(diisopropyl)amino-methylpolystyrene resin (PS-DIEA), (3.40g, 12.27 mmol), and O-(7-azabenzotriazol- 1 -yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (ΗATU) (1.56 g, 4.09 mmol) was stirred in anhydrous acetonitrile (50 L) at room temperature under nitrogen for 5 minutes. Then 3-(dimethylamino)propylamine (0.42 g, 4.09 mmol) was added and the temperature was taken up to 50 °C and the mixture was left to stir at this temperature for 18 hours. The mixture was allowed to cool and tetrafluorophthalic anhydride (2.70 g, 12.27 mmol) was added and the mixture was allowed to stir for 5 hours. The workup and purification was the same as described in Example 112. The title compound was isolated as a white solid 0.62g, 44 % yield (mp 165 °C).
Example 115 5-Chloro-3-phenyl-lH-indole-2-carboxylic acid (3-dimethylamino-propyl)- amide (CFM2408)
5-Chloro-3-phenyl-lH-indole-2-carboxylic acid (1.00 g, 3.68 mmol), N,N- (diisopropyl)amino-methylpolystyrene resin (PS-DIEA), (3.00 g, 11.04 mmol), and O-(7-azabenzotriazol- 1 -yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (ΗATU) (1.49 g, 3.68 mmol) was stirred in anhydrous acetonitrile (50 mL) at room temperature under nitrogen for 5 minutes. Then 3-(dimethylamino)propylamine (0.38 g, 3.68 mmol) was added and the temperature was taken up to 50 °C and the mixture was left to stir at this temperature for 18 hours. The mixture was allowed to cool and tetrafluorophthalic anhydride (2.43 g, 11.00 mmol) was added and the mixture was allowed to stir for 5 hours. The workup and purification was the same
as described in Example 112. The title compound was isolated as a white solid 0.24 g, 18.5 % yield (mp 143-144 °C).
Example 116 N-(3-Dimethylamino-propyl)-2-(2-phenylsulfamoyl-phenylsulfanyl)- benzamide(CFM2349)
2-(2-Phenylsulfamoyl-phenylsulfanyl)-benzoic acid (1.10 g, 2.60 mmol), NN- (diisopropyl)amino-methylpolystyrene resin (PS-DIEA), (2.18g, 7.78 mmol), and O- (7-azabenzotriazol-l -yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (HATU) (0.98 g, 2.6 mmol) was stirred in anhydrous acetonitrile (50 mL) at room temperature under nitrogen for 5 minutes. Then 3-(dimethylamino)propylamine (0.26 g, 2.60 mmol) was added and the temperature was taken up to 50 °C and the mixture was left to stir at this temperature for 18 hours. The mixture was allowed to cool and tetrafluorophthalic anhydride (1.70 g, 7.78 mmol) was added and the mixture was allowed to stir for 5 hours. The workup and purification was the same as described in Example 112. The title compound was isolated as a white solid (0.1 g, 9 %), (mp 75-76 °C).
Example 117 2-Benzylsulfanyl-Ν-(3-dimethylamino-propyl)-benzamide (CFM2351)
2-Benzylsulfanyl-benzoic acid (1.00 g, 4.09 mmol), N,N-(diisopropyl)amino- methylpolystyrene resin (PS-DIEA), (3.40 g, 12.27 mmol), and O-(7- azabenzotriazol- 1 -yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (HATU) (1.55 g, 4.09 mmol) was stirred in anhydrous acetonitrile (50 mL) at room temperature under nitrogen for 5 minutes. Then 3-(dimethylamino)propylamine
(0.42 g, 4.09 mmol) was added and the temperature was taken up to 50 °C and the mixture was left to stir at this temperature for 18 hours. The mixture was allowed to cool and tetrafluorophthalic anhydride (2.60 g, 12.27 mmol) was added and the mixture was allowed to stir for 5 hours. The workup and purification was the same
as described in Example 112. The title compound was isolated as a white solid 0.41g, 30.5 % yield (mp 85-86 °C).
Example 118 6,8-Di-tert-butyI-4-oxo-4H-chromene-2-carboxylic acid (3-dimethylamino- propyl)-amide (CFM2339)
6,8-Di-tert-butyl-4-oxo-4H-chromene-2-carboxylic acid (1.00 g, 3.31 mmol), N,N- (diisopropyl)amino-methylpolystyrene resin (PS-DIEA), (2.78 g, 9.93 mmol), and O-(7-azabenzotriazol- 1 -yl)-N,NN,N-tetramethyluronium hexafluorophosphate (ΗATU) (1.25 g, 3.31 mmol) was stirred in anhydrous acetonitrile (50 mL) at room temperature under nitrogen for 5 minutes. Then 3-(dimethylamino)propylamine (0.34 g, 3.31 mmol) was added and the temperature was taken up to 50 °C and the mixture was left to stir at this temperature for 18 hours. The mixture was allowed to cool and tetrafluorophthalic anhydride (2.18 g, 9.93 mmol) was added and the mixture was allowed to stir for 5 hours. The workup and purification was the same as described in Example 112. The title compound was isolated as a white solid (0.26g) in 20 % yield (mp 135-136 °C).
Example 119 3-(4-Chloro-phenyl)-4-cyano-5-isobutylsulfanyl-thiophene-2-carboxylic acid (3- dimethylamino-propyl)-amide (CFM2346)
3-(4-Chlorophenyl)-4-cyano-5-isobutylsulfanyl-thiophene-2-carboxylic acid (1.00 g, 2.84 mmol), N,N-(diisopropyl)amino-methylpolystyrene resin (PS-DIEA), (2.37 g, 8.53 mmol), and O-(7-azabenzotriazol-l-yl)-N,N,N,N-teframethyluronium hexafluorophosphate (ΗATU) (1.08g, 2.84 mmol) was stirred in anhydrous acetonitrile (50 mL) at room temperature under nitrogen for 5 minutes. Then 3- (dimethylamino)propylamine (0.3 g, 2.84 mmol) was added and the temperature was taken up to 50 °C and the mixture was left to stir at this temperature for 18 hours. The mixture was allowed to cool and tetrafluorophthalic anhydride (1.87 g, 8.52 mmol) was added and the mixture was allowed to stir for 5 hours. The workup and
purification was the same as described in Example 112. The title compound was isolated as a white oil/solid 0.3 g, 24 % yield.
Example 120 4-(4-Chloro-phenoxy)-N-(3-dimethylamino-propyl)-3-nitro-benzamide
(CFM2347)
4~(4-Chlorophenoxy)-3-nitro-benzoic acid (1.00 g, 3.40 mmol), N, N- (diisopropyl)amino-methylpolystyrene resin (PS-DIEA), (2.84 g, 10.20 mmol), and O-(7-azabenzotriazol- 1 -yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (HATU) (1.29 g, 3.40 mmol) was stirred in anhydrous acetonitrile (50 mL) at room temperature under nitrogen for 5 minutes. Then 3-(dimethylamino)propylamine (0.35 g, 3.40 mmol) was added and the temperature was taken up to 50 °C and the mixture was left to stir at this temperature for 18 hours. The mixture was allowed to cool and tetrafluorophthalic anhydride (2.24 g, 10.20 mmol) was added and the mixture was allowed to stir for 5 hours. The workup and purification was the same as described in Example 112. The title compound was isolated as a yellow solid (0.6 g) in 46.5% yield (mp 165-167 °C.
Example 121 Ν-(3-Dimethylamino-propyI)-4-(4-phenyl-thiazol-2-yl)-benzamide (CFM2405)
4-(4-Phenyl-thiazol-2-yl)-benzoic acid (1.38 g, 4.91 mmol), N,N-(diisopropyl)amino- methylpolystyrene resin (PS-DIEA), (3.84 g, 14.70 mmol), and O-(7- azabenzotriazol-1 -yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (HATU) (1.87 g, 4.91 mmol) was stirred in anhydrous acetonitrile (50 mL) at room temperature under nitrogen for 5 minutes. Then 3-(dimethylamino)propylamine
(0.50 g, 4.91 mmol) was added and the temperature was taken up to 50 °C and the mixture was left to stir at this temperature for 18 hours. The mixture was allowed to cool and tetrafluorophthalic anhydride (3.24 g, 14.70 mmol) was added and the mixture was allowed to stir for 5 hours. The workup and purification was the same as described in Example 112. The title compound was isolated as a white solid (1.18 g) in 66% yield (mp 204-205 °C).
Example 122 l-(3-Dimethylamino-propyl)-3-(2-phenoxyphenyl)-urea (CFM2260)
2-Phenoxybenzoic acid (1.50 g, 7.00 mmol) was stirred in anhydrous toluene (50 mL) at 50 °C under nitrogen. To this mixture was added triethylamine (0.71 g, 7.00 mmol) and the temperature was increased to 80 °C at which stage diphenylphosphorylazide (DPP A) (1.92 g, 7.00 mmol) was added and the mixture was left to stir at this temperature for 5 hours. After this period 3- (dimethylamino)propylamine (0.71 g, 7.00 mmol) was added and the mixture was left to stir at 80 °C overnight under nitrogen. The solvent was removed on a vacuum concentrator The residue was taken up in chloroform (100 mL) and washed with IM sodium hydroxide (2 x 50 mL). The organic fraction was washed with saturated sodium chloride solution and then dried (Na2S04). The solvent was removed on a vacuum concentrator. The crude product was purified by flash chromatography using a gradient from 5 to 10% MeOH (in CHC13) and the title compound was isolated as a white solid (1.00 g ) in 46% yield (mp 126- 128 °C).
Example 123 l-[4-(4-Chloro-phenylsulfanyl)-thiophen-3-yl]-3-(3-dimethylamino-propyl)-urea (CFM2356)
4-(4-Chlorophenylsulfanyl)-thiophene-3-carboxylic acid (1.30 g, 4.80 mmol) was stirred in anhydrous toluene (50 mL) at 50 °C under nitrogen. To this mixture was added triethylamine (0.48 g, 4.80 mmol) and the temperature was increased to 80 °C at which stage diphenylphosphorylazide (DPP A) (1.32 g, 4.80 mmol) was added and the mixture was left to stir at this temperature for 5 hours. After this period 3-
(dimethylamino)propylamine (0.48 g, 4.80 mmol) was added and the mixture was left to stir at 80 °C overnight under nitrogen. The solvent was removed on a vacuum concentrator. The residue was taken up in chloroform (100 mL) and washed with IM sodium hydroxide (2 x 50 mL). The organic fraction was washed with saturated sodium chloride solution and then dried (Na2S04). The solvent was removed on a
vacuum concentrator. The crude product was purified by flash chromatography using a gradient from 5 to 10% MeOH (in CHC13) and the title compound was isolated as a white solid (0.50 g ) in 28% yield (mp 125-126 °C).
Example 124 l-(3-Dimethylamino-propyI)-3-(2'-fluoro-biphenyl-4-yl)-urea (CFM2363)
2-Fluoro-biphenyl-4-carboxylic acid (1.00 g, 4.63 mmol) was stirred in anhydrous toluene (50 mL) at 50 °C under nitrogen. To this mixture was added triethylamine (0.47 g, 4.63 mmol) and the temperature was increased to 80 °C at which stage diphenylphosphorylazide (DPP A) (1.27 g, 4.63 mmol) was added and the mixture was left to stir at this temperature for 5 hours. After this period 3- (dimethylamino)propylamine (0.48 g, 4.63 mmol) was added and the mixture was left to stir at 80 °C overnight under nitrogen. The solvent was removed on a vacuum concentrator. The residue was taken up in chloroform (100 mL) and washed with IM sodium hydroxide (2 x 50 mL). The organic fraction was washed with saturated sodium chloride solution and then dried (Na2S04). The solvent was removed on a vacuum concentrator. The crude product was purified by flash chromatography using a gradient from 5 to 10% MeOH (in CHC13) and the title compound was isolated as a orange oil (0.50 g ) in 34% yield.
Physical data for some of the compounds synthesised in the Examples is given in Table 3.
TABLE 3: Physical Data
Activity Example 1 Compounds of the invention were assayed to determine their ability to activate sGC. The assay employed was an enzyme immunoassay to measure changes in cGMP. To perform the assay recombinant soluble Guanylate cyclase was added to 1.1 mg/ml IBMX, 2.6 mg/ml GTP, 667 nM DeaNO and the test compound (lOμM). The mixture was then incubated at room temperature for 10 minutes. Compounds were formulated in DMSO diluted in Tris HCI (pH 7.4) buffer and with a final DMSO concentration of <0.5%.
To determine the amount of cGMP produced, the Biotrak™ cGMP enzyme immunoassay system commercially available from Amersham™ was used.
The assay is based on the competition between unlabelled cGMP and a fixed quantity of peroxidase labelled cGMP for a limited amount of cGMP specific antibody. The peroxidase ligand that is bound to the antibody is immobilised on precoated microtitre wells. The amount of labelled cGMP is determind using a one pot stabilised substrate. The concentration of unlabelled cGMP in a sample is determined by interpolation from a standard curve. The results are shown in Tables 4 to 7. The results shown in Tables 6 and 7 relate to commercially available compounds.
Activity Example 2
The ability of the compounds of the invention to inhibit platelet aggregation was also determined. IC50 values were measured as set out below.
Materials
Prostacyclin (PGI2 ; ICN Pharmaceuticals, Oxford) in Tris (0.05M, pH 9), Sodium citrate solution, Tyrodes solution without calcium (140mM NaCl; 3mM KC1; 12mM NaHCO3; 0.4mM NaH2PO4.H2O; 2mM MgCl2.6H2O; 0.1% Glucose) contains 0.05M Hepes, pH7.4. Collagen (collagenreagent Horm, Nycomed Arzneimittel GmbH, Munchen).
PGI2 dissolved in Tris buffer (0.05M, pH9). Test compounds dissolved in DMSO (at lOmM) and subsequent dilutions made in Tyrodes; final assay concentration of DMSO did not exceed 0.1% (which is without effect on platelet reactivity).
Platelet Preparation
Platelets prepared according to Vagas, J.R., Radomski, M. and Moncada, S. The use of prostacyclin in the separation from plasma and washing of human platelets. PROSTAGLANDINS 1982; 23:6:929-945.
Briefly, fresh human blood was collected into tubes containing 1 :9 sodium citrate (3.15%) and centrifuged immediately at 260g for 20 minutes to separate the red cells from the platelet rich plasma (PRP). The PRP was decanted and PGI2 (0.3μg/ml) was added. The PRP was then centrifuged at 180g for lOmins to sediment the remaining red and white cells. The resulting PRP was decanted into new tubes,
PGI2 (0.15μg/ml) added and centrifuged at 950 g for 10 mins to sediment the platelets. The resultant platelet poor plasma (PPP) was discarded and the platelet pellet was resuspended in an equal volume of Tyrodes buffer by gently pipetting up and down. The suspension was centrifuged at 870 g for lOmins at 4 °C. The supernatant was discarded and the platelet pellet was resuspended in an equal volume of Tyrodes buffer as before. The platelets were counted (using a Coulter Counter model T540 (address)) and normalised to 250,000cells/μl using Tyrodes. The resultant suspension was placed on ice for approximately 1 hour until use.
Platelet A ssays
Platelet aggregation was monitored using either a Chrono-Log model 560-CA dual channel ormodel 570-4S four channel aggregometer (Chrono-Log Co ., Havertown, PA). Aggregation was analysed by using 0.5 mL aliquots of the platelet suspension at 37 °C using % light transmittance.
For each sample, baseline reading was established for a 3 min period, followed by addition of test compound or buffer. An EC50 dose of collagen was added 1 min later and the response measured 3 min after addition of collagen.
Data Analysis
The amplitude of each aggregatory response, normalised to the collagen control, was used to plot dose-response curves. The concentration of drug that inhibited collagen-induced platelet aggregation by 50% (IC50) was calculated from the dose-response curves.
The results are shown in Tables 4 to 7. The results shown in Tables 6 and 7 relate to commercially available compounds.
Table 4
Table 5
Table 6
Table 7
Claims
1. Use of a compound of the formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the activation of soluble guanylate cyclase
84 \ P Xzb NRιR2 ro
wherein: - R{ and R2 are the same or different and each represent a CrC6 alkyl group, or R, and R2 together form a C3-C6 alkylene group; Z is a CrC4 alkylene group;
P is a direct bond or a moiety -X-, -Y-, -W-, -XY-, -YW- or -XYW-, wherein: - W is -O-, -S-, or -NR3, wherein R3 is hydrogen or CrC6 alkyl;
Y is a moiety -U-V- wherein V is a direct bond or a CrC6 alkylene group and U is -CS-, -CO-, -S(O)2- or -C(=NR)- wherein R is hydrogen, hydroxy or CrC6 alkyl; X is -O- or -NR6- wherein R6 is hydrogen, CrC6 alkyl, C2-C5 alkenyl, C2-C6 alkynyl, aryl or heteroaryl; and
R4is C,-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, a group -R-A wherein R is -(C C6 alkyl)-, -(C2-C6 alkenyl)- or -(C2-C6 alkynyl)- and A is aryl, heteroaryl, carbocycyl or heterocyclyl, or R4 is a group -COR", -COzR , -S(O)2R" or -CONR'R" wherein R' is hydrogen, CrC6 alkyl, C2-C6 alkenyl or
C2-C6 alkynyl and R" is is aryl, heteroaryl, carbocyclyl or heterocyclyl.
2. Use according to claim 1, wherein R, and/or R2 are methyl.
3. Use according to claim 1 or 2, wherein Z is propylene.
4. Use according to any one of the preceding claims, wherein P is -XYW- or -YW-.
5. Use according to any one of the preceding claims, wherein W is -O- or -NR - wherein R3 is as defined in claim 1.
6. Use according to any one of the preceding claims, wherein Y is -CO-.
7. Use according to any one of the preceding claims wherein X is -NH-.
8. Use according to any one of the preceding claims wherein R4 is CrC6 alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, -(C,-C6 alkyl)-aryl, -(CrC6 alkyl)- heteroaryl or -COR" , -CO2R" or -CONRR" wherein R' is hydrogen or CrC6 alkyl and R" is an aryl, heteroaryl, carbocyclyl or heterocyclyl group.
9. Use according to any one of the preceding claims, wherein P is -XYW-, X is - NH- and R4 is phenyl, thienyl or pyrazolyl.
10. Use according to any one of claims 1 to 8, wherein P is -YW- and R4 is a chromonyl, pyrazolyl, thienyl, phenyl or indolyl group.
11. Use according to claim 1, wherein the compound of formula (I) is 1 -(3-Dimethylamino-propyl)-3-(2-phenoxy-phenyl)-urea l-[2-(4-Chloro-phenoxy)-pyridin-3-yl]-3-(3-dimethylaminopropyl)-urea
1 -(3-Dimethylamino-propyl)-3-pyren- 1 -ylmethyl-urea
1 -(3 -Dimethylamino-propyl)-3 -[( 1 R,2R)-5-phenyl-2-( 1 -phenyl-methanoyl)- cyclohexyl]-urea l-(3-Dimethylamino-propyl)-3-[2-(4-phenoxy-phenyl)-ethyl]-urea l-(3-Dimethylamino-propyl)-3-[3-methyl-5-(4-methyl-[l,2,3]thiadiazol-5- yl)- 1 -(4-trifluoromethoxy-phenyl)- lH-pyrazol-4-yl]-urea
2'-[3-(3-Dimethylamino-propyl)-ureido]-biphenyl-2-carboxylic acid (4- fluoro-phenyl)-amide
N-(3-Chloro-4-methyl-phenyl)-4-[3-(3-dimethylamino-propyl)-ureido]-3- phenyl-b utyramide l-[4-(4-Chloro-phenylsulfanyl)-thiophen-3-yl]-3-(3-dimethylamino-propyl)- urea l-[2-(3,4-Dimethoxy-phenyl)-6-methyl-quinolin-4-yl]-3-(4-dimethylamino- propyl)-urea l-(6-Bromo-2-thiophen-3-yl-quinolin-4-yl)-3-(3-dimethylamino-propyl)-urea l-[3-(4-Chloro-phenyl)-4-cyano-5-isobutyIsulfanyl-thiophen-2-yl]-3-(3- dimethylamino-propyl)-urea l-[6-(2,4-Dichloro-phenyl)-cyclohex-3-enyl]-3-(3-dimethylamino-propyl)- urea l-(2-Benzylsulfanyl-phenyl)-3-(3-dimethylamino-propyl)-urea
2-{2-[3-(3-Dimethylamino-propyl)-ureido]-phenylsulfanyl}-N-phenyl- benzenesulfonamide l-(3-Dimethylamino-propyl)-3-(2'-fluoro-biphenyl-4-yl)-urea
N-(3,5-Dichloro-phenyl)-2-{3-[3-(3-dimethylamino-ρropyl)-ureido]-pyridin-
2-ylsulfanyl} -acetamide
1 -(3 -Dimethylamino-propyl)-3 - {2-[l -(1 -trifluoromethyl- 1 ,3,4,9-tetrahydro-b- carbolin-2-yl)-methanoyl]-phenyl}-urea 8-{2-[3-(3-Dimethylamino-propyl)-ureido]-phenylsulfanyl}-naphthalene-l- carboxylic acid methylamide
1 - [ 1 -(3 ,4-Dichloro-benzyl)-6-oxo- 1 , 6-dihydro-pyridin-3 -yl] -3 -(3 - dimethylamino-propyl)-urea
1 -(3-Dimethylamino-propyl)-3-(3-oxo- 1 ,2,3-triphenyl-propyl)-urea l-[5-(4-Chloro-phenyl)-l-(3,4-dichloro-phenyl)-lH-pyrazol-3-yl]-3-(3- dimethylamino-propyl)-urea
1 - {4-[4-(4-Chloro-phenyl)-thiazol-2-yl]-phenyl} -3-(3-dimethylamino- propyl)-urea l-(3-Dimethylamino-propyl)-3-[5-(4-fluoro-phenyl)-thiophen-2-yl]-urea l-[3-(4-tert-Butyl-benzyloxy)-thiophen-2-yl]-3-(3-dimethylamino-propyl)- urea l-(3-Dimethylamino-propyl)-3-[4-(4-phenyl-thiazol-2-yl)-phenyl]-urea 1 - [3 -(3 ,4-Dichloro-benzylsulfanyl)-thiophen-2-yl] -3 -(3 -dimethylamino- propyl)-urea l-[2-(5-Chloro-l-methyl-3-phenyl-lH-pyrazol-4-ylmethylsulfanyl)-phenyl]- 3-(3-dimethylamino-propyl)-urea l-[2-(4-Chloro-benzylsulfanyl)-3-methyl-4-oxo-3,4-dihydro-quinazolin-7-yl]- 3-(3 -dimethylamino-propyl)-urea l-(3-Dimethylamino-propyl)-3-{4-[4-(4-methoxy-phenyl)-pyrimidin-2- ylsulfanylmethyl] -phenyl} -urea l-(4-Bromophenyl)-3-(3-(l-pyrrolidinyl) propyl) urea l-(4-Bromophenyl)-3-(3-dimethylamino propyl) urea 3-(4-Bromophenyl)-l-methyl-l-(3-dimethylamino propyl) urea l-(3-Phenyl-5-methoxy phenyl)-3-(3-dimethylamino propyl) urea
3-(4-Chlorophenyl)-l-methyl-l-(3-dimethylamino propyl) urea l-(3-Nitrophenyl)-l-benzyl-3-(3-dimethylamino propyl) urea l-Benzyl-l-(4-methyl-3-pyridinyl)-3-(3-dimethylamino propyl) urea l-Methyl-l-(3,5-bistrifluoromethylphenyl)-3-(3-dimethylaminopropyl)urea l-(2-Phenacyl-4-chorophenyl)-l-methyl-3-(3-dimethylamino propyl) urea l-(2-Chloro-4-trifluoromethylphenyl)-3-(3-dimethylaminopropyl) urea l-(3-Fluoro-5-trifluoromethylphenyl)-3-(3-dimethylaminopropyl) urea l-(3-N-tert-butoxycarbonyl-benzylamino)-3-(3-dimethylaminopropyl) urea N-(3-Dimethylamino-propyl)-2-[l-(4-fluorobenzoyl]-benzamide 2-[l-(4-Chlorobenzoyl]-N-(3-dimethylamino-propyl)-benzamide 5-(4-Chloro-phenyl)-l -phenyl- lH-pyrazole-3-carboxylic acid (3- dimethylamino-propyl)-amide
5-Chloro-3-phenyl- lH-indole-2-carboxylic acid (3-dimethylamino-propyl)- amide
N-(3-Dimethylamino-propyl)-2-(2-phenylsulfamoyl-phenylsulfanyl)- benzamide
2-Benzylsulfanyl-N-(3-dimethylamino-propyl)-benzamide 6,8-Di-tert-butyl-4-oxo-4H-chromene-2-carboxylic acid (3-dimethylamino -propyl)-amide
3-(4-Chloro-phenyl)-4-cyano-5-isobutylsulfanyl-thiophene-2-carboxylic acid (3-dimethylamino-propyl)-amide
4-(4-Chloro-phenoxy)-N-(3-dimethylamino-propyl)-3-nitro-benzamide N-(3-Dimethylamino-propyl)-4-(4-ρhenyl-thiazol-2-yl)-benzamide l-(3-Dimethylamino-propyl)-3-(2-phenoxyphenyl)-urea l-[4-(4-Chloro-phenylsulfanyl)-thiophen-3-yl]-3-(3-dimethylamino-propyl)
-urea
1 -(3 -Dimethylamino-propyl)-3-(2'-fluoro-biphenyl-4-yl)-urea
N-(3-Dimethylamino-propyl)-2-[ 1 -(4-fluorobenzoyl]-benzamide N-(3-Dimethylamino-propyl)-3-phenoxy-benzamide
N-(3-Dimethylamino-propyl)-2-phenoxy-benzamide 2-(4-Chloro-phenoxy)-N-(3-dimethylamino-propyl)-nicotinamide 4'-n-Propyl-biphenyl-4-carboxylic acid (3-dimethylamino-propyl)-amide 2-[l-(4-Bromo-phenyl)-methanoyl]-cyclohexanecarboxylic acid (3- dimethylamino-propyl)-amide
5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid (3-dimethylamino- propyl)-amide
2-[ 1 -(4-Chlorobenzoyl]-N-(3-dimethylamino-propyl)-benzamide
2-Phenyl-quinoline-4-carboxylic acid (3-dimethylamino-propyl)-amide 2-[l-(4-Chloro-3-nitrobenzoyl)]-N-(3-dimethylamino-propyl)-benzamide
N-(3 -Dimethylamino-propyl)-2-pyren- 1 -yl-acetamide
N-(3-Dimethylamino-propyl)-2-[l-(3-methyl-benzo[b]thiophen-2-yl)- methanoylj-benzamide 4-Chloro-N-(3-dimethylamino-propyl)-2-phenoxy-benzamide
N-(3-Dimethylamino-propyl)-3-(4-phenoxy-phenyl)-propionamide
N-(3 -Dimethylamino-propyl)-2- [ 1 -( 1 -trifluoromethyl- 1 ,3 ,4,9-tetrahydro-b- carbolin-2-yl)-methanoyl]-benzamide l-(4-Chloro-phenyl)-2,5-dimethyl-l-pyrrole-3-carboxylic acid (3- dimethylamino-propyl)-amide
2-{l-[(3-Dimethylamino-propylcarbamoyl)-methyl]-cyclopentyl}-N-(4- trifluoromethoxy-phenyl)-acetamide
8-[2-(3-Dimethylamino-propylcarbamoyl)-phenylsulfanyl]-naphthalene-l- carboxylic acid methylamide 3-Methyl-5-(4-methyl-[l,2,3]thiadiazol-5-yl)-l-(4-trifluoromethoxy-phenyl)- lH-pyrazole-4-carboxylic acid (3 -dimethy lamino-propyl)-amide
6,8-Di-tert-butyl-4-oxo-4H-chromene-2-carboxylic acid (3-dimethylamino- propyl)-amide
2-(Furan-2-yl)-quinoline-4-carboxylic acid (3-dimethylamino-propyl)-amide Biphenyl-2,2 '-dicarboxylic acid 2'-[(3-dimethylamino-propyl)-amide]-2-[(4- fluoro-phenyl)-amide]
3-Phenyl-pentanedioic acid (3-chloro-4-methyl-phenyl)-amide (3- dimethylamino-propyl)-amide
2-(3,4-Dimethoxy-phenyl)-6-methyl-quinoline-4-carboxylic acid (3- dimethylamino-propyl)-amide
6-Bromo-(2-thiophen-3-yl)-quinoline-4-carboxylic acid (3-dimethylamino- propyl)-amide
3-(4-Chloro-phenyl)-4-cyano-5-isobutylsulfanyl-thiophene-2-carboxylic acid
(3 -dimethylamino-propyl)-amide 4-(4-Chloro-phenoxy)-N-(3-dimethylamino-propyl)-3-nitro-benzamide
6-(2,4-Dichloro-phenyl)-cyclohex-3-ene carboxylic acid (3-dimethylamino- propyl)-amide
N-(3-Dimethylamino-propyl)-2-(2-phenylsulfamoyl-phenylsulfanyl)- benzamide
2'-Fluoro-[l,r-biphenyl]-4-carboxylic acid (3-dimethylamino-propyl)-amide
2-Benzylsulfanyl-N-(3-dimethylamino-propyl)-benzamide
Pyrazine-2,3-dicarboxylic acid 2-[(3-dimethylamino-propyl)-amide] 3-
[(5,6,7,8-tetrahydro-naphthalen-l-yl)-amide] 2-[(3,5-Dichloro-phenylcarbamoyl)-methylsulfanyl]-N-(3-dimethylamino- propyl)-nicotinamide
2-(3-Trifluoromethyl-phenyl)-thiazole-4-carboxylic acid (3-dimethylamino- propyl)-amide
2-(4-Chloro-phenyl)-thiazole-4-carboxylic acid (3-dimethylamino-propyl)- amide
5-Chloro-l-(2,4-dichloro-benzyl)-6-oxo-l,6-dihydro-pyridine-3-carboxylic acid (3-dimethylamino-propyl)-amide l-(2,4-Dichloro-benzyl)-6-oxo-l ,6-dihydro-pyridine-3-carboxylic acid (3- dimethylamino-propyl)-amide 5-Chloro-l-(3,4-dichloro-benzyl)-6-oxo-l,6-dihydro-pyridine-3-carboxylic acid (3-dimethylamino-propyl)-amide
1 -(3, 4-Dichloro-benzyl)-6-oxo-l,6-dihydro-pyridine-3 -carboxylic acid (3- dimethylamino-propyl)-amide
5-Chloro-l-(2,6-dichloro-benzyl)-6-oxo-l,6-dihydro-pyridine-3-carboxylic acid (3-dimethylamino-propyl)-amide l,l-Dimethyl-indan-4-carboxylic acid (3-dimethylamino-propyl)-amide
N-(3-Dimethylamino-propyl)-2-[l-(4-ethyl-phenyl)-methanoyl]-benzamide
N-(3-Dimethylamino-propyl)-3-(2,4,5-trimethyl-phenyl)-butyramide
2- [3 -(3 ,4-Dichloro-phenyl)-ureido]-N-(3 -dimethylamino-propyl)-benzamide N-(3-Dimethylamino-propyl)-4-oxo-2,3,4-triphenyl-butyramide
5-(4-Chloro-phenylsulfanyl)-[l ,2,3]thiadiazole-4-carboxylic acid (3- dimethylamino-propyl)-amide
2-(3-Chloro-5-trifluoromethyl-pyridin-2-ylsulfanyl)-3-methyl-3H-imidazole- 4-carboxylic acid (3-dimethylamino-propyl)-amide
2-(2-Chloro-4-trifluoromethyl-phenyl)-[l ,3]-thiazole-4-carboxylic acid (3- dimethylamino-propyl)-amide
2-(2,3-Dihydro-l-benzofuran-5-yl)-l,3-thiazole-4-carboxylic acid (3- dimethylamino-propyl)-amide 2-(2,3-Dichloro-phenyl)-l,3-thiazole-4-carboxylic acid (3-dimethylamino- propyl)-amide
4-[4-(4-Chloro-phenyl)-thiazol-2-yl]-N-(3-dimethylamino-propyl)-benzamide
5-(4-Fluoro-phenyl)-thiophene-2-carboxylic acid (3-dimethylamino-propyl)- amide 4-Methyl-2-(3-trifluoromethyl-phenyl)-thiazole-5-carboxylic acid (3- dimethylamino-propyl)-amide
3-(4-tert-Butyl-benzyloxy)-thiophene-2-carboxylic acid (3-dimethylamino- propyl)-amide
4-Oxo-3-(3-trifluoromethyl-phenyl)-3,4-dihydro-phthalazine-l-carboxylic acid (3-dimethylamino-propyl)-amide
2-(4-Chloro-phenyl)-N-(3-dimethylamino-propyl)-4-oxo-4-phenyl- butyramide
5-(4-Chloro-phenyl)-l -phenyl- lH-pyrazole-3 -carboxylic acid (3- dimethylamino-propyl)-amide N-(3-Dimethylamino-propyl)-4-(4-phenyl-thiazol-2-yl)-benzamide
1 -(2,4,5-Trichloro-phenylsulfonyl)-pyrrolidine-2-carboxylic acid (3- dimethylamino-propyl)-amide
3-(3,4-Dichloro-benzylsulfanyl)-thiophene-2-carboxylic acid (3- dimethylamino-propyl)-amide 5-Chloro-3-phenyl-lH-indole-2-carboxylic acid (3-dimethylamino-propyl)- amide
N-(3-Dimethylamino-propyl)-2-[l-(4-fluoro-benzyl)-lH-indol-3-yl]- acetamide 2-Phenyl-imidazo[l,2-a]pyridine-3 -carboxylic acid (3-dimethylamino- propyl)-amide
N-(3-Dimethylamino-propyl)-2-(7-ethyl-lH-indol-3-yl)-4-oxo-4-phenyl- butyr amide
Phenyl-trifluoromethyl-thieno[3,2-b]pyridine-2-carboxylic acid (3- dimethylamino-propyl)-amide
3-(4-Nitro-3-trifluoromethyl-phenoxy)-thiophene-2-carboxylic acid (3- dimethylamino-propyl)-amide
2-(5-Chloro-l-methyl-3-phenyl-lH-pyrazol-4-ylmethylsulfanyl)-N-(3- dimethylamino-propyl)-benzamide 2-(4-Chloro-benzylsulfanyl)-3-methyl-4-oxo-3,4-dihydro-quinazoline-7
-carboxylic acid (3-dimethylamino-propyl)-amide
N-(3-Dimethylamino-propyl)-4-[4-(4-methoxy-phenyl)-pyrimidin-2
-ylsulfanylmethy 1] -b enzamide l-(4-chlorobenzyl)-3-(2-N,N-dimethylethylamido)-6-pyridone l-(2,6-dichlorobenzyl)-3-(3-N,N-dimethylpropylamido)-6-pyridone l-(3-trifluoromethylbenzyl)-3-(2-N,N-dimethylethylamido)-2-pyridone l-(2,6-dichlorobenzyl)-3-(2-N,N-dimethylethylamido)-2-pyridone l-(3,4-dichlorobenzyl)-3-(N-[2,N,N-dimethylaminoethylamido])-2-pyridone l-(2,6-dichlorobenzyl)-3-(N-[2-N,N-dimethylaminoethylamido])-6-pyridone 5-chloro-l-(3,4-dichlorobenzyl)-3-(2-N,N-dimethylaminoethylamido)-6
-pyridone
5-chloro-3-(2-N,N-dimethylaminoethylamido)-l-(3-trifluoromethylbenzyl)-6- pyridone 5-chloro-l-(3,4-dichlorobenzyl)-3-N-(2-[N',N'-dimethylaminoethylamido])-2- pyridone
5-chloro-l-(4-chlorobenzyl)-3-N-(2-(N',N'-dimethylamino)ethyl)amido-2- pyridone 5-chloro-l-(3-trifluoromethylbenzyl)-3-N-(2-(N',N'-dimethylamino)ethyl) amido-2-pyridone l-benzyl-5-chloro-3-N-(2-[N',N'-dimethylamino]ethyl)carboxamido-6- pyridone
5-chloro-l-(4-chlorobenzyl)-3-N-(2-[N',N'-dimethylamino]ethyl)carboxamido -6-pyridone
4-(2,4-dichlorobenzoyl)pyrrole-2-N-dimethylaminopropylcarboxamide
4-[(N-[3-(N',N,-dimethylaminopropyl)]carboxamido]-2-phenylthiazole
4-(N-(3-N',N'-dimethylaminopropyl)carboxamido)-2-(4-pyridinyl)thiazole
2-[4-(N-[3-N',N'-dimethylaminopropyl]carboxamido)phenyl-4- (3 -trifluoromethylphenyl)]thiazole
4-(4-chlorophenyl)-2-(4-[3-N',N'-dimethylaminopropyl]carboxamido)phenyl) thiazole l-(3,5-bis(trifluoromethyl)benzyl)-3-[N-(2-dimethylaminoethyl) carboxamido]-2[lH]-pyridone N-(3-dimethylaminopropyl)-4-(3-chloro-5-trifluoromethyl-2-pyridyloxy) phenylsulfonamide
Nl-[3-(dimethylamino)propyl]-3-[3-chloro-5-(trifluoromethyl)-2-pyridyl] propanamide
3-(N-(2-dimethylaminoethyl)carboxamido]-l-(4-trifluoromethylbenzyl))-2 [lH]-pyridone l-ethyl-3-(3-dimethylaminopropyl)urea
1 -(3 -(dimethylamino)-propyl)-3 -phenylurea
Nl-[2-(2,4-dichlorophenoxy)phenyl]-N2-[3-(dimethylamino)propyl] ethanediamide N4-[3-(dimethylamino)propyl]-3-(2,6-dichlorophenyl)-5-methylisoxazole-4-c arboxamide
N-[[3-(2,6-dichlorophenyl)-5-methylisoxazol-4-yl]carbonyl]-N'-[3-(dimethyla mino)propyl]urea N-(4-chlorophenyl)-N'-[3-dimethylaminopropyl]urea
N-(3,5-Dichloro-phenyl)-3-(3-dimethylamino-propylamino)-propionamide
[3-(2-Ethyl-6-methyl-pyridin-3-yloxy)-propyl]-dimethyl-amine
8-(3-Dimethylamino-propoxy)- 1 ,3 ,7-trimethyl-3 ,7-dihydro-purine-2,6-dione
2-(3-Dimethylamino-propylamino)-isophthalonitrile Dimethylamino-(3 -methyl-benzo [b]thiophen-2-yl)-propan- 1 -one (HCI)
N-Benzo[l ,3]dioxol-5-ylmethyl-N,N-dimethyl-propane- 1 ,3-diamine
N,N-Dimethyl-N-(5-nitro-quinolin-8-yl)-propane-l,3-diamine
1 -(4-Chloro-phenyl)-3 -(3 -dimethy lamino-propyl)-urea
2-Amino-N-(3-dimethylamino-propyl)-benzamide 3 -Phenyl- acrylic acid 3-dimethylamino-propyl ester
3,5-Dinitro-benzoic acid 2-dimethylamino-ethyl ester
[4-(4-Bromo-phenyl)-3-(3-dimethylamino-propyl)-3H-thiazol-2-ylidene]- phenyl-amine
3 -Methyl -benzofuran-2-carboxylic acid dimethylamino-dimethyl-propyl ester N'-(2-Chloro-4-rritro-phenyl)-N,N-dimethyl-propane-l,3-diamine
[3-(3-Dimethylamino-propyl)-5-(4-nitro-phenyl)-3H-thiazol-2-ylidene]- phenyl-amine
[3-(10,ll-Dihydro-dibenzo[a,d]cyclohepten-5-ylidene)-propyl]-dimethyl- amine 2,3-Dimethyl-lH-indole-5-carboxylic acid 2-dimethylamino-ethyl ester
N'-(3,4-Dinitro-5-pyridin-2-yl-thiophen-2-yl)-N,N-dimethyl-propane-l,3- diamine
Cyclooctyl-dithiocarbamic acid 2-dimethylamino-ethyl ester (HCI)
N-(2,6-Difluoro-phenyl)-C-dimethylamino-acetamide 2-Acetylamino-3-(4-chloro-phenyl)-N-(3-dimethylamino-propyl)-acrylamide
N-[2-[5-(4-Bromo-phenyl)-furan-2-yl]-l-(3-dimethylamino-propyl carbamoyl)-vinyl]-4-methyl-benzamide
2,6-Bis-(3-dimethylamino-propylamino)-3-nitro-benzonitrile N-[2-(2,4-Dichloro-phenoxy)-phenyl]-N'-(3-dimethylamino-propyl)- oxalamide
3,5-Dichloro-N-(3-dimethylamino-propyl)-2,6-dimethoxy-benzamide
2-Dimethylaminomethyl-3 ,4-dihydro-2H-naphthalen- 1 -one (HCI)
2-({l-[N-(3-Dimethylamino-propyl)-3-trifluoromethyl-phenyl]- methanimidoyl}-amino)-6-fluoro-benzoic acid
2,4-Dichloro-N-(3-dimethylamino-propyl)-N'-hydroxy-benzamidine
3-(3-Methyl-ureido)-4-oxo-3,4-dihydro-quinazoline-2-carboxylic acid
(3-dimethylamino-propyl)-amide
5-Bromo-N-(3-dimethylamino-propyl)-2-hydroxy-benzamide N-(2,4-Dichloro-phenyl)-6-(2-dimethylamino-ethylsulfanyl)-4- trifluoromethyl-nicotinamide l-(2,6-Dichloro-benzyl)-2-oxo-l,2-dihydro-pyridine-3-carboxylic acid
(2-dimethylamino-ethyl)-amide
3-Amino-4-oxo-3,4-dihydro-quinazoline-2-carboxylic acid (3-dimethylamino-propyl)-amide
12. Use according to any one of the preceding claims, wherein the medicament is for use as a vasodilator or to inhibit platelet aggregation.
13. Use according to claim 12, wherein the medicament is for use in the treatment or prevention of a peripheral vascular disease, glaucoma, age- related macular degeneration, preeclampsia, Raynaud's Syndrome, stroke or erectile dysfunction.
14. A method of treating a patient in need of an activator of soluble guanylate cyclase, which method comprises administering to said patient an effective amount of a compound according to any one of claims 1 to 11 , or a pharmaceutically acceptable salt thereof.
15. A compound of the formula (I), as defined in any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, for use in the treatment of the human or animal body by therapy.
16. A compound of the formula (I), as defined in any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, excluding the following compounds: 2-Benzylsulfanyl-N-(3-dimethylamino-propyl)-benzamide N-(3-Dimethylamino-propyl)-3-phenoxy-benzamide l-(4-chlorobenzyl)-3-(2-N,N-dimethylethylamido)-6-pyridone l-(2,6-dichlorobenzyl)-3-(3-N,N-dimethylpropylamido)-6-pyridone l-(3-trifluoromethylbenzyl)-3-(2-N,N-dimethylethylamido)-2-pyridone l-(2,6-dichlorobenzyl)-3-(2-N,N-dimethylethylamido)-2-pyridone l-(3,4-dichlorobenzyl)-3-(N-[2,N,N-dimethylaminoethylamido])-2-pyridone l-(2,6-dichlorobenzyl)-3-(N-[2-N,N-dimethylaminoethylamido])-6-pyridone 5-chloro-l-(3,4-dichlorobenzyl)-3-(2-N,N-dimethylaminoethylamido)-6- pyridone
5-chloro-3-(2-N,N-dimethylaminoethylamido)-l-(3-trifluoromethylbenzyl)-6- pyridone 5-chloro-l-(3,4-dichlorobenzyl)-3-N-(2-[ ',N'-dimethylaminoethylamido])-2- pyridone
5-chloro-l-(4-chlorobenzyl)-3-N-(2-(N',N'-dimethylamino)ethyl)amido-2- pyridone
5-chloro-l-(3-trifluoromethylbenzyl)-3-N-(2-(N',N'-dimethylamino)ethyl) amido-2-pyridone l-benzyl-5-chloro-3-N-(2-pSf',N'-dimethylamino]ethyl)carboxamido-6- pyridone
5 -chloro- 1 -(4-chlorobenzyl)-3 -N-(2- [N',N'-dimethylamino] ethyl) carboxamido-6-pyridone 4-(2,4-dichlorobenzoyl)pyrrole-2-N-dimethylaminopropylcarboxamide
4-[(N-[3-(N',N'-dimethylaminopropyl)]carboxamido]-2-phenylthiazole
4-(N-(3-N',N'-dimethylaminopropyl)carboxamido)-2-(4-pyridinyl)thiazole
2-[4-(N-[3-N',N'-dimethylaminopropyl]carboxamido)phenyl-4-
(3-trifluoromethylphenyl]thiazole 4-(4-chlorophenyl)-2-(4-[3-N',N'-dimethylaminopropyl]carboxamido)phenyl) thiazole l-(3,5-bis(trofluoromethyl)benzyl)-3-rN-(2-dimethylaminoethyl) carboxamido] -2 [ 1 H] -pyridone
N-(3-dimethylaminopropyl)-4-(3-chloro-5-trifluoromethyl-2-pyridyloxy) phenylsulfonamide
Nl-[3-(dimethylamino)propyl]-3-[3-chloro-5-(trifluoromethyl)-2-pyridyl] propanamide
3-(N-(2-dimethylaminoethyl)carboxamido]-l-(4-trifluoromethylbenzyl))-2
[IH] -pyridone l-ethyl-3 -(3 -dimethy laminopropyl)urea l-(3-(dimethylamino)-propyl)-3-phenylurea
Nl-[2-(2,4-dichlorophenoxy)phenyl]-N2-[3-(dimethylamino)propyl] ethanediamide
N4-[3-(dimethylamino)propyl]-3-(2,6-dichlorophenyl)-5-methylisoxazole-4-c arboxamide
N-[[3-(2,6-dichlorophenyl)-5-methylisoxazol-4-yl]carbonyl]-N'-[3-
(dimethylamino)propyl]urea
N-(4-chlorophenyl)-N'-[3-dimethylaminopropyl]urea
N-(3,5-Dichloro-phenyl)-3-(3-dimethylamino-propylamino)-propionamide [3-(2-Ethyl-6-methyl-pyridin-3-yloxy)-propyl]-dimethyl-amine
8-(3-Dimethylamino-propoxy)-l,3,7-trimethyl-3,7-dihydro-purine-2,6-dione
2-(3-Dimethylamino-propylamino)-isophthalonitrile
Dimethylamino-(3-methyl-benzo[b]thiophen-2-yl)-propan-l-one (HCI) N-Benzo[l,3]dioxol-5-ylmethyl-N,N-dimethyl-propane-l,3-diamine
N,N-Dimethyl-N-(5-nitro-quinolin-8-yl)-propane-l,3-diamine l-(4-Chloro-phenyl)-3-(3-dimethylamino-propyl)-urea
2-Amino-N-(3-dimethylamino-propyl)-benzamide
3 -Phenyl- acrylic acid 3-dimethylamino-propyl ester 3,5-Dinitro-benzoic acid 2-dimethylamino-ethyl ester
[4-(4-Bromo-phenyl)-3-(3-dimethylamino-propyl)-3H-thiazol-2-ylidene]- phenyl-amine
3-Methyl-benzofuran-2-carboxylic acid dimethylamino-dimethyl-propyl ester
N'-(2-Chloro-4-nitro-phenyl)-N,N-dimethyl-propane-l,3-diamine [3-(3-Dimethylamino-propyl)-5-(4-nitro-phenyl)-3H-thiazol-2-ylidene]- phenyl-amine
[3-(10,l l-Dihydro-dibenzo[a,d]cyclohepten-5-ylidene)-propyl]-dimethyl- amine
2,3-Dimethyl-lH-indole-5-carboxylic acid 2-dimethylamino-ethyl ester N'-(3,4-Dinitro-5-pyridin-2-yl-thiophen-2-yl)-N,N-dimethyl-propane-l,3- diamine
Cyclooctyl-dithiocarbamic acid 2-dimethylamino-ethyl ester (HCI)
N-(2,6-Difluoro-phenyl)-C-dimethylamino-acetamide
2-Acetylamino-3-(4-chloro-phenyl)-N-(3-dimethylamino-propyl)-acrylamide N-[2-[5-(4-Bromo-phenyl)-furan-2-yl]-l-(3-dimethylamino- propylcarbamoyl)-vinyl]-4-methyl-benzamide
2,6-Bis-(3-dimethylamino-propylamino)-3-nitro-benzonitrile
N-[2-(2,4-Dichloro-phenoxy)-phenyl]-N'-(3-dimethylamino-propyl)- oxalamide 3,5-Dichloro-N-(3-dimethylamino-propyl)-2,6-dimethoxy-benzamide 2-Dimethylaminomethyl-3 ,4-dihydro-2H-naphthalen- 1 -one (HCI) 2-({l-[N-(3-Dimethylamino-propyl)-3-trifluoromethyl-phenyl]- methanimidoyl} -amino)-6-fluoro-benzoic acid 2,4-Dichloro-N-(3-dimethylamino-propyl)-N'-hydroxy-benzamidine
3-(3-Methyl-ureido)-4-oxo-3,4-dihydro-quinazoline-2-carboxylic acid (3-dimethylamino-propyl)-amide
5-Bromo-N-(3-dimethylamino-propyl)-2-hydroxy-benzamide N-(2,4-Dichloro-phenyl)-6-(2-dimethylamino-ethylsulfanyl)-4- trifluoromethyl-nicotinamide l-(2,6-Dichloro-benzyl)-2-oxo-l,2-dihydro-pyridine-3-carboxylic acid
(2-dimethylamino-ethyl)-amide
3-Amino-4-oxo-3 ,4-dihydro-quinazoline-2-carboxylic acid
(3-dimethylamino-propyl)-amide
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9926286 | 1999-11-05 | ||
GBGB9926286.7A GB9926286D0 (en) | 1999-11-05 | 1999-11-05 | Activators of soluble guanylate cyclase |
US20138200P | 2000-05-02 | 2000-05-02 | |
US201382P | 2000-05-02 | ||
PCT/GB2000/004249 WO2001032604A1 (en) | 1999-11-05 | 2000-11-06 | Activators of soluble guanylate cyclase |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1237849A1 true EP1237849A1 (en) | 2002-09-11 |
Family
ID=26316060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00973061A Withdrawn EP1237849A1 (en) | 1999-11-05 | 2000-11-06 | Activators of soluble guanylate cyclase |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1237849A1 (en) |
JP (1) | JP2003513064A (en) |
AU (1) | AU1161601A (en) |
CA (1) | CA2389773A1 (en) |
WO (1) | WO2001032604A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014084312A1 (en) * | 2012-11-30 | 2014-06-05 | アステラス製薬株式会社 | Imidazopyridine compound |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001266345B2 (en) | 2000-06-30 | 2006-03-02 | Sumitomo Dainippon Pharma Co., Ltd. | Five-membered-ring compound |
JP2003081937A (en) * | 2001-09-07 | 2003-03-19 | Bayer Ag | Benzenesulfonamide derivative |
DK1482931T3 (en) | 2002-03-05 | 2011-12-19 | Transtech Pharma Inc | Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with RAGE |
DE10216145A1 (en) * | 2002-04-12 | 2003-10-23 | Bayer Ag | Use of stimulators of soluble guanylate cyclase to produce a medicament for treating glaucoma |
US20040121994A1 (en) * | 2002-12-20 | 2004-06-24 | Anderson Steven N. | Novel amides that activate soluble guanylate cyclase |
CN1802159B (en) | 2003-03-24 | 2013-04-24 | 阿克西金药品公司 | 2-phenoxy- and 2-phenylsulfomamide derivatives with CCR3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders |
JP2007084437A (en) * | 2003-12-26 | 2007-04-05 | Dai Ichi Seiyaku Co Ltd | Aminoalkylpyrazole derivative |
ATE552251T1 (en) * | 2004-01-09 | 2012-04-15 | Lilly Co Eli | THIOPHENE AND FURAN COMPOUNDS |
US20070179137A1 (en) * | 2004-03-24 | 2007-08-02 | Rimonyx Pharmaceuticals Ltd. | Screening of anti-viral drugs and pharmaceuticals composition containing thiazolidinone derivatives |
WO2006089076A2 (en) * | 2005-02-18 | 2006-08-24 | Neurogen Corporation | Thiazole amides, imidazole amides and related analogues |
DE102005011534A1 (en) * | 2005-03-10 | 2006-09-21 | Merck Patent Gmbh | Chromen-4-one derivatives |
DE102005047945A1 (en) * | 2005-07-16 | 2007-01-18 | Bayer Healthcare Ag | Use of soluble guanylate cyclase activators for the treatment of Raynaud's phenomena |
JP2009523748A (en) * | 2006-01-18 | 2009-06-25 | シエナ ビオテク ソシエタ ペル アチオニ | Modulators of α7 nicotinic acetylcholine receptors and their use in therapy |
TW200901974A (en) | 2007-01-16 | 2009-01-16 | Wyeth Corp | Compounds, compositions, and methods of making and using them |
WO2009032249A1 (en) * | 2007-09-06 | 2009-03-12 | Merck & Co., Inc. | Soluble guanylate cyclase activators |
DE102008018675A1 (en) * | 2008-04-14 | 2009-10-15 | Bayer Schering Pharma Aktiengesellschaft | Oxo-heterocyclic substituted carboxylic acid derivatives and their use |
JP2011521941A (en) * | 2008-05-30 | 2011-07-28 | ミトロジクス | ANT-ligand molecules and biological applications |
US8580833B2 (en) | 2009-09-30 | 2013-11-12 | Transtech Pharma, Inc. | Substituted imidazole derivatives and methods of use thereof |
MX336559B (en) | 2010-03-17 | 2016-01-25 | Axikin Pharmaceuticals Inc | Arylsulfonamide ccr3 antagonists. |
CN102250006B (en) * | 2011-05-12 | 2014-03-05 | 范如霖 | 3-pyrazole carboxylic acid amide compounds, preparation method thereof and application thereof in preparation of medicament serving as CB1 receptor inhibitor |
CN103608347B (en) | 2011-05-30 | 2016-04-27 | 安斯泰来制药株式会社 | Imidazopyridine |
WO2016023885A1 (en) * | 2014-08-14 | 2016-02-18 | Bayer Pharma Aktiengesellschaft | Substituted quinoline-4-carboxamides and use thereof |
CN106831494B (en) * | 2017-03-14 | 2018-04-17 | 青岛科技大学 | A kind of mebenil base hexichol carbamide compounds and application thereof |
EP4378932A1 (en) * | 2022-11-30 | 2024-06-05 | Universität Bern | Novel cd93 inhibitors |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE890958C (en) * | 1940-06-11 | 1953-09-24 | Bayer Ag | Process for the preparation of sulfonamide compounds |
US2553093A (en) * | 1947-11-04 | 1951-05-15 | Rhone Poulenc Sa | Aminoalkylethanesulfonamide |
US2628224A (en) * | 1951-01-16 | 1953-02-10 | Du Pont | Vinyl dialkylaminohydrocarbonamides |
DE1020636B (en) * | 1954-11-12 | 1957-12-12 | Geigy Ag J R | Process for the preparation of 3-phenyl-7-acylamino-coumarins |
US2777853A (en) * | 1955-09-06 | 1957-01-15 | Hoffmann La Roche | Mercapto benzothiazole compounds |
US3170955A (en) * | 1958-04-25 | 1965-02-23 | Abbott Lab | Amino and halogen substituted-n-diloweralkylamino-alkyl-benzamides |
DE1156080B (en) * | 1959-02-07 | 1963-10-24 | Laeaeketehdas Orion Oy | Process for the production of aromatic acid amides substituted in the two ortho positions |
FR1586112A (en) * | 1968-05-27 | 1970-02-13 | ||
IE47458B1 (en) * | 1977-11-07 | 1984-03-21 | Leo Pharm Prod Ltd | Quinolylguanidine derivatives |
DE4038128A1 (en) * | 1990-11-27 | 1992-06-04 | Schering Ag | 8-EN-19, 11 (BETA) BRIDGED STEROIDS, THEIR PRODUCTION AND THEIR PHARMACEUTICAL PREPARATIONS CONTAINING THEM |
FR2670780B1 (en) * | 1990-12-20 | 1993-07-09 | Synthelabo | DERIVATIVES OF 4- (ACYLAMINO) BENZOPYRANS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION. |
DE19744026A1 (en) * | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazole derivatives, their preparation and their use in medicinal products |
DE19756388A1 (en) * | 1997-12-18 | 1999-06-24 | Hoechst Marion Roussel De Gmbh | New 2-aryl-4-amino-6,7-di:methoxy-quinazoline derivatives useful as guanylate cyclase activators for treating cardiovascular diseases, etc. |
DE19836697A1 (en) * | 1998-08-13 | 2000-02-17 | Hoechst Marion Roussel De Gmbh | New substituted 4-amino-2-aryl-pyrimidines, are soluble guanylate cyclase activators useful e.g. for treating atherosclerosis, hypertension, angina pectoris, thrombosis, asthma or diabetes |
GB9824310D0 (en) * | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
-
2000
- 2000-11-06 JP JP2001534758A patent/JP2003513064A/en active Pending
- 2000-11-06 AU AU11616/01A patent/AU1161601A/en not_active Abandoned
- 2000-11-06 EP EP00973061A patent/EP1237849A1/en not_active Withdrawn
- 2000-11-06 WO PCT/GB2000/004249 patent/WO2001032604A1/en not_active Application Discontinuation
- 2000-11-06 CA CA002389773A patent/CA2389773A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO0132604A1 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014084312A1 (en) * | 2012-11-30 | 2014-06-05 | アステラス製薬株式会社 | Imidazopyridine compound |
Also Published As
Publication number | Publication date |
---|---|
AU1161601A (en) | 2001-05-14 |
JP2003513064A (en) | 2003-04-08 |
WO2001032604A1 (en) | 2001-05-10 |
CA2389773A1 (en) | 2001-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001032604A1 (en) | Activators of soluble guanylate cyclase | |
TWI286550B (en) | Benzophenones as inhibitors of reverse transcriptase | |
TWI417096B (en) | Phenyl and pyridyl compounds for inflammation and immune-related uses | |
TWI242005B (en) | Ortho, ortho-substituted nitrogen-containing bisaryl compounds, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | |
DE69432984T2 (en) | THERAPEUTIC SUBSTITUTED GUANIDINE | |
EP1383750B1 (en) | Urea derivatives as integrin alpha 4 antagonists | |
US8039493B2 (en) | Biaryl sulfonamide derivatives | |
KR100252453B1 (en) | Compounds and methods for inhibition of hiv and related viruses | |
US20060223879A1 (en) | Non-steroidal farnesoid x receptor modulators | |
US20020143186A1 (en) | Glucagon antagonists/inverse agonists | |
US6762176B1 (en) | 2-aminopyridine derivatives, their use as medicines and pharmaceutical compositions containing them | |
JP4644714B2 (en) | New cyclohexane derivatives | |
US20070135499A1 (en) | Hydrazide compounds | |
AU2008205047A2 (en) | 6-aminoisoquinoline compounds useful as kinase modulators | |
DE10110750A1 (en) | Novel aminodicarboxylic acid derivatives with pharmaceutical properties | |
KR20020014797A (en) | Glucagon antagonists/inverse agonists | |
MXPA04005864A (en) | Chalcone derivatives and their use to treat diseases. | |
PT934301E (en) | AMINOTIOFENOCARBOXAMIDAS | |
KR101872553B1 (en) | Trpm8 receptor antagonists | |
UA75891C2 (en) | Pharmaceutically active sulfonamides derivatives having either lipophilic fragments and those capable to ionize as inhibitors of protein- jun-kinases, a pharmaceutical composition, a method for obtaining these compounds (variants) and intermediary compounds | |
DE19541146A1 (en) | Imidazole derivatives and their use as nitric oxide synthase inhibitors | |
US6380229B1 (en) | 2-(N-cyanoimino)thiazolidin-4-one derivatives | |
KR102132744B1 (en) | Imidazopyridine derivatives useful in treating diabetes | |
HUT72601A (en) | 2,5-diaryl tetrahydro-thiophenes-furans and analogs for the treatment of inflammatory and immune disorders | |
AU2004276128A1 (en) | Amide-type carboxamide derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020521 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20030602 |